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INTRODUCTION 
1. INTRODUCTION 
Atherosclerosis is an arterial disease that is the chief cause of death in Western 
Europe and the United States. The epidemiological delineation of several risk 
factors, including cigarette smoking, hypertension, diabetes mellitus, age, and 
plasma lipid and lipoprotein levels (1-3), has not only provided a valuable means 
of identifying those at increased risk of developing coronary heart disease but has 
also contributed to the understanding of the pathogenesis of atherosclerosis. In this 
thesis, the crucial role of plasma lipoprotein levels in the development of 
atherosclerosis in humans will be discussed. 
1.1 Plasma Lipids and Lipoproteins 
Lipoproteins are dynamic particles that transport lipids and proteins in the 
circulation (4,5). Plasma lipoproteins are generally spherical particles with a surface 
that consists largely of phospholipid, free cholesterol, and proteins and a core that 
contains mostly triglycerides and cholesterol esters. The density of plasma 
lipoproteins is determined by their relative content of protein and lipid. Density, 
composition, and electrophoretic mobility have been used to divide lipoproteins into 
four major classes: chylomicrons, very low density lipoproteins (VLDL), low density 
lipoproteins (LDL), and high density lipoproteins (HDL). The main function of the 
protein constituents of the lipoproteins, known as apolipoproteins, is the transport 
of lipids in plasma in a soluble form. The characteristics of the lipoproteins in 
normolipidemic subjects are indicated in Table 1. 
TABLE 1 . Composition of the 4 major lipoproteins isolated from normolipidemic subjects 
Lipoprotein 
class 
Chylomicrons 
VLDL 
LDL 
HDL 
Density range 
Ig/ml) 
•C0.940 
0.940-1 006 
1.019-1.063 
1.063-1.210 
Electrophc 
mobility 
Origin 
Prebeta 
Beta 
Alpha 
jretic 
Prot 
1-2 
6-10 
18-22 
45-55 
Composition 
TG 
85-95 
50-65 
4-8 
2-7 
FC 
1-3 
4-8 
7-10 
3-5 
(%) 
CE 
2-4 
16-22 
45-50 
15-20 
PL 
3-6 
15-20 
18-24 
26-32 
Apo 
B-48 
B-100 
B-100 
AI /A 11 
VLDL denotes very low density lipoproteins, LDL low density lipoproteins, HDL high density 
lipoproteins, Prot protein, TG triglycerides, FC free cholesterol, CE cholesteryl ester, PL 
phospholipid, and Apo mam apolipoprotein constituent. 
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1.2 Metabolism of Plasma Lipoproteins 
A schematic view of lipoprotein metabolism is shown in Fig 1 
The chylomicrons - large triglyceride rich particles - are produced in the intestine 
in response to dietary fat (6) These particles are normally not present in the 
plasma after a fast of 12 to 14 hours and are catabolized to form chylomicron 
remnants by lipoprotein lipase (activated by apolipoprotein C-ll) and hepatic lipase 
During this process, triglyceride is removed by lipolysis to form free fatty acids 
which are taken up by tissues The chylomicron remnants that contain В 48 and 
apoE are subsequently taken up by a supposed receptor-mediated mechanism via 
the apolipoprotein В and E receptors or chylomicron-remnant receptor in the liver 
A new candidate for this elusive receptor seems to be the LDL receptor related 
protein (LRP)(7,8) Apolipoprotein E facilitates the uptake of chylomicron remnants, 
whereas apolipoprotein CHI inhibits this process 
VLDL synthesis occurs in the liver In the circulation, the VLDL triglycerides and 
phospholipids are hydrolyzed by the enzymatic activity of lipoprotein lipase and 
hepatic lipase In this process, some VLDL constituents (apoE and the apoCs) are 
transferred to HDL, while apolipoprotein B-100 remains with the VLDL particle The 
remaining particles are called VLDL-remnants or intermediate density lipoproteins 
(IDL). The larger VLDL particles are taken up directly from the plasma after 
delipidation, without conversion to IDL and LDL, whereas the smaller VLDL 
particles are converted to IDL and LDL (9,10) 
The IDL particles are delipidated further and gradually lose their apolipoproteins С 
and in part apolipoprotein E They contain one single molecule of apolipoprotein B-
100 They are taken up by the liver and other tissues by a receptor mediated 
mechanism, the LDL receptor, or they are converted to LDL by largely unknown 
mechanisms, in which both cholesteryl ester transfer protein (CETP), lipoprotein 
lipase, and hepatic lipase may be involved (4,5) 
LDL are the major cholesterol-carrying lipoprotein fraction in normal human plasma 
Most LDL appear to be derived from catabolism of VLDL via IDL, but some may be 
synthesized directly by the liver. The major protein constituent of LDL is 
apolipoprotein B-100 The LDL can be catabolized in various cell types by both 
receptor dependent (LDL (apoB,E) receptor or scavenger receptor) and receptor 
independent mechanisms (11) 
Direct production of HDL occurs in both the liver and the intestine, whereas in the 
circulation HDL are formed as a result of the catabolism of triglyceride rich 
lipoproteins. Apolipoprotein Al and All are the major proteins of HDL HDL serve 
as acceptors of lipid, especially free cholesterol, from various tissues HDL particles 
may play an important role in the so called reverse cholesterol transport from 
14 
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peripheral tissues back to the liver. They also regulate the lipid transfer between 
lipoproteins and the transfer of apolipoproteins (12). 
FIGURE 1. Separate pathways for receptor-mediated metabolism of lipoproteins carrying endogenous 
and exogenous cholesterol (reprinted with permission of Dr. MS Brown, N Engl J Med 1983;309:288-
296, Fig.1). 
Exogenous Pathway Endogenous Pathway 
Рі іагу Bile Adds 
Cholesterol Ì 
LDL Receptor 
Remnants 
Ι В-4 E < . B-48 
[ Capillaries J 
Lipoprotein Lipase 
• ^ ^ 
Extrahepatic 
Tissues 
H D L 
B-100 E I I I L B - 1 0 0 
I Capillaries J 
Lipoprotein Lipase 
Recently, lipoprotein (a) (Lp(a)) a relatively new lipoprotein, discovered by Berg in 
1963, has gained much interest (13,14). The composition is similar to that of LDL, 
containing apoB and a similar lipid content. Additionally, Lp(a) contains a 
glycoprotein, designated apo(a), which is linked to apoB-100 by a disulphide 
linkage. Most likely Lp(a) is derived solely from the liver and thus not via the VLDL 
pathway. There is conflicting evidence as to whether Lp(a) is catabolized via the 
LDL receptor pathway. 
This whole lipoprotein spectrum of human plasma may be divided into 
atherosclerotic and anti-atherosclerotic lipoproteins. The cholesteryl-ester rich, 
apoB containing lipoproteins, i.e., LDL, IDL, and Lp(a) are especially atherogenic, 
whereas HDL is designated as the anti-atherosclerotic lipoprotein. Epidemiological 
studies have demonstrated that the levels of plasma LDL are positively correlated 
to the risk of coronary heart disease (1), whereas the level of HDL is inversely 
related to the risk of coronary heart disease (15). 
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1.3 Low Density Lipoproteins and Atherosclerosis 
One of the earliest events in the formation of atherosclerotic plaques is the massive 
accumulation of cholesterol in scavenger cells in the artery wall (16-18) These 
scavenger cells have ingested large amounts of cholesterol, mainly derived from 
plasma LDL, and have become so stuffed with cholesteryl ester that they are 
converted into foam cells. Most of these foam cells arise either from resident 
macrophages in the artery wall or from monocytes that enter the wall at sites of 
endothelial damage (19). 
However, although elevated LDL cholesterol levels are unquestionably an important 
risk factor for atherosclerosis, the mechanism by which increased LDL leads to 
cholesterol accumulation in macrophages is not readily apparent, because cultured 
macrophages do not accumulate cholesterol ester, even when incubated with very 
high concentrations of native LDL (20). The uptake of native LDL occurs normally 
through the process of receptor-mediated endocytosis. The initial event is the 
binding of the lipoprotein to a cell surface receptor, the LDL receptor. After LDL 
enters the macrophage, LDL bound cholesteryl esters are delivered to lysosomes, 
where they are hydrolyzed by an acid lipase. The liberated cholesterol crosses the 
lysosomal membrane and enters the cytoplasma where it is re-estenfied by a 
microsomal enzyme and stored in the cytoplasma as cholesteryl ester droplets or 
used for membrane synthesis. It also triggers three regulatory responses that 
assure cholesterol homeostasis. 1. suppression of HMG-CoA reductase, which 
turns off cholesterol synthesis by the cell; 2. activation of acyl-coenzymeA 
cholesterol-acyltransferase (ACAT), which reestenfies excess cholesterol for 
storage as cholesteryl ester droplets; 3 suppression of the synthesis of LDL 
receptors, which prevents an over accumulation of cholesterol via the receptor 
pathway (20). So, alternative mechanisms are necessary to explain the accumula-
tion of cholesterol in macrophages. 
As discovered by Brown and Goldstein, macrophages also express a so-called 
scavenger or acetyl-LDL-receptor which mediates the endocytosis of several forms 
of modified LDL (21-23). This receptor is not under the control of intracellular 
cholesterol. In culture, the uptake of modified LDL by the scavenger receptor can 
therefore lead to the accumulation of cholesterol, which is then stored in the form 
of lipid droplets, giving rise to cells with an appearance typical of foam cells 
1.4 Modified Low Density Lipoproteins and Atherogenesis 
Modification of LDL is a prerequisite for macrophage uptake and cellular ac-
cumulation of cholesterol, as discussed above. Fig. 2 shows a schematic diagram 
indicating several of the mechanisms available to the macrophage by which it may 
accumulate lipoprotein lipids and be converted to a foam cell 
16 
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FIGURE 2. Schematic diagram indicating several of the mechanisms available to the macrophage by 
which it may accumulate lipoprotein lipids and be converted to a foam cell (reprinted with permission 
of Dr. D. Steinberg, Arteriosclerosis 1983;3:283-310) 
Chylomicrons 
and/or VLDL 
MONOCYTE 
platelets 
7 
malondialdehyde 
β-VLDL receptor(s) 
for β -VLDL 
receptor(s) 
for modified 
LDL 
£Q_ v ^ Endothelial 
modified c e " 9 
LDL 
FOAM CELL 
Chemical modification of LDL (acetylation, acetoacetylation) has been shown to 
lead to cholesterol accumulation in macrophages in vitro, but this does not occur 
in the circulation. Fogelman and colleagues showed that malondialdehyde-modified 
LDL was a ligand for the scavenger receptor. Because malondialdehyde was known 
to occur in vivo as a product of enzymatic and nonenzymatic lipid peroxidation 
reactions, it was proposed as a potential biologic LDL ligand for this receptor (24). 
A further advance was the recognition that certain types of cultured cells, including 
endothelial cells (25,26), smooth muscle cells (27), monocyte-macrophages 
(28,29), and even fibroblasts were capable of modifying LDL in a way that also led 
to its accelerated uptake in macrophages, at least partly by the scavenger receptor. 
The mechanism for the cell-induced modification of LDL was shown to involve free 
radical peroxidation of LDL (30,31). Oxidative modification of LDL by cultured cells 
results in a number of compositional and structural changes to LDL (32,33), which 
lead to a complete structural rearrangement of the protein creating new epitopes 
which do not bind to the LDL(apoB,E) receptor but to the scavenger receptor 
(34,35). In addition, oxidation of LDL has been shown to result in numerous 
changes in its biologic properties that could have pathogenetic importance (18,36), 
including accelerated uptake in macrophages, cytotoxicity, and chemotactic 
activity for monocytes (37-40). It has been shown that identical changes occur 
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when LDL ¡s oxidized in the absence of cells, by incubation with transition metal 
ions such as copper (41,42). 
The lipid peroxidation process of LDL starts, after consumption of the antioxidants 
present in LDL, with the peroxidation of polyunsaturated fatty acids in LDL lipids 
and their degradation to a complex variety of products as conjugated dienes and 
aldehydes (32,33). Hence, both the antioxidant content and the polyunsaturated 
fatty acid composition and concentration of LDL obviously play an important role 
in determining the susceptibility of LDL to oxidative modification (43-47). Several 
studies have shown that antioxidant therapy results in LDL that is highly resistant 
to oxidative modification and is only minimally recognized by macrophages. In 
human, vitamin E, ß-carotene, and ubiquinol-ЮаІІ appear to be important endoge­
nous antioxidants in LDL (43,44,46,47). Recently, the capacity of dietary 
modification of LDL fatty acid content in order to reduce its susceptibility to 
modification was demonstrated (45). 
Finally, other factors, including size of particle, inherent properties of apoB, 
location of fatty acids (e.g. on surface phospholipids or in core triglycerides or 
cholesteryl esters) may affect the oxidizability of LDL (18). 
Oxidative modification is not likely to occur in the circulation because of its high 
antioxidant contents. Furthermore, in vivo studies have shown that even very slight 
degrees of oxidation of LDL led to more rapid removal of the LDL from plasma, 
presumably by the scavenger receptors present on sinusoidal cells of the liver (48-
50). 
So, it is assumed that the oxidative modification takes place primarily in the intima, 
in microdomains which are devoid of well-equipped antioxidant mechanisms. 
Nevertheless, some studies have suggested that at least a modest degree of 
oxidative modification of LDL occurs in plasma (51,52). 
Several studies have provided evidence for the presence in vivo of oxidized LDL, 
which is confined to atherosclerotic tissue. Immunocytochemical techniques have 
demonstrated that LDL extracted from arterial lesions resembles in vitro oxidized 
LDL with respect to physical properties, immunoreactivity with antibodies to 
epitopes of oxidized LDL and by its enhanced uptake in macrophages, mediated by 
one or more scavenger receptor pathways (53-55). Recently, two candidate 
scavenger receptors have been purified (56-58). In addition, modification of LDL 
renders it immunogenic and various antibodies have been used in studies to 
demonstrate the presence of oxidized LDL in vivo (59-61). Finally, convincing 
evidence for the role of oxidative modification in lesion formation comes from 
studies demonstrating that antioxidants such as probucol or butylated hydroxy-
toluene can inhibit lesion formation in WHHL rabbits and cholesterol-fed rabbits, 
respectively (62-65). So, the relevance of oxidized LDL in the atherosclerotic 
process in vivo may thus have therapeutic implications. However, we still need 
clinical studies to demonstrate that inhibition of oxidation of LDL will inhibit the 
atherosclerotic process (66-68). 
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A number of other modifications of LDL convert it to forms taken up more readily 
by macrophages. These include self-aggregation (69), complex formation with a 
variety of other macromolecules, including proteoglycans (70), various matrix 
proteins, and immune complex formation (71), leading to macrophage uptake via 
Fc receptor pathways. Also, overexpression of the LDL receptor activity, which 
may be due to metabolic stimulation of the macrophages by various pathological 
conditions, may result in foam cell formation through the mechanism of LDL 
receptor mediated endocytosis of native LDL (72,73). 
2. LDL HETEROGENEITY 
2.1 Identification and Classification of LDL Subfractions 
During the past several years it has become evident that plasma LDL are a 
heterogeneous collection of particles with distinct physical and chemical 
characteristics (74-86) The metabolic basis and physiological significance of LDL 
subpopulations are largely unknown, although certain LDL subpopulations have 
been suggested to be more atherogenic than others Using a wide variety of 
techniques, LDL has been fractionated into a maximum of 7 subclasses, dependent 
on the methods used A number of investigators have employed ultracentrifugal 
methods to characterize heterogeneity of LDL particles, on the basis of differences 
in particle buoyant density (76,78,80-82). Using analytical ultracentrifugation, 
Hammond and Fisher demonstrated multiple peaks in the Schlieren profiles of 
S, 0-20 lipoproteins, in both patients with hypertriglyceridemia and normolipidemic 
sub|ects (76). Krauss and Burke used equilibrium density gradient 
ultracentrifugation of previously isolated LDL and demonstrated multiple, distinct 
isopycnic bands which could be divided into 4 major LDL subspecies (78) In our 
laboratory, density gradient ultracentrifugation of prestained total plasma was 
employed to assess LDL heterogeneity; in normal subjects up to 3 major LDL 
subfractions could be distinguished (LDL1 d = 1 030-1 033 g/ml; LDL2 d = 1 033-
1.040 g/ml; LDL3 d = 1.040-1.045 g/ml)(81) Further evidence for the discrete 
nature of LDL subclasses has been provided by non-denaturing gradient gel 
electrophoresis, which separates lipoprotein particles on the basis of differences 
in size and shape. LDL analyzed by this technique in individual subjects exhibited 
up to 7 distinct bands (83-85) 
By analytical ultracentrifugation, Fisher distinguished subjects with mono- and 
polydisperse LDL. Most of the mass of monodisperse LDL was found within a 
narrow region of the LDL density range and the preponderance of the lipoprotein 
was similar in molecular weight. By contrast, polydisperse LDL was heterogeneous 
in molecular size, and the lipoprotein mass was distributed over the whole LDL 
density range (77). 
Using gradient gel electrophoresis, Austin and Krauss have postulated that there 
are two predominant LDL subfraction pattern distributions, based on the size of the 
major LDL subfraction; LDL subfraction pattern A enriched m predominantly large, 
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light LDL particles ( > 2 5 . 5 nm) versus LDL subfraction pattern В enriched with 
small, dense LDL particles ( < 2 5 . 5 nm) (85). 
Swinkels and colleagues, using density gradient ultracentrifugation, observed a 
specific LDL subfraction distribution for each individual, characterized by the 
relative contribution of three major LDL subfractions, LDL1, LDL2, and LDL3 to 
total LDL. They introduced a continuous variable, the LDL density variable, to 
describe each individual LDL subfraction profile (86). 
So, in the literature, a great variety in both the techniques for detection and 
isolation of LDL subfractions and the classifications of LDL subfraction profiles has 
been reported 
2.2 Origin of LDL Heterogeneity 
LDL formation is a dynamic process that occurs mtravascularly and involves 
remodeling and dehpidation of precursor VLDL (11, see 1 2) Numerous studies 
have investigated the enzyme mediated modifications of plasma VLDL necessary 
for conversion to LDL and its subfractions (87) The importance of lipoprotein 
lipase and hepatic lipase and neutral lipid transfer proteins has been well 
established (88-91 ). Deckelbaum and coworkers have postulated that exchange of 
LDL cholesteryl ester for VLDL triglyceride, mediated by the cholesteryl ester 
transfer protein (CETP), results in a net transfer and a significant enrichment of the 
LDL with triglyceride Subsequent action of lipoprotein lipase results in hydrolysis 
of a significant amount of the LDL triglycerides and a significant decrease in LDL 
particle size. The relative pool sizes of the triglyceride-nch lipoproteins versus the 
cholesteryl ester-rich lipoproteins influence the rate and the magnitude of the 
exchange of cholesteryl esters and triglycerides between the two types of 
particles, thus contributing to LDL heterogeneity (92,93) 
However, metabolic heterogeneity of plasma VLDL has been demonstrated, only 
a proportion of the plasma VLDL becomes LDL, the actual proportion of which 
differs among individuals and among pathological conditions (9,10,94-96) 
Stalenhoef et al showed that the large VLDL particles present in the plasma of 
patients with lipoprotein lipase deficiency were rapidly removed from the circulation 
and only a small proportion was converted to LDL (9,10) Packard et al 
demonstrated that in normal individuals the production of LDL from larger 
triglyceride-nch VLDL was low (10% of that injected), whereas a much greater 
portion ( > 40%) of small VLDL became LDL after injection into the circulation (96) 
It has been concluded that only small VLDL secreted into the circulation are 
destined to become plasma LDL. The small VLDL formed from larger plasma VLDL 
are removed from the circulation without conversion to LDL However, recent 
studies by Marzetta et al , studying the conversion of plasma VLDL and IDL 
precursors into various LDL subpopulations, using density gradient 
ultracentrifugation, underscore the complexities of apo В metabolism (97). 
Nevertheless, the heterogeneity in precursor VLDL may contribute to LDL 
heterogeneity. 
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Recently, m vivo kinetic studies of VLDL and LDL metabolism indicate that LDL 
arise not only from VLDL but also from direct secretion of LDL into the circulation 
(98,99). The proportion of LDL produced by direct secretion versus by conversion 
of VLDL also differs among individuals. 
Hence, the sequential actions of lipid transfer proteins and lipases, together with 
possible substrate specificity, in addition to suggested heterogeneity among apoB 
containing precursor particles, and the occurrence of free fatty acid-mediated size 
reduction of LDL (100) could account for the multiple different subspecies of LDL 
observed in normal and hyperlipidemic subjects. 
2.3 Compositional Heterogeneity of LDL 
Each LDL particle contains one apohpoprotem B-100 which interacts with 
phospholipids and free cholesterol to form the polar, outer shell of the lipoprotein, 
encompassing a non-polar core containing triglycerides and cholesterol esters The 
cholesteryl esters are the major constituents of LDL, representing 3 6 % to 4 3 % of 
total LDL mass whereas free cholesterol, phospholipids, and triglycerides contribute 
approximately 9%, 2 0 % , and 4 % , respectively, to total LDL mass With increasing 
density of LDL, the relative content of cholesteryl esters, free cholesterol, and 
phospholipids diminishes, whereas the relative content of protein increases The 
absolute amount of apoB per LDL particle is remarkably constant So, the more 
heavy, dense LDL particles are characterized by a lower cholesterol to protein ratio 
Although the protein in LDL subfractions consists of predominantly apoB ( > 95%) 
small amounts of apoE, apoAl, and apoCIII ( < 5 % ) have been found (81,83,86) 
Recently, differences in carbohydrate content of LDL subfractions have been 
reported; there is a progressive reduction in neutral carbohydrate content of both 
LDL lipids and apoB from the largest to the smallest LDL subfractions (101). 
The intra-mdividual variation in the size, density, and chemical composition of the 
LDL particles appears to be minimal, when maintaining a stable life style pattern 
(86,102). The LDL subfraction composition and profile may be influenced by 
considerable changes in diet, body weight, exercise habits, and hormonal status 
in women (103-107) The compositional heterogeneity of LDL may be of potential 
structural and metabolic importance 
2.4 LDL Heterogeneity and Metabolism 
At least two-third of the LDL is cleared from plasma each day via the LDL receptor 
in the liver (108). Besides the hepatocytes several other cells have the capacity to 
express the LDL receptor e д., fibroblasts, HepG2 cells, and human monocyte-
denved macrophages 
Recently, differences in metabolic characteristics between several LDL 
subfractions, isolated from normolipidemic subjects, in fibroblasts (109,110), 
HepG2 cells (111), and the U-937 monocyte-like cell line were reported (112) 
Although different methods for the isolation of LDL subfractions were used, with 
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different density cuts, all studies revealed similar results by indicating that the 
association and degradation of the LDL subfractions by the LDL receptor decreases 
progressively with increasing density Kleinmann et al confirmed this relationship 
by demonstrating a defect of cellular metabolism of the small, dense LDL particles 
present in hypertnglyceridemic subjects; the small, dense LDL particles exhibited 
lower affinity toward the LDL receptor in cultured human skin fibroblasts and were 
less efficient regulators of cellular sterol synthesis and cellular receptor activity 
After bezafibrate therapy, the triglyceride levels reverted toward normal and the 
small, dense LDL particles were replaced by large, light LDL particles, which 
showed normal cellular metabolism (113-115) 
The molecular basis for the defective affinity of dense LDL toward the receptor is 
unknown but several studies have indicated that the small differences in 
core/surface constituents or size of LDL influences the conformation of apoB, 
resulting in loss of reactivity of epitopes, necessary for the interaction of LDLapoB 
with the LDL receptor, thus resulting in an altered affinity of LDL for the LDL 
receptor (116) In agreement with this hypothesis, Teng et al showed that 
antibodies to antigenic sites close to the binding region react more strongly with 
light than with heavy LDL (117,118) 
In vivo kinetic studies have revealed that the fractional catabolic rate of light LDL 
subfractions was higher than that for heavy LDL subfractions (119) So, the 
preferential catabolismi of light LDL through the LDL receptor pathway as shown 
by the in vitro studies might contribute to the greater fractional catabolic rate of 
light LDL in the in vivo kinetic studies 
Several in vivo kinetic studies have underscored the kinetic heterogeneity of LDL 
(120-122) Marzetta et al. showed that the various LDL density subpopulations in 
subjects with normohpidemia and familial combined hyperhpidemia (FCH) revealed 
complex metabolic behavior that differed among subjects (122) Another two 
studies have examined the metabolic behavior of various LDL subfractions isolated 
from hypertnglyceridemic or hyperapobetalipoproteinemic patients (121) Again, 
kinetic heterogeneity was required to describe the metabolic behavior of the LDL 
subfractions in these subjects 
2.5 LDL Heterogeneity and Atherosclerosis 
An increased concentration of LDL cholesterol in plasma is strongly associated with 
an increased risk for coronary artery disease (CAD) (1) However, several studies 
have identified other features of LDL that show particularly strong relationships 
with risk of atherosclerosis Among many patients with angiographically 
documented CAD, normal or near-normal concentrations of LDL cholesterol were 
found whereas the LDL apoB concentrations were increased Hence, increased 
numbers of LDL particles with a reduced ratio of cholesterol to protein were 
present The pathophysiological importance of smaller, denser LDL particles in 
coronary disease has been suggested by several other investigators 
(77,82,85,86,123-128) Crouse et al demonstrated a significantly lower LDL 
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molecular mass (dense LDL) for angiographically ascertained CAD patients than for 
controls. However, LDL molecular mass decreased as plasma triglycerides 
increased and concentrations of triglycerides were greater in CAD patients than in 
controls. After covanance adjustment for triglycerides there was no LDL molecular 
mass difference between CAD patients and controls (123) Similarly, Fisher et al 
reported an increased association of polydisperse LDL (decreased lipid to protein 
ratio = dense LDL) with atherosclerosis in hypertriglycendemic diabetics, though 
not in other individuals (77) Using gradient gel electrophoresis, Austin et al 
reported that in a case-control study of non fatal myocardial infarctions LDL 
subclass pattern В was associated with a three fold increased risk of myocardial 
infarction, independent of age, sex, and relative weight In addition, pattern В was 
associated with increases in plasma levels of triglycerides and apoB, with mass of 
VLDL and IDL and with decreases in HDL cholesterol (85). 
Recently, these results were confirmed by Campos et al in 275 men with CAD and 
822 controls; small LDL particles were more prevalent in CAD patients than in 
controls and highly associated with elevated plasma triglyceride levels and 
decreased HDL cholesterol levels (124) Tornvall et al addressed the issue more 
directly and showed that a preponderance of dense and triglyceride enriched LDL 
correlated significantly with coronary lesion severity and progression assessed by 
angiography in 36 young post-infarction patients The preponderance of small, 
dense LDL particles was associated with elevated plasma VLDL triglyceride 
concentrations (128). 
The frequently observed relationship of the LDL subfraction distribution with 
plasma triglyceride and HDL cholesterol levels could be explained by the hypothesis 
of Deckelbaum et al (see 2 2), that size and density of LDL are partly determined 
by the exchange of triglycerides from VLDL for cholesteryl esters from LDL, 
followed by particle size reduction through lipase action 
Furthermore, several studies have indicated that the presence of small, dense LDL 
was significantly more common in men than in women and increased with age 
(84,86,125) 
Hence, the LDL subfraction pattern distribution appears to be influenced by gender, 
age, and plasma lipoprotein levels, factors that are known to influence the risk of 
atherosclerosis As indicated above, the small, dense LDL subfraction profile is not 
independently associated with CAD after other established risk factors such as 
smoking, hypertension, diabetes, and lipid and lipoprotein parameters have been 
taken into account. It has been postulated that the small, dense LDL subfraction 
profile might primarily reflect a metabolic trait resulting in a set of lipoprotein 
disturbances that lead to increased risk of CAD. The question remains whether the 
small, dense LDL particles per se are atherogenic 
2.6 LDL Heterogeneity and Hyperlipoproteinemia 
The heterogeneity of plasma LDL in subjects with various forms of 
hyperlipoproteinemia has been documented by several investigators (129,130). In 
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patients with familial hypercholesterolemia (FH) there is a shift toward more 
buoyant, larger LDL particles, which are relatively cholesterol enriched and protein 
depleted (129,130). In the presence of many cholesteryl ester rich lipoproteins 
with only few triglyceride rich lipoproteins, there is little transfer of cholesteryl 
esters from LDL into VLDL or of triglycerides from VLDL into LDL, explaining the 
accumulation of large LDL particles containing much cholesteryl ester and little 
triglyceride in subjects with FH. 
At the other extreme, in hypertriglyceridemia (HTG), there is an accumulation of 
triglyceride rich lipoproteins with a high exchange rate of triglyceride and 
cholesteryl ester, resulting in VLDL that are enriched in cholesteryl ester, relative 
to normal, and small LDL that are enriched in triglycerides and lower in cholesteryl 
ester than normal. Because transferred triglycerides in LDL are susceptible to lipase 
activities, they become smaller and denser. So, in hypertriglyceridemia there is a 
shift toward small, dense LDL particles, that are cholesterol depleted and protein 
enriched (92,93). 
Goldstein et al. first identified the condition called familial combined hyperlipidemia 
(FCH), known as a genetic disorder in which VLDL and/or LDL levels are raised and 
in which overproduction of apoB leads to high plasma apoB levels. FCH is strongly 
associated with CAD (131). The LDL subspecies in FCH are heterogeneous, with 
a propensity toward particles that are smaller, lipid depleted, and less buoyant than 
those found in normal individuals (132). Some of these physicochemical changes 
could be accounted for by hypertriglyceridemia, which is associated with many of 
the changes noted above. In hypertriglyceridemic subjects with FCH, the LDL 
particles had a tendency to be homogeneously small and dense. However, the LDL 
isolated from subjects with FCH who were normotriglyceridemic but had increased 
levels of LDL were observed to have greater heterogeneity with the appearance of 
more buoyant LDL particles in addition to the dense LDL, that appears to 
characterize this disorder (132). 
In 1 9 8 1 , Kwiterovich et al. introduced the term hyperapobetalipoproteinemia 
(hyperapoB) to indicate the presence of increased concentrations of LDL apoB in 
plasma with normal or near normal concentrations of LDL cholesterol (133). So, 
hyperapoB is also a lipoprotein phenotype characterized by increased numbers of 
small, dense LDL and appeared strongly associated with CAD (134,135). Patients 
with hyperapoB may be normolipidemic, hypertriglyceridemic or when the number 
of LDL particles increases sufficiently, hypercholesterolemic. 
Recently, Austin et al. have designated the small dense LDL pattern В with the 
associated plasma lipoprotein changes and the increased risk for atherosclerosis as 
the atherogenic lipoprotein phenotype (ALPK136). 
These published data suggest biochemical, genetic, and metabolic relationships 
between hyperapobetalipoproteinemia, FCH, and the atherogenic lipoprotein 
phenotype (ALP). 
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2.7 LDL Heterogeneity and Heritability 
Possible genetic control of LDL heterogeneity was first reported by Fisher et al. 
based on molecular weight measurement of LDL in five families (137). A single 
genetic locus without dominance was proposed. Also, among patients with 
hyperapobetalipoproteinemia and FCH genetic influences in the etiology have been 
proposed. A dominant mode of inheritance has been suggested for both disorders. 
However, the existence of a common recessive allele at a very high frequency has 
not been excluded (131). 
Recently, Austin et al. provided new evidence that the distribution of the LDL 
subfraction pattern in a healthy population has a genetic base (138,139). Using 
gradient gel electrophoresis, the LDL subclass phenotype B, characterized by a 
predominance of small LDL particles appeared to be influenced by an allele at a 
single genetic locus with a population frequency of 0.25-0.30 and an autosomal 
dominant inheritance, but with full penetrance only in males age 20 and over and 
in postmenopausal women. Again, among the family members the small dense LDL 
subclass phenotype В was found to be closely associated with variation in plasma 
levels of other lipid and lipoprotein levels, resulting in the atherogenic lipoprotein 
phenotype (ALP). A similar mode of inheritance for the small, dense LDL 
subfraction profile was found among families with FCH although in these families 
an additional significant multifactorial inheritance component was found ( 140). Due 
to the close similarities between FCH, hyperapobetalipoproteinemia, and the 
atherogenic lipoprotein phenotype, they may all represent the same genetic 
disorder. 
Further elucidation of the chromosomal location of the proposed locus responsible 
for the ALP may help us to better understand the genetic and metabolic basis for 
this phenotype. Recently, linkage of FCH to the APOAI-C3-A4 gene cluster on 
chromosome 11 ( 141 ) and linkage of ALP to the LDL receptor on chromosome 19 
(142) was demonstrated, whereas no linkage with the АРОВ gene was found in 
either FCH or ALP (143,144). 
3. OUTLINE OF THIS THESIS 
Low density lipoproteins are a heterogeneous collection of particles with distinct 
physical characteristics, chemical composition, immunological properties, kinetic 
behaviour, and origin. The small, dense LDL particles have been associated with 
an atherogenic lipoprotein profile and an increased risk of atherosclerosis. However, 
the biochemical and genetic base for the existence of discrete LDL subfractions and 
their varying relationships to coronary disease risk are still not understood. 
The objective of the studies presented in this thesis is to provide more insight into 
the metabolic and genetic factors influencing the LDL subfraction profile. 
Furthermore, we tried to elucidate potential mechanisms involved in the different 
atherogenic properties of the various LDL subfractions. 
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To study LDL heterogeneity it is essential to have a reproducible and reliable 
method to detect and isolate the LDL subfractions. In literature, both density 
gradient ultracentrifugation and gradient gel electrophoresis have been frequently 
used to detect LDL heterogeneity. Unfortunately, the different techniques for 
detection and isolation of LDL subfractions complicates the comparison of the 
results of different studies. Therefore, we compared both methods for detecting 
LDL subfractions in one study, including 41 healthy individuals (Chapter 2). In 
addition, the influence of storage of the sera on the LDL subfraction patterns 
obtained with the two methods was studied. The advantages, limitations, and 
similarities in these two different methods used to detect and separate LDL 
subfractions are discussed (Chapter 2). 
Several lines of evidence have shown that the heavy, dense LDL subfractions are 
associated with elevated plasma triglyceride levels and decreased HDL cholesterol 
levels and predisposes to CAD. However, the question remains whether the small, 
dense LDL subfractions per se may be atherogenic. In chapter 3 and 4, we 
addressed this question by studying two possible mechanisms which may 
contribute to an enhanced atherogenic potential of small, dense LDL per se. 
In Chapter 3, we determined the susceptibility of the various LDL subfractions, 
present in normolipidemic subjects, to oxidative modification in vitro, as several 
studies have indicated the relevance of oxidized LDL in the formation of foam cells, 
the hall-mark of atherosclerotic plaques. Both the vitamin E and fatty acid 
composition and concentration in the LDL subfractions were determined to reveal 
their contribution to possible differences in oxidizability between LDL subfractions. 
A suggested alternative mechanism leading to foam cell formation is the uptake of 
native LDL through the upregulated LDL receptor in activated macrophages. In 
Chapter 4, possible differences in atherogenicity between normolipidemic LDL 
subfractions were studied by determining the rates of LDL receptor mediated 
catabolism of LDL subfractions by human monocyte-derived macrophages, as these 
cells play a crucial role in the development of atherosclerosis. 
The relevance of small, dense LDL in contributing to a more atherogenic lipoprotein 
profile associated with an increased risk of atherosclerosis has been demonstrated 
in several studies including patients with myocardial infarction or angiographically 
proven coronary artery disease. Another group of subjects which have been 
reported to exhibit an increased risk of atherosclerosis are women using oral 
contraceptives. In Chapter 5, the prevalence of the small, dense LDL subfraction 
profile was determined among oral contraceptive users and non users and the 
relevance of the small, dense LDL subfraction as an independent risk factor for 
atherosclerosis is discussed. 
To investigate the metabolic basis of LDL heterogeneity, we applied density 
gradient ultracentrifugation and/or gradient gel electrophoresis to study the LDL 
subfraction profiles in normolipidemics and in subjects with various forms of 
hyperlipoproteinemia, both before and after lipid-lowering drug treatment (Chapter 
6 and 7). 
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In Chapter 6, the effect of simvastatin on the LDL subfraction profile was 
investigated in sera of 26 patients with familial hypercholesterolemia. In Chapter 
7, the effect of increased plasma triglyceride levels on the LDL subfraction profile 
was studied in subjects with various degrees of hypertriglyceridemia (type IV and 
V hyperlipoproteinemia). The effect of Clofibrate treatment, a lipid-lowering drug 
due to mechanisms different from that of simvastatin, was investigated to 
determine its effect on the LDL subfraction profile. 
In addition, to look for possible differences in atherogenic potential between the 
dense LDL subfractions present in hypertriglyceridemic subjects and normolipidemic 
subjects, we determined their susceptibility to oxidative modification in vitro, both 
before and after Clofibrate treatment. 
In chapter 8 and 9, the influence of genetic factors on the LDL subfraction profile 
was investigated. In Chapter 8, the LDL subfraction profiles were determined 
among 19 large kindreds of 2 generations by density gradient ultracentrifugation. 
Complex segregation analysis was then used to investigate the inheritance of the 
LDL subfraction patterns, by comparing the likelihood of different modes of 
inheritance, both genetic and environmental. The results have indicated that a 
major locus may be involved in determining the LDL subfraction profile. In an 
attempt to map the chromosomal location of this proposed major locus, in Chapter 
9, we evaluated the impact of 7 genes on the LDL subfraction profile by performing 
linkage analysis using the candidate gene approach; those genes which products 
are known or suspected to be involved in the atherogenic process and lipid 
metabolism, i.e., the АРОВ gene, the APOA2 gene, the APOE-C1-C2, and APOA1-
C3-A4 gene clusters, the lipoprotein lipase gene, the hepatic lipase gene and the 
LDL receptor gene, were studied. 
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TWO METHODS FOR DETECTING LDL HETEROGENEITY COMPARED 
ABSTRACT 
Single spin density gradient ultracentrifugation (DGU) has proven to be a repro-
ducible method for detection of low density lipoprotein (LDL) heterogeneity 
Recently another method has been described for this, gradient gel electrophoresis 
(GGE) of serum, a method that might be more suitable for screening To gain 
insight into the relationship of GGE to DGU and into their reproducibility, we 
determined LDL heterogeneity by DGU and GGE in 41 healthy individuals. In 90 .2% 
(n = 37) of the subjects, the number of LDL subfractions found by both methods 
agreed In addition, the density and the relative migration distance of the pre-
dominant LDL subfraction observed with the respective methods showed a strong 
correlation (Pearson correlation, r = 0 85, p < 0 0001) Although it was not possible 
to compare for all aspects of LDL heterogeneity, these data suggest that GGE is 
a valid method of analysis for LDL heterogeneity In screening programs, it may be 
necessary to store samples. Therefore, we studied in 24 sera the influence of 
storage at -80°C for one, four, and 12 weeks on the LDL subfraction distribution 
detected by each method. LDL heterogeneity was maintained during storage under 
these conditions. 
INTRODUCTION 
Human low density lipoproteins (LDL) consist of discrete subfractions, each of 
which may have a different effect on the development of atherosclerosis (1 4). 
Various methods have been described for detecting or isolating LDL subfractions 
(5-10). Because single spin density gradient ultracentrifugation (DGU) has proven 
to be a reproducible method for detection of LDL heterogeneity (4,11 ), this method 
provides a criterion with which other methods can be compared A drawback of 
DGU is the need for expensive equipment and experienced personnel To facilitate 
research on LDL heterogeneity, a relatively simple, inexpensive method for 
detecting LDL subfractions in small volumes of serum is needed. For this purpose 
gradient gel electrophoresis (GGE), based on electrophoresis in a gradient gel, 
appears to be the method of choice (12). This technique separates LDL 
subfractions on the basis of differences in particle size, whereas DGU separation 
is based on differences in buoyant density. For the various classes of lipoproteins, 
both physical criteria are strongly related. LDL particle size decreases with 
increasing density (7,8,13). Therefore, applying GGE to the same sera is expected 
to result in similar patterns of LDL heterogeneity as DGU. Surprisingly, however, 
results obtained with both methods by various authors clearly differ with regard to 
the number of bands in the individual sera as well as the distribution of LDL 
subfraction patterns among the populations studied, probably caused by technical 
variations in the procedures. 
In the present study, therefore, in which both methods were compared, we paid 
special attention to the number of LDL subfractions detected. Even when using a 
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sophisticated deconvolution procedure, we were unable to obtain completely 
reproducible results for the electrophoresis peaks. Therefore, we looked for a 
presentation of the results that would best describe the relationship between the 
densities and the migration patterns obtained in either method 
We also studied the influence of storage of the sera at -80°C for as long as 12 
weeks on the LDL subfraction patterns obtained with the two methods. 
MATERIALS AND METHODS 
Study Protocol 
Blood was sampled in evacuated collection tubes (CorvacR, Becton-Dickmson, 
3 8 2 4 1 , Cedex, France) from 41 apparently healthy persons after fasting overnight 
Subjects had filled out questionnaires regarding gender, age, weight, height, drug 
use, and smoking habits. Sera were isolated within 2 h and were analyzed either 
immediately or after storage for the defined times described below. Characteristics 
of the population studied are given in Table 1. 
TABLE 1 Characteristics of the population studied 
Age (yrs) 
BMI (kg/m'l 
Serum cholesterol* 
Serum triglyceride* 
HDL cholesterol' 
LDL1 cholesterol' 
LDL2 cholesterol' 
LDL3 cholesterol' 
DV" 
men (n = 26) 
40 ± 9 
23 93 ± 2 43 
5 69 ± 0 87 
1 81 ± 0 91 
1 15 ± 0 30 
0 30 ± 0 37 
0 84 ± 0 52 
0 96 ± 0 63 
103 87 ± 0 26 
women (n = 1 5) 
33 ± 9 
22 37 ± 3 0 4 
5 26 ± 0 72 
1 11 ± 0 47 
1 50 ± 0 42 
0 67 ± 0 44 
1 08 ± 0 37 
0 57 ± 0 31 
103 67 ± 0 23 
total (n = 41) 
38 ± 10 
23 39 ± 2 76 
5 54 ί 0 84 
1 57 ± 0 86 
1 27 ± 0 39 
0 43 ± 0 43 
0 93 ± 0 49 
0 82 ± 0 57 
103 79 ± 0 27 
Results are presented as mean ± SD 'Values in mmol/l bLDL density variable (DV), as defined in 
the text BMI, Body mass index; HDL, high density lipoproteins, LDL, low density lipoproteins 
Methods for Determining LDL Heterogeneity 
Single Spin Density Gradient Ultracentrifugation 
We performed the DGU procedure as described (11), modifying the density 
gradient slightly to improve peak identification and to facilitate isolation of the LDL 
subfractions. We dissolved 0.42 g of KBr in 3 ml of fresh serum to increase the 
density to 1.10 kg/I, then pipetted 3 ml of this solution into a polycarbonate 
centrifuge tube. We stained the serum by adding 20 μ\ of a freshly prepared 15 g/l 
aqueous solution of Coomassie Brilliant Blue R (CBBR), then overlayered this 
successively with four solutions of decreasing relative density (d): 1.5 ml of 
d = 1.065, 3 ml of d = 1.035, 3 ml of d = 1.020, and 2 ml of d = 1.006. After 
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ultracentrifugation for 19.5 h at 37,000 rpm (160,000 g.v) at 20°C in a Model L7-
55 ultracentrifuge equipped with a SW 40 rotor (Beekman Instruments Ine , Palo 
Alto, CA), the stained LDL subfractions were visible in the middle of the tube The 
tubes were then placed in a specially designed rack and photographed as described 
(4). Subsequently, the LDL bands were isolated by aspiration and their cholesterol 
contents determined All isolations were performed by the same experienced 
technician to minimize analytical variation. 
LDL subfractions were quantified in triplicate by densitometnc scanning of the 
slides with a Model 2202 Ultrascan laser densitometer (LKB, Bromma, Sweden), 
followed by peak identification (peak search- 1 0) Fitting each peak by using 
gaussian curves and calculating the relative contribution of each peak area to the 
total LDL band were performed by the LKB Gelscan program with an Apple lie 
computer, essentially as described previously (4) The predominant LDL subfraction 
was identified by its peak area In 40 of the subjects (97 6 % ) , this was also the 
most intense LDL subfraction The position of the predominant peak in the tube 
was determined from the densitometnc curve, taking the midpoint of the meniscus 
as a reference point 
The profile of the density gradient was determined after ultracentrifugation of a 
d = 1 006 solution, instead of serum Fractions of 0.5 ml each were aspirated 
carefully. The relative (to water) density (d) of each fraction was determined with 
a densitometer (DMA 35, Mettler/Paar, Graz, Austria) In the LDL density range 
(d = 1.019 - 1.063), the density gradient was linear (data not shown) Mean 
density ranges of LDL subfractions were determined after ultracentrifugation of a 
pooled serum (consisting of sera of six healthy persons with a predominant LDL1, 
LDL2, or LDL3 subfraction, respectively) LDL1 (1 030 to 1 033 g/ml), LDL2 
(1 033 to 1 040 g/ml), and LDL3 (1 040 to 1.045 g/ml). Because this density 
gradient appeared linear in the LDL density range (1 019-1 063 g/ml), the density 
of the predominant LDL subfraction of each individual serum could be accurately 
estimated from its position in the ultracentrifugation tube Note that lipoprotein(a) 
has a higher density, between 1 048-1 080 g/ml, and is not confused with LDL 
subfractions (14) 
Gradient Gel Electrophoresis 
We also separated LDL subfractions by gradient gel electrophoresis (GGE), using 
2-16% Polyacrylamide gradient gels (PAA 2/16 gels, Pharmacia, Uppsala, 
Sweden). Serum aliquots were mixed with one-tenth volume of a solution of 
glycerol (660 ml/l) and bromophenol blue (2 5 ml/I) The electrophoresis unit 
(Model GE 2/4, Pharmacia) was filled with fresh buffer per liter, 0 09 mmol of 
Tris HCl, О 08 mmol of boric acid, and 2 5 μπηοΙ of Na2EDTA, pH 8 4 After pre-
electrophoresis for 20 minutes at 70 V, we added 10 μ\ of the prepared samples 
to each lane of the gel, according to the prescriptions of the manufacturer, then 
further electrophoresed them for 30 mm at 70 V and for 5 5 h at 400 V and 8°C 
After electrophoresis we agitated the gels overnight in ethanol, 450 ml/l The gels 
were stained for 1 h with Sudan Black В (Paragon Lipostain; Beekman Instruments 
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1 ml of Paragon Lipostain dissolved in 100 ml of 550 ml/l ethanol solution) and 
destained for 2 hr in 550 ml/l ethanol. To restore gel shape, we stored the gels in 
60 ml/I acetic acid solution for 24 h before scanning Gels were scanned in 
triplicate with the LKB 2202 Ultrascan laser densitometer A serum standard was 
prepared by pooling sera from 6 subjects with a predominant LDL1, LDL2, or LDL3 
subfraction (as determined by DGU), to cover the complete spectrum of LDL 
subfractions. This serum was stored in small ahquots at -80°C In each gel this 
serum was applied in two lanes to serve as a reference for the LDL bands in the 
samples to be analyzed. To control for possible deviation in the migration, samples 
applied to the outer lanes of a gel were always also added to an inner lane as well. 
The migration distance of the predominant peak of each individual serum was 
determined from the densitometnc curves by using the predominant peak of the 
serum standard as a reference point. Thus, the migration distance could have a 
positive or negative sign Because lipoprotein(a) is larger than the LDL subfractions, 
it does not migrate as far as the LDL subfractions. On the basis of these 
differences in migration distance, any interference by LP(a) is absent (15) 
Storage Experiments 
Serum was used from 24 subjects (10 women, average age 32 years; and 14 men, 
average age 40 years), selected without conscious bias from the population 
described above. The individual sera were subdivided into six portions and stored 
at -80°C. After storage for one, four, or 12 weeks, the aliquots were thawed in 
air at room temperature for 1 h and subjected to both DGU and GGE 
To study the influence of storage on LDL heterogeneity detected by DGU, we used 
sera classified on the basis of the density of the predominant LDL subfraction. In 
addition, we also quantified LDL subfractions by densitometnc scanning as 
described above and expressed the relative contribution of each subfraction as a 
percentage of the total LDL. From these values for each serum we calculated the 
LDL density variable as (% of LDL1 X 1.0315) + (% of LDL2 X 1.0365) + (% of 
LDL3 X 1.0425). This procedure results in a continuous variable for LDL 
heterogeneity (4) In this equation, the weighted factors 1.0315, 1.0365, and 
1.0425 represent the midpoints of the density intervals of the LDL subfractions 
determined with DGU for LDL1, LDL2, and LDL3, respectively 
Analogous to the analysis of fresh sera, DGU was followed by subsequent isolation 
of LDL subfractions and determination of their cholesterol concentration These 
values were not corrected for any losses that may have occurred during the 
isolation procedure. 
To determine the influence of freezing on LDL heterogeneity after GGE, we 
measured the migration distance of the predominant peak of each serum after 
storage for one, four, and 12 weeks The standard serum, which served as a 
reference point for the migration distance, was also stored at -80°C for one, four, 
and 12 weeks. 
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Analytical Methods 
Cholesterol and triglycerides in serum and cholesterol in isolated LDL subfractions 
were determined by enzymatic methods (CHOD-PAP reagent no. 237574, 
Boehrmger, Mannheim, F.R.G., and Sera-Рак triglycerides, Miles, Milan, Italy) with 
a centrifugal analyzer (Multistat III; Instrumentation Laboratory, Lexington, MA) 
High density lipoprotein (HDL) cholesterol was determined in whole serum by the 
polyethylene glycol method (16). 
STATISTICAL ANALYSIS 
The Pearson correlation coefficient was computed to determine the correlation 
between the density (determined with DGU) and the migration distance (deter­
mined with GGE) of the predominant LDL subfraction. 
To examine the influence of storage on the LDL density variable calculated after 
DGU, we used a two-way analysis of variance (ANOVA) The dependent variable 
was the LDL density variable, and the independent variables were the period of 
storage (4 levels) and the subjects (24 levels) Similar procedures were performed 
with the cholesterol concentrations obtained for LDL1, LDL2, and LDL3 and for the 
density of the predominant LDL subfraction as the dependent variable 
The Tukey's studentized range test was used to test for differences in the mean 
value of the density of the predominant LDL subfraction between the periods of 
storage 
To analyze the influence of storage on the LDL subfraction pattern determined by 
GGE, we also used a two-way ANOVA The dependent variable was the migration 
distance of the predominant LDL subfraction, with the period of storage (4 levels) 
and the subjects (24 levels) as the independent variables 
The statistical analyses were performed with procedures available in the Statistical 
Analysis System software package (SAS Institute Ine , Cary, NC). 
RESULTS 
Density Gradient Ultracentrifugation 
In the 41 sera studied, one (n = 1, 2 4%), two (n = 6; 14 6%), or three (n = 34, 
82.9%) stained bands were recognizable in the ultracentrifugation tube (d = 1 030-
1.045 g/ml) (Figure 1, top). This was confirmed by densitometric scanning of the 
tubes (Figure 1, bottom). For all triplicates, the shape, height, distances between 
the peaks, and number of the peaks were identical LDL1 was apparently the 
predominant LDL subfraction in 7 individuals (17.1%), LDL2 in 24 (58 5%), and 
LDL3 in 10 individuals (24 4%) 
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Gradient Gel Electrophoresis 
GGE of the individual sera revealed discrete LDL subfractions (Figure 2, top). The 
number of LDL subfractions found in the 41 individuals ranged from 1 to 5. This 
was confirmed by densitometry scanning of the gels (Figure 2, bottom). Attempts 
to quantify the areas under the curves, as described in Materials and Methods for 
DGU, failed. Probably because of the steep asymmetric peaks (Figure 2, bottom), 
quantification with the software used appeared to produce variable results. 
Therefore, we chose another criterion for the comparison, the migration distance 
of the predominant LDL subfraction. 
Each lane was scanned in triplicate. Within all triplicates, the number of peaks and 
the migration distances of the predominant LDL subfraction agreed well, and the 
shapes of the densitometric curves were similar. 
Density Gradient Ultracentrifugation versus Gradient Gel Electrophoresis. 
Although both DGU and GGE produced distinct LDL bands, the shape of the 
densitometric curves differed between the techniques in all sera (Figures 1 and 2). 
Nevertheless, the number of bands detected by GGE was in almost all cases similar 
to the number determined by DGU. In 4 cases (9.8%) the number of bands 
detected by GGE was larger. Figure 3 shows the comparison of the two methods, 
taking the predominant LDL subfraction into account. Migration distance of the 
predominant LDL subfraction after GGE correlated strongly (r = 0.85, ρ < 0.0001) 
with the density of the predominant LDL band after DGU. 
Influence of Freezing and Storage. 
Storage of serum at -80°C for one, four, or 12 weeks showed no clear effect on 
the number of the LDL subfractions or on the shape of the densitometric curves in 
both DGU and GGE. After determination of the relative contribution of the LDL 
subfractions detected with DGU, the LDL density variable was calculated from 
these values. Mean values are shown in Table 2. A two-way ANOVA revealed no 
significant differences in LDL density variable or in the cholesterol concentrations 
of the LDL subfractions. However, storage of sera for one and four weeks induced 
a small but significant (Tukey's test, ρ < 0.0001) increase in the density of the 
predominant LDL subfraction; after storage for 12 weeks, a smaller, though 
significant (p<0.0001) increase of this density was observed (Table 2). No 
systematic error was detected. 
Similar statistical analysis (two-way ANOVA) of results obtained with GGE, with 
the migration distance of the predominant LDL subfraction as dependent variable, 
showed no changes. 
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FIGURE 1 . DGU distribution of LDL subfractions in six subjects 
^ 
mm _ ^ ^ 
• l b 
density lg/mll 
Top: bands 1, 2, and 3 represent LDL1, LDL2, and LDL3, respectively (note: the photographic procedure 
decreases the sensitivity). 
Bottom: Densitometrie scanning of slides taken of the tubes followed by computerized mathematical 
modeling. 
( ), curves obtained by densitometry scanning; (....), gaussian curves determined by deconvolution 
analysis of the measured curve; ( ), sum of the gaussian curves. Densities are indicated for each 
peak. The area occupied by each gaussian curve can be expressed as the percentage of the area 
occupied by the resulting summed curve ( — ) , representing the percentage of the subfractions of total 
LDL 
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FIGURE 2. LDL banding patterns after GGE of the same six sera 
• 
5 S2 S1 6 
relative migration distance (mm ) 
Top: The sera and the serum standard (S1) were added to lanes in the same gel (S2, another serum 
standard, not used for this study). Bottom: Densitometrie scanning of the lanes of the gels. The number 
of LDL subfractions that could be discriminated is identical for all sera except the first, for which GGE 
revealed one additional LDL subfraction 
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FIGURE 3. Relationship of density (by DGUI and migration distance (by GGE) of the predominant LDL 
subfraction in sera from 41 healthy individuals 
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In DGU, the position of the predominant LDL subfraction in the ultracentrifugation tube was determined 
by using the midpoint of the meniscus as a reference point. Migration distance was determined by using 
the predominant LDL subfraction of a serum standard as a reference point. The predominant LDL 
subfraction showed a strong correlation (r = 0.85, p < 0 . 0 0 0 1 ) of dense LDL with a decreasing particle 
size. 
TABLE 2. LDL density variable and cholesterol concentrations of LDL1, 
and frozen sera after single spin density gradient ultracentrifugation" 
LDL2, and LDL3 in fresh 
Weeks of storage at -80°C 
Fresh 1 12 
DV" 
LDL1 mmol/l 
LDL2 mmol/l 
LDL3 mmol/l 
Density g/тГ 
103.84 ± 0.30 
0 68 + 0 23 
1.08 ± 0 37 
0.99 ± 0.59 
1.035 ± 0.005" 
104 02 ± 0.38 
0.65 ± 0.21 
1.05 ± 0.34 
0.95 ± 0.52 
1.038 ± 0.005 
103.81 ± 0.35 
0.63 ± 0.17 
1.10 ± 0.39 
1 02 ± 0 59 
1 038 ± 0.006 
103 84 ± 0 33 
0.60 ± 0 21 
1 06 ± 0 37 
0 99 ± 0.59 
1.036 ± 0.005 
Results are presented as mean ± SD "Sera (n = 24| were subjected to single spin density gradient 
ultracentrifugation when fresh and after storage at -80°C for one, four, and 12 weeks, respecti­
vely bThe LDL density variable (DV) as defined in the text. 'Mean density of the predominant LDL 
subfractions. < I P<0.0001 vs density after storage for one, four, and 12 weeks. 
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DISCUSSION 
Human plasma LDL exhibit heterogeneity in buoyant density, particle diameter, 
isoelectric point, and chemical composition. Krauss and Burke (13) used both an 
analytical ultracentrifugation and a gradient gel electrophoresis method in one 
study for elucidation of LDL heterogeneity and demonstrated seven distinct LDL 
bands differing in size and density. In contrast to the present study, they 
performed their experiments with previously isolated LDL. McNamara et al. (12) 
analyzed LDL subfraction distribution by GGE of plasma and discriminated seven 
groups, classified by their most intense LDL band. Swinkels et al. (4) demon-
strated three distinct major LDL subfractions, using DGU of prestained serum for 
detection and isolation of LDL subfractions; they used the continuous LDL density 
variable to characterize LDL subfraction patterns. Austin et al. (3, 17) made use of 
GGE of plasma for their study of LDL subfraction patterns and distinguished no 
more than two different LDL subfraction patterns, based on the size of the LDL 
particles of the major LDL subfraction (either smaller or larger than 25.5 nm). The 
foregoing discussion indicates a great variety in both the techniques for detection 
and isolation of LDL subfractions and in the classifications of LDL subfraction 
patterns, making comparison of the results of the different studies difficult. 
Here we compare the discrimination of distinct LDL subfractions on the basis of 
buoyant density (by means of DGU) and particle size (by means of GGE) in 41 
healthy individuals. All criteria on which the authors mentioned above base their 
classifications describe a different facet of LDL heterogeneity. We originally 
intended to compare LDL heterogeneity in both methods by taking the complete 
LDL subfraction pattern into account. However, assessment of LDL subfraction 
distribution obtained after GGE, by using gaussian fitting of the densitometric 
curves, appeared not reproducible, probably because of the nongaussian shape of 
the peaks of the densitometric curves. Therefore, to allow comparison of the two 
methods, we classified sera by their predominant LDL subfraction, as was done 
previously by McNamara et al. (12). 
A strong correlation existed between location (density) of the predominant LDL 
subfraction in the tube after DGU and the migration distance (particle size) in the 
gel after GGE (r = 0.85, p<0.0001) . With respect to number of peaks, we found 
high agreement (n = 37, 90.2%). Remarkable, however, were the differences 
between DGU and GGE in the shapes of the peaks obtained after densitometric 
scanning. 
In some sera ( n = 4 , 9.8%) more peaks could be distinguished by GGE than by 
DGU. Differences in staining procedure (lipid staining in GGE versus protein staining 
in DGU) might account for these discrepancies between the methods. Attempts to 
use a similar staining procedure in both techniques failed; modification of the 
staining procedure in either one of the methods also led to a loss of discriminatory 
power (results not shown). 
Another reason for differences in results between the two methods under study 
could be the appearance of artifacts in one of the methods. However, uniformity 
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and reproducibility of the results obtained with both methods suggest that the 
electrophoretic and ultracentrif ugation procedures do not produce major alterations 
in LDL particles. 
Although we could not compare both methods by taking all aspects of LDL 
heterogeneity into account, we conclude that agreement of the results of both 
methods concerning some important aspects of LDL heterogeneity (the density of 
the predominant LDL subfraction and the number of LDL subfractions detected) 
suggests that GGE may be used as a substitute for DGU. Further, GGE has a higher 
capacity, a smaller sample-volume requirement, and simpler equipment than does 
DGU. 
If LDL subfractions are used as a marker in the risk estimation for coronary heart 
disease in epidemiological studies, one might need to store samples. McNamara et 
al. (12) tested for stability of LDL subfractions in storage at -70°C in a few sera 
and observed no changes in migration or band intensity after GGE. We found that 
freezing samples at -80°C and storing them for up to twelve weeks resulted in a 
small but significant increase in the density. Whether these differences were 
caused by analytical variation or were a true result of the storage could not be 
distinguished. However, the number of the LDL subfractions discerned, the shape 
of the densitometry curve, the concentrations of cholesterol in the various LDL 
subfractions, and the LDL density variable did not change significantly after 
storage. 
In addition, using a pooled serum as a reference, we did not observe a change in 
relative migration distance of the predominant LDL subfraction by GGE after 
storage. 
In conclusion, our results indicate that, for some important characteristics, LDL 
heterogeneity obtained with DGU and GGE shows a high degree of agreement. 
Furthermore, for both methods, reproducible results can be expected for samples 
stored at least 12 weeks. 
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SUSCEPTIBILITY TO IN VITRO OXIDATION OF LDL SUBFRACTIONS 
ABSTRACT 
Oxidative modification of low density lipoprotein (LDL) has been implicated as a 
factor in the generation of macrophage-denved foam cells, the hallmark of 
atherosclerotic plaques. Because LDL consists of discrete subfractions with 
different physicochemical characteristics, the question arises as to whether these 
LDL subfractions differ in their susceptibility to oxidative modification. To answer 
this question, three LDL subfractions, LDL1, LDL2, and LDL3, were isolated from 
the plasmas of 11 healthy volunteers by density gradient ultracentrifugation. The 
LDL subfractions were oxidatively modified by incubation with copper ions. 
Differences in the subfractions' susceptibilities to lipid peroxidation were studied 
by measuring the formation of the 234-nm-absorbmg oxidation products every 
three minutes on an ultraviolet spectrophotometer. A significant inverse linear 
relation was found between LDL subfractions and lag time (regression coefficient = 
-8.50, p < 0.001), indicating that both the dense LDL3 and the light LDL2 were 
less well protected against oxidative modification than the very light LDL1. The 
LDL subfractions showed a positive linear relation with the rate of oxidation 
(regression coefficient = 0.46, p < 0 001) and the amount of conjugated dienes 
formed in the LDL subfractions after 4 h of oxidation (regression coefficient = 
9 24, p < 0.001). Thus, both LDL3 and LDL2 were more extensively modified in 
time than LDL1, which may be explained by the significantly higher concentration 
of polyunsaturated fatty acids in LDL3 (//mol/g LDL cholesterol) compared with 
LDL1 (Tukey's test, p<0 .05) . These results indicate that the more dense LDL 
subfractions, that is, LDL2 and LDL3, are more susceptible to oxidative modifica-
tion and therefore may contribute more to foam cell formation than the less dense 
LDL subfraction LDL1. 
INTRODUCTION 
Plasma levels of low density lipoproteins (LDL) are positively correlated with the 
incidence of coronary artery disease (CAD) (1). In the last decade, evidence has 
accumulated that human plasma LDL comprises discrete subfractions, varying in 
size, density, and lipid content (2-6). Two to three LDL subfractions can be 
detected and isolated from normolipidemic plasma by density gradient 
ultracentrifugation (7). These LDL subfractions have been found to differ in 
chemical composition and molecular size (7). Several lines of evidence suggest that 
the heavy LDL3 subfraction in particular predisposes to CAD (8-12). However, the 
mechanism for the suggested higher atherogenicity of LDL3 has not yet been 
elucidated. 
An early event in the development of atherosclerosis is the accumulation of lipid 
loaded "foam-cells" in the subendothelial space of the vessel wall. Recent studies 
have demonstrated that most of the foam cells are derived from monocyte 
macrophages (13-15). Native LDL is taken up by these macrophages through the 
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LDL-receptor (apolipoprotein [apo] B/E receptor) at a rather low rate and without 
a marked accumulation of cholesterol (16). However, cultured macrophages 
accumulate large amounts of cholesterol lipids and develop a foam cell-like 
appearance when incubated with chemically or biologically modified LDL (17-19). 
The uptake of these modified forms of LDL occurs through the so-called scavenger 
receptor, which is not downregulated by the amount of internalized cholesterol 
(16,20). Therefore, modification of native LDL is necessary to transform 
macrophages into foam cells. Steinbrecheretal. (21) recognized a clear connection 
between lipid peroxidation and modification of LDL. This biologically modified form 
of LDL can be generated in vitro by incubation of LDL with endothelial cells (21-
24), smooth muscle cells (24,25), and macrophages (26,27). These cells can 
oxidize LDL by a lipid peroxidation process. The cell-induced oxidative modification 
can be mimicked by simply incubating LDL in a serum-free medium in the presence 
of copper or iron (21,28). Hence, oxidized LDL is now considered a candidate for 
naturally occurring modified LDL. The lipid peroxidation process starts, after 
consumption of the antioxidants present in LDL, with the peroxidation of the 
polyunsaturated fatty acids (PUFAs) in LDL lipids and their degradation to a 
complex variety of products as conjugated dienes and aldehydes (29). The kinetics 
of the lipid peroxidation process can be followed by continuously measuring the 
increase of the 234-nm absorbance on an ultraviolet (UV) spectrophotometer. This 
absorption develops in LDL during oxidation by the conversion of the PUFAs into 
fatty acid hydroperoxides with conjugated double bonds (30) and by the formation 
of other oxidation products absorbing in this region (31 ). The aim of our study was 
to compare the susceptibility of the three LDL subfractions to in vitro lipid 
peroxidation as a model of biologic modification. 
MATERIALS AND METHODS 
Experimental Protocol 
LDL subfractions were isolated from the plasmas of 11 healthy volunteers. The 
susceptibility to oxidation of the three LDL subfractions from each subject was 
determined in parallel by measuring the changes in the 234-nm absorption on a UV 
spectrophotometer every three minutes during the incubation of the subfractions 
with copper ions (30). 
Plasma 
Blood samples were obtained from 11 healthy volunteers, 6 men and 5 women 
aged 20-45 years, after an overnight fast. All subjects gave their informed consent. 
The blood was collected into EDTA (1 mg/ml)-containing tubes. Plasma was 
isolated immediately and supplemented with butylated hydroxytoluene (BHT, 4.4 
//g/ml). All subjects were normolipidemic and did not use any medication. 
Concentrations of serum triglycerides, total cholesterol, high density lipoprotein 
52 
SUSCEPTIBILITY TO IN VITRO OXIDATION OF LDL SUBFRACTIONS 
(HDL) cholesterol, and LDL cholesterol in the subjects studied ranged from О 64 to 
1.83 mmol/l, 3.6 to 6 0 mmol/l, 0.95 to 2.36 mmol/l, and 1.52 to 4.81 mmol/l, 
respectively 
Low Density Lipoprotein Subfractionation 
Isolation of LDL subfractions was performed by density gradient ultracentrifugation, 
essentially as described previously (7), with some slight modifications to increase 
the distance between the LDL subfractions to facilitate the isolation of the various 
subfractions by aspiration. From each subject, 3 0 ml of freshly isolated plasma 
containing EDTA (1 mg/ml) and BHT (4.4/yg/ml) was pipetted into 6 polycarbonate 
centrifuge tubes The density of the plasma was raised to 1 10 g/ml by dissolution 
of 0 42 g KBr. As a reference for the position of the LDL subfractions, 20 μ\ freshly 
prepared 15 g/l aqueous solution of Coomassie Brilliant Blue R (CBBR) was added 
to one of the tubes. The plasma was then successively overlayered by four density 
solutions of decreasing density (2 ml of d = 1 065 g/ml, 3 0 ml of d = 1 035 g/ml, 
3.0 ml of d = 1 020 g/ml, and 1 5 ml of d = 1 006 g/ml solution) For optimal 
staining, the density solutions used in the reference tube were adjusted to pH 4 5-
5.0 with 1 M HCl. After ultracentrifugation at 37,000 rpm (160,000ga v) at 20°C 
for 19 5 h m a Beekman SW 40 rotor in Beekman L7-55 ultracentrifuges (Beekman 
Instruments, Palo Alto, CA), three LDL subfractions (LDL1 d = 1 030-1 033 g/ml, 
LDL2 d = 1 033-1 040 g/ml, LDL3 d = 1 040-1 045 g/ml) for all individuals were 
visible as distinct bands in the middle of the tube With use of the reference tube 
for each subject, LDL subfractions were then accurately isolated by aspiration with 
a rubber bulb pipet from tubes to which no stain had been added The non-stained 
LDL subfractions of each subject were pooled and concentrated by a second run 
in a fixed-angle rotor (type TFT 45,6, Sorvall, Kontron Instruments, Milano, Italy) 
for 12 h at 36,000 rpm (156,000ga v), 20°C 
The EDTA/BHT-containing LDL subfractions from each person were dialyzed 
separately in the dark for 48 hours at 4°C against 3 I 0.01 M phosphate buffer (pH 
7 4), containing 0.16 M NaCI and 0 1 //g/ml chloramphenicol The buffer was 
made oxygen-free by vacuum degassing followed by purging with nitrogen, the 
buffer was changed after 24 hours. The EDTA/BHT-free LDL subfractions from the 
plasma of each subject were filtered through a 0 45-//m filter and then used for 
oxidation study immediately 
Oxidation of Low Density Lipoprotein Subfractions 
The oxidation experiments were performed essentially as described by Esterbauer 
et al. (30). The EDTA/BHT-free dialyzed LDL subfractions were diluted with the 
dialysis buffer to a final concentration of 0 25 mg/ml. Oxidation was initiated by 
addition of freshly prepared 1.66 μΜ CuCI2 solution. The kinetics of the oxidation 
of LDL subfractions was determined by monitoring the change in the 234-nm 
absorbance at 37°C on a Beekman Model 25 UV spectrophotometer equipped with 
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a four-position automatic sample changer. The absorbance curves of the three LDL 
subfractions from each subject were determined in parallel. The initial absorbance 
at 234 nm was set to zero, and the increase in absorbance was then recorded 
every 3 minutes for 4 hours. The change in absorbance at 234 nm versus time was 
divided into three consecutive phases, that is, a lag phase, a propagation phase, 
and a decomposition phase (Fig. 1). 
The lag time was defined as the interval between the intercept of the tangent of 
the slope of the curve with the time-scale axis, expressed in minutes. As shown 
in Figure 1, the lag time for LDL3 in this subject was 76.5 minutes. The maximal 
rate of oxidation, calculated from the slope of the absorbance curve during the 
propagation phase, was expressed in Aabsorbance/min. As lipid hydroperoxides 
rapidly accumulate during the propagation phase indicating that their rate of 
formation is much higher than their rate of degradation to aldehydes and other 
234-nm-absorbing oxidation products (31), the molar absorptivity of conjugated 
dienes (e 234 = 29,500 l/mol/cm) was used to express the maximal rate of 
oxidation as nanomoles of dienes formed per minute per milligram of LDL protein 
subfraction. The maximal increase in absorbance was read from the absorbance 
curve as the difference in absorbance found at the beginning of the decomposition 
phase minus the absorbance found at the start of the lag phase. With this value, 
the total amount of conjugated dienes (in nanomoles) formed per milligram of LDL 
protein could be calculated in the same way as described above for the maximal 
rate of oxidation. The absorbance profiles of the LDL subfractions appeared 
reproducible on repeated analysis of freshly isolated plasma, obtained from 2 
different subjects, with an interval of 2 months (coefficient of variation (CV) < 5% 
for the three parameters derived from the absorbance curves). 
Agarose Gel Electrophoresis and Sodium Dodecyl Sulfate-Polyacrylamide Gel 
Electrophoresis 
Agarose gel electrophoresis was performed at pH 8.6 in a barbital buffer using the 
Beekman Paragon system (Beekman Instruments, lnc.)(32). The eventual 
degradation of apo B-100 in the LDL subfractions was studied by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis using 3%/4% discontinuous Polyacryl-
amide disc gels as described earlier (33). 
Vitamin E Measurement 
In native and oxidized LDL subfractions, vitamin E concentrations were measured 
on a high-performance liquid chromatography (HPLC) Spectra Physics Model 8800 
(Spectra Physics, Eindhoven, The Netherlands) with fluorescence detection 
essentially as described previously (34). BHT (4.4//g/ml) and EDTA (1 mg/ml) were 
added to the native samples to prevent oxidation. Samples were stored at -20°C 
for less than 3 weeks. For extraction of vitamin E, 0.2 ml LDL subfraction was 
vortex mixed with 2 ml acetone and 2 ml petroleum ether (40-60°C). The organic 
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phase was then removed by pipet, followed by two extractions of the aqueous 
phase with 2 ml petroleum ether. The pooled organic phase was evaporated to 
dryness under a stream of nitrogen. The samples were dissolved in 0 4 ml 
methanol and injected into the Chromatograph. A ChromSep column, packed with 
Sphensorb ODS 5 (chrompack, Middelburg, The Netherlands) was used. The f low 
rate was 0.4 ml/mm with 9 8 % methanol as the mobile phase. Fluorescence was 
measured with a fluorescence spectrophotometer (Applied Biosystems, Maarssen, 
The Netherlands). The excitation wavelength was set at 288 nm, and the emitted 
fluorescence was measured at 340 nm The chromatogram results were quantified 
by peak heights using an external standard for vitamin E. 
Assay of Fatty Acids in LDL Subfractions 
LDL subfractions, stored for 6 weeks at -20°C in the presence of BHT (4 4 /yg/ml) 
and EDTA (1 mg/ml), were saponified by mixing 0.4 ml of each LDL subfraction 
with 1 6 ml 0 3 M NaOH in 9 0 % ethanol (vol/vol), followed by incubation at 37°C 
for 1 hour. To 0.4 ml of the mixture, diluted to 0.8 ml with Millipore-water 
(Millipore Corp., Ettenleur, The Netherlands), 50 μ\ 3 7 % HCl was added Fatty 
acids were extracted twice by vortex mixing with 2 ml n-hexane. The pooled 
organic phase was evaporated to dryness under a stream of nitrogen. The residue 
was dissolved in 100 μ\ ethanol containing 400 //mol/l heptadecanoic acid as an 
internal standard. Denvatization to 4-nitrophenylhydrazides was performed as 
described (35). Briefly, to 100 μ\ of the ethanolic mixture of LDL subfraction 
sample, 200 μ\ of a 20 mM solution of 4-nitrophenylhydrazine hydrochloride in 
25% ethanol and 400 μ\ of an ethanol solution containing 125 mM 1-ethyl-3-(3-
dimethylaminopropyDcarbodiimide hydrochloride and 1 5% pyridine were added, 
and the mixture was heated at 60°C for 20 minutes To the resulting mixture of 
hydrazides, 0.2 ml 0.5 M Tris (pH 10.0) and 2 ml n-hexane were added. After 
vortexing for 30 seconds and centrifugaron at 1,500g for 5 minutes, the n-hexane 
layer was taken and evaporated under a stream of nitrogen at room temperature 
This procedure was repeated twice. The residue was dissolved in 800 μ\ 100% 
methanol, and a 2-μ\ aliquot was injected into the Chromatograph Fatty acids were 
measured on an HPLC Spectra Physics Model 8800 with spectrophotometric 
detection. A ChromSep column was used, which was packed with Chromspher C8 
(2x10-cm, chrompack) to achieve the separation of the fatty acids. Using a mixture 
of 8 0 % acetonitnle and 2 0 % water (vol/vol) as a mobile phase and after 
adjustment to pH 4.5 with sulfuric acid, peak absorbances at 390 nm were 
registrated on a spectrophotometer (model SP 8450, Spectra Physics) at a f low 
rate of 0.25 ml/mm. The chromatogram results were quantified by peak heights 
using the internal standard of heptadecanoic acid. 
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Analytical Methods 
Total cholesterol (TC), unestenfied (free) cholesterol (FC), phospholipids (PL), and 
triglycerides (TG) were measured by commercially available enzymatic reagents 
(Boehringer-Mannheim, Mannheim, F.R.G., Nos. 237574, 310328, 691844; and 
No. 6639, Sera Pak, Miles, Italy, respectively). The protein content of the LDL 
subfractions was determined by the method of Lowry et al (36). From these data, 
the mean ratio of cholesterol (FC + cholesterol moiety of cholesteryl ester [CE; » 
0.59 χ weight of CE]) to protein was calculated. HDL cholesterol was determined 
in whole plasma by the polyethylene glycol 6000 method (37). LDL cholesterol 
was calculated with the Friedewald formula (38). 
STATISTICAL ANALYSIS 
The influence of the LDL subfractions on lag time was analyzed with a two-way 
analysis of variance (ANOVA). The dependent variable was the lag time, and the 
independent variables were subjects and LDL subfractions The same model was 
used to analyze the influence of the LDL subfractions on 1) the maximal rate of 
oxidation, 2) the amount of conjugated dienes, 3) the vitamin E concentration, 4) 
the fatty acid concentrations, and 5) the relative amounts of FC, CE, PL, TG and 
protein in the LDL subfractions Differences in the mean value of the lag time, the 
maximal rate of oxidation, the amount of conjugated dienes, the vitamin E 
concentration, the fatty acid concentrations, and the amounts of FC, CE, PL, TG, 
and protein among the LDL subfractions were tested for significance by Tukey's 
studentized range test Therefore, Tukey's test was used as a contrast test 
additional to the ANOVA. 
To investigate the relation of vitamin E (milligrams per gram of LDL protein) with 
lag time, the rate of oxidation, and the amount of conjugated dienes, this variable 
was added as a covanable to the above-mentioned models, together with all 
possible two-variable interaction terms (three-way analysis of covanance 
[ANCOVA]). The statistically insignificant interaction terms were deleted from the 
model. The same procedure was used to determine the relation of the chemical 
composition data (FC, CE, PL, TG, and protein) and the fatty acid concentrations 
of the 3 LDL subfractions with the lag time, the rate of oxidation, and the amount 
of conjugated dienes. 
Pearson's correlation coefficients were computed to determine correlations 
between plasma lipoproteins, that is, TC, TG, LDL cholesterol, HDL cholesterol, 
and the mean lag time, the mean rate of oxidation, the mean amount of conjugated 
dienes, and the mean vitamin E concentration for all three LDL subfractions 
The statistical analyses were performed with procedures available in the Statistical 
Analysis System software package (SAS Institute Inc., Cary, N.C.). 
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RESULTS 
Low Density Lipoprotein Subfraction Pattern 
Three LDL subfractions were observed, separated by a clear interface, after density 
gradient ultracentrifugation of the plasma from each subject: the very light LDL1, 
the light LDL2, and the heavy LDL3 (LDL1 d = 1.030-1.033 g/ml; LDL2 d = 1.033-
1.040 g/ml; and LDL3 d = 1.040-1.045 g/ml). The subfractions were isolated by 
aspiration and were used for the oxidation experiments. 
Physicochemical Characteristics of LDL Subfractions 
The analysis of the chemical composition data of the LDL subfractions revealed 
significant differences in FC (ANOVA, p < 0 . 0 0 1 ) , CE (ANOVA, p < 0 . 0 1 ) , PL 
(ANOVA, p < 0 . 0 0 1 ) , and protein (ANOVA, p < 0 . 0 0 1 ) content among some of the 
LDL subfractions. The TG content did not differ significantly among the LDL 
subfractions. The relative content of FC, CE, and PL decreased and that of protein 
increased with increasing density, although not all differences were statistically 
significant (Table 1). Except for TG, LDL1 and LDL3 differed significantly in all 
constituents. For CE, PL, and protein, LDL2 was different from LDL3. For FC, LDL2 
was different from LDL1 (Tukey, p < 0 . 0 5 ) . Mean values are presented in Table 1. 
The mean ratio of cholesterol (i.e., FC plus cholesterol moiety of CE [ = 0.59 χ 
weight of CE]) to protein was 1.46 ± 0 . 2 1 , 1.31 ± 0.20, and 0.99 ± 0.11 for 
LDL1, LDL2, and LDL3, respectively. This ratio was used to convert LDL protein 
concentration to LDL cholesterol concentration for each LDL subfraction in the 
vitamin E assay and in the calculation of the fatty acid concentrations of the LDL 
subfractions to correct for differences in cholesterol content among LDL sub-
fractions. 
Vitamin E 
Per gram of LDL protein, a significant influence of the native LDL subfractions was 
found on the vitamin E concentration (ANOVA, p < 0 . 0 5 ) . LDL3 contained 
significantly less vitamin E (milligrams per gram of LDL protein) than did either 
LDL1 or LDL2 (Tukey, p < 0 . 0 5 ) . LDL1 did not differ significantly from LDL2 in the 
concentration of vitamin E (Table 1). When corrected for the differences in 
cholesterol content among LDL subfractions, no significant difference in vitamin E 
concentration (milligrams per gram of LDL cholesterol) among the three LDL 
subfractions was found (ANOVA, p > 0 . 0 5 , Table 1). After 4 hours of oxidation, 
no detectable amounts of vitamin E were present in the LDL subfractions. 
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Fatty Acids 
Because of technical errors, data from only eight subjects were available for the 
analysis of the fatty acid concentrations in the LDL subfractions. In all three LDL 
subfractions, approximately 5 0 % of the total fatty acids consisted of PUFAs The 
main PUFAs were hnoleic acid (18:2, 70%) and arachidonic acid ( 2 0 4 , 30%) 
(Table 1 ). Per gram of LDL protein, no significant differences in the concentrations 
of the fatty acids among LDL subfractions were found. However, when corrected 
for the differences in cholesterol content among the LDL subfractions, significant 
differences in total fatty acid concentration and total PUFA concentration among 
the LDL subfractions were found (ANOVA, ρ < 0.001) The total fatty acid and 
PUFA concentrations (μιτιοΙ per gram of LDL cholesterol) were significantly higher 
in LDL3 than in either LDL1 or LDL2 (Tukey, p < 0 . 0 5 ) LDL1 and LDL2 did not 
differ significantly in the concentrations of total fatty acids and PUFAs (Table 1) 
ANOVA of each individual fatty acid (¿/mol per gram of LDL cholesterol) revealed 
significant differences (p<0.01) in the concentrations of mynstic acid (14 0), 
palmitic acid (160) , stearic acid (18 0), oleic acid (18:1), linoleic acid (18 2), and 
arachidonic acid (20 4) among LDL subfractions. For all individual fatty acids, the 
concentration in LDL3 (μπηοΙ per gram of LDL cholesterol) was significantly higher 
than in either LDL1 or LDL2 (Tukey, p < 0 05). No significant differences were 
found between LDL1 and LDL2 in the concentration of each individual fatty acid 
(Table 1) Furthermore, it was found that the total PUFA concentration (jumol per 
milligram of vitamin E) differed significantly among LDL subfractions (ANOVA, 
p < 0 01). The total PUFA concentration (//mol per milligram of vitamin E) was 
significantly higher in LDL3 than in LDL1 (Tukey, p < 0 05). LDL1-LDL2 and LDL2-
LDL3 values did not differ significantly The higher PUFA concentration m LDL3 
could be explained by the significantly higher concentration of hnoleic acid (//mol 
per milligram of vitamin E) in LDL3 compared with LDL1 (Tukey, p < 0 05, Table 
1 ) The total fatty acid concentration (//mol per milligram of vitamin E) did not differ 
significantly among LDL subfractions (ANOVA, p > 0 05, Table 1) 
Continuous Monitoring of Oxidation of LDL Subfractions 
Differences in absorbance curves among LDL1, LDL2, and LDL3 were found in all 
subjects. Representative absorbance curves of the three LDL subfractions of one 
subject are shown in Figure 1. 
The curve of LDL1 was situated below that for LDL3 in all subjects (n = 11 ) The 
curve of LDL2 was intermediate between that for LDL1 and LDL3 in most subjects 
(n = 8). In three subjects, the curves for LDL2 and LDL3 were similar The distance 
between the pairwise absorbance curves of LDL1, LDL2, and LDL3 differed among 
subjects, indicating that each subject had his/her own characteristic LDL 
subfraction absorbance profile The absorbance curves were divided into three 
consecutive phases, that is, a lag phase, a propagation phase, and a decomposition 
phase (Figure 1) 
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TABLE 1 Chemical composition, vitamin E content, and fatty acid content in low density lipopro 
tem subfractions, before oxidation 
LDL1 LDL2 LDL3 
Physicochemical variable ln= 11) 
Density range lrj/ml) 
Cholesteryl ester (%| 
Triglycerides (%l 
Free cholesterol (%) 
Phospholipids (%) 
Protein (%) 
Ratio chol/prot 
Vit E (mg/e LDL ρ) 
Vit E (mg/g LDL с) 
1 0 3 0 1 033 
39 61 ± 2 90 
4 46 ± 1 14 
10 80 ± 1 17" 
21 31 ± 1 33 
23 82 ± 2 98 
1 46 ± 0 21 
4 53 ± 0 95 
3 06 ± 0 39 
Fatty acid content (цтоі/д LDL cholesterol, η = 
14 0 
1 6 0 
1 8 0 
18 1 
18 2 
20 4 
Total FAS 
Total PUF As 
76 18 ± 23 30 
4 4 0 63 ± 92 43 
139 35 ± 33 84 
376 10 ± 77 16 
782 69 + 157 54 
282 72 ± 61 59 
2097 66 ± 400 27 
1065 41 ± 210 83 
1 0 3 3 · 1 0 4 0 
39 49 ± 3 82 
4 29 ± 1 59 
9 85 ± 1 22 
20 61 ± 1 62 
25 76 ± 2 74 
1 3 1 ± 0 20 
4 66 ± 0 65 
3 46 ± 0 69 
-8) 
83 93 ± 34 63 
4 8 4 19 ± 156 30 
155 76 ± 54 43 
3 8 0 19 ± 111 20 
897 86 ± 230 27 
272 02 ± 59 90 
2273 95 ± 572 50 
1169 88 ± 278 57 
1 0 4 0 1 045 
35 0 3 ± 4 2 1 " 
5 71 ± 2 55 
9 38 ± 1 23 
19 27 ± 0 9 7 ' 
30 62 ± 1 8 5 ' 
0 99 ± 0 11 
3 73 ± 0 9 8 ' 
3 81 ± 1 02 
110 02 ± 39 72" 
636 63 ± 96 8 7 ' 
204 45 ± 37 36" 
550 46 ± 84 12" 
1140 08 ± 232 35* 
363 80 ± 75 25" 
3005 44 ± 473 67" 
1503 88 ± 288 7 1 " 
Fatty acid content frmol/mg vitamin Ε, η-81 
1 4 0 
1 6 0 
1 8 0 
18 1 
18 2 
20 4 
Total FAs 
Total PUFAs 
22 59 ± 7 21 
131 30 ± 28 12 
41 82 ± 9 46 
122 21 + 36 0 0 
232 73 ± 50 12 
79 30 ± 18 13 
629 97 ± 126 72 
312 03 ± 63 94 
24 18 ± 8 04 
142 47 ± 43 28 
45 44 ± 13 85 
112 51 ± 3 7 0 4 
255 59 ± 66 59 
79 37 ± 9 83 
659 57 ± 159 98 
334 96 ± 73 26 
28 12 ± 13 46 
152 93 ± 44 55 
48 14 ± 16 40 
131 43 ± 37 88 
319 0 0 ± 71 05" 
95 35 ± 28 13 
774 97 ± 202 79 
4 1 4 36 ± 96 33 c 
Values (except for density) are mean ± SD LDL, low density lipoprotein, FAs, fatty acids, PUFAs, 
polyunsaturated fatty acids, chol/prot, cholesterol to protein ratio, Vit E, vitamin E, LDL ρ, LDL 
protein, LDL с, LDL cholesterol " p < 0 05 versus LDL1 and LDL2, b p < 0 05 versus LDL2 and 
LDL3, e p < 0 05 versus LDL1 
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FIGURE 1 . Curve plot of oxidizability of three low density lipoprotein (LDL) subfractions in subject 1 
О 5 0 1 0 0 150 2 0 0 
lag phase propagation phase decomposition phase 
Kinetics of the oxidation process of the LDL subfractions was determined by measuring changes in 
absorbance (y-axisl at 2 3 4 nm every three minutes on an ultraviolet spectrophotometer LDL 
subfractions (0.25 mg/ml) in 0.01 M phosphate buffer, pH 7.4, 0.16 M NaCI, were supplemented with 
1.66 μΜ CuCI2 as pro-oxidant. D = LDL1, • = LDL2, V = LDL3. 
A highly significant difference in lag time among LDL subfractions was found 
(ANOVA, p < 0.001). The lag time of LDL1 was significantly longer than those for 
LDL2 and LDL3 (Tukey, ρ < 0.05). The difference in lag time between LDL2 and 
LDL3 did not reach statistical significance (Table 2). These results suggest a 
negative linear trend for the lag time with the LDL subfractions. To demonstrate 
this possible linear relation between lag time and LDL subfractions, the same 
models as mentioned in "Statistical Analysis" were used except that the variable 
LDL subfractions were defined as covariates (definition used: LDL1 : = 1, LDL2: = 2, 
LDL3: = 3) instead of class variables. Indeed, a negative linear relation between the 
LDL subfractions and lag time was found (regression coefficient = -8.50 ± 1.78 
min per g/ml, p < 0 . 0 0 1 ) . 
Three-way ANCOVA models were applied to determine the influence of the vitamin 
E concentration, the total fatty acid and PUFA concentrations, and the relative 
amounts of FC, CE, TG, PL, and protein in the LDL subfractions on lag time. Only 
the amount of FC (percent of LDL dry mass) contributed significantly to the 
explanation of the difference in lag time among LDL subfractions. The estimated 
regression coefficient for FC in the model was 4.94 ± 2 . 3 1 , p < 0.05. 
The maximal rate of oxidation among LDL subfractions differed significantly 
(ANOVA, p < 0 . 0 0 1 ) . The maximal rate of oxidation of LDL3 was significantly 
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higher than that for LDL1 (Tukey, p < 0 . 0 5 ) . The maximal rate of oxidation for LDL2 
was intermediate between those for LDL1 and LDL3. The differences between 
LDL1-LDL2 and LDL2-LDL3 did not reach statistical significance (Table 2). The 
suggested positive trend was confirmed by linear regression analysis, which 
showed a significant positive linear relation between the rate of oxidation and the 
LDL subfractions (regression coefficient = 0.46 ± 0 06 nmol dienes/mm/mg LDL 
per g/ml, p < 0 . 0 0 1 ) . 
Three-way ANCOVA models revealed that the chemical composition data for FC, 
CE, TG, and PL in the LDL subfractions, the vitamin E concentration, and total fatty 
acid and PUFA concentrations in the LDL subfractions had no significant influence 
on the oxidation rate. Only the amount of protein (percent of LDL dry mass) in the 
LDL subfractions contributed significantly to the model (regression coefficient = 
0.097 ± 0.038, p < 0 05) 
The amount of conjugated dienes formed per milligram of LDL protein subfraction 
differed significantly among LDL subfractions (ANOVA, p < 0 . 0 0 1 ) After 4 hours 
of oxidation, the amount of conjugated dienes formed per milligram protein of LDL1 
was significantly lower than in either LDL2 or LDL3 (Tukey, ρ < 0.05) The 
concentration of conjugated dienes in LDL2 and LDL3 did not differ significantly 
(Table 2). Linear regression analysis showed a significant positive relation between 
LDL subfractions and the amount of dienes formed per milligram of LDL protein 
after 4 hours of oxidation (regression coefficient = 9 24 ± 1 42 nmol dienes/mg 
LDL per g/ml, p < 0 001). 
Of the chemical composition data (FC, CE, TG, PL, and protein), the vitamin E 
concentration, and the total fatty acid and PUFA concentrations, only the amount 
of protein (percent of LDL dry mass) in the LDL subfractions related significantly 
to the amount of dienes formed in the LDL subfractions (three-way ANCOVA, 
regression coefficient= 2 94 ± 0.70, p < 0 001). 
No significant correlations between mean lag time, mean rate of oxidation, mean 
amount of conjugated dienes over all three LDL subfractions, and TC, TG, LDL 
cholesterol, and HDL cholesterol were found (Pearson) 
TABLE 2 Characteristics of absorbance curves during oxidation of low density lipoprotein 
subfractions 
LDL subfraction 
LDL1 
LDL2 
LDL3 
Lag phase 
(lag time [mm]) 
86 35 ± 23 54* 
71 17 ± 17 82 
69 35 ± 16 15 
Propagation phase 
(rate of oxidation 
[nmol dienes/mm/mg LDL)) 
3 69 ± 0 67" 
4 11 ± 0 72 
4 61 ± 0 96 
Decomposition phase 
(amount of dienes 
[nmol dienes/mg LDL)) 
197 42 ± 16 0 4 ' 
204 46 ± 12 03 
215 89 + 1 6 0 8 
Values are reported as mean ± SD, n = 11 LDL, low density lipoprotein 
" p < 0 05 versus LDL2 and LDL3, ь p < 0 05 versus LDL3 
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DISCUSSION 
By means of single spin density gradient ultracentrifugation, three LDL 
subfractions, very light LDL1, light LDL2, and heavy LDL3, were detected and 
isolated from normolipidemic plasma. Each subject (n = 11) had his/her own LDL 
subfraction pattern that was characterized by the distribution of LDL among the 
three LDL subfractions. These LDL subfractions differed in chemical composition 
as shown in Table 1. The relative content of FC, CE, and PL decreased and that of 
protein increased with increasing density. A preponderance of small, dense LDL 
particles has been associated with a threefold increased risk of myocardial 
infarction, independent of age, sex, and relative weight (12). Also in patients with 
hyperapobetalipoproteinemia, there is an increase of the heavy LDL3 subfraction 
in plasma and an increased risk of atherosclerosis (10,11,39). However, the reason 
for the suggested higher atherogenicity of LDL3 is not yet clear. 
The biological modification of LDL seems to play an important role in the 
development of atherosclerosis (for review, see Reference 40). In vivo, the most 
likely process responsible for this modification of LDL is lipid peroxidation (41,42). 
In our study, we showed that the three LDL subfractions differed in their 
susceptibility to lipid peroxidation in vitro; the heavy LDL3 was less well protected 
against oxidative modification than the very light LDL1. Once oxidation started, 
LDL3 was more extensively modified in time than was LDL1. The oxidation profile 
of LDL2 was intermediate between those of LDL1 and LDL3 but did not differ 
significantly from the oxidation profile of LDL3 (Table 2). These findings provide 
a hypothetical but intriguing explanation for the suggested higher atherogenicity 
of the more dense LDL subfractions, that is, LDL2 and LDL3: they are more 
susceptible to oxidative modification and, therefore, contribute more to foam cell 
formation during atherogenesis than does the less dense LDL subfraction (LDL1). 
In our study, the kinetics of the lipid peroxidation process was determined by 
measuring the formation of 234-nm-absorbing oxidation products every three 
minutes on a UV spectrophotometer (30,31). This method requires only a small 
sample size and provides the opportunity to follow the lipid peroxidation process 
more continuously than does the measurement of malondialdehyde as a thiobar-
bituric acid-reactive substance (43). 
Several studies have shown that the initiation of lipid peroxidation in LDL is 
intimately linked with its antioxidant content (29,31,44). However, in our study the 
concentration of vitamin E (milligrams per gram LDL protein) in the LDL subfrac-
tions did not contribute to the explanation in the variation of the lag time among 
LDL subfractions (Table 2). Apparently, variable concentrations of additional 
antioxidants (lycopine, retinoids, carotenoids) in the different LDL subfractions may 
be responsible for their differences in lag time, in agreement with findings of others 
(45,46). In this study, it was found that the concentration of PUFAs per milligram 
of vitamin E was significantly higher in LDL3 than in LDL1 (Table 1 ), suggesting a 
relative deficiency of vitamin E in LDL3. This could help to explain the shorter lag 
time of LDL3 compared with that of LDL1. 
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Once the lipid peroxidation process started (propagation phase. Fig 1 ), the rate of 
oxidation for LDL3 was higher than that for LDL1 (Table 2), indicating that the 
breakdown of PUFAs in dense LDL3 was faster than that in very light LDL1 The 
main PUFAs in the LDL subfractions were linoleic acid (70%) and arachidonic acid 
(30%) (Table 1) These PUFAs differ in their susceptibility to oxidation, the more 
unsaturated the fatty acids, the more susceptible they are to oxidation (44,47) 
The concentration of arachidonic acid (//mol per gram of LDL cholesterol) in LDL3 
was significantly higher than in LDL1 (Table 1), which may explain the higher rate 
of oxidation of LDL3 compared with that of LDL1 After 4 h of oxidation, the 
amount of conjugated dienes formed in LDL3 was higher than m LDL1 (Table 2) 
As the concentration of PUFAs (//mol per gram of LDL cholesterol and //mol per 
milligram of vitamin E) in LDL3 was higher than in LDL1 (Table 1), presumably 
more PUFAs will be degraded to conjugated dienes and other oxidation products 
during the oxidation process of LDL3 than of LDL1 However, no significant 
influence of the fatty acid and PUFA concentrations on the rate of oxidation or the 
amount of conjugated dienes in the LDL subfractions was found This may be 
explained by the small number of subjects (n = 8) and the relatively large variation 
in the concentration of the fatty acids among the subjects, together with the fact 
that the total fatty acid and PUFA concentrations were calculated by adding the 
individual fatty acids 
In trying to explain the differences in response to oxidation among LDL 
subfractions, we also considered the different physicochemical properties of the 
LDL subfractions The LDL subfractions differ in chemical composition as shown 
in Table 1 Several studies have indicated that differences in chemical composition 
can lead to conformational changes of the LDL particle (48,49) This could 
theoretically result in a different exposure of the antioxidants and PUFAs in the LDL 
subfractions to attack by free radicals during the lipid peroxidation process A 
possible association between structural differences and susceptibility to oxidation 
was studied by investigating the influence of the chemical composition data on the 
parameters of the oxidation profile of the three LDL subfractions The shorter lag 
time of LDL3 may result from enhanced consumption of antioxidants due to the 
structure of the LDL3 particle Statistical analysis revealed that only the FC content 
of the LDL subfractions helped to explain the difference in lag time among the LDL 
subfractions The biologic relevance of this finding remains unclear Also, we found 
that the amount of protein in the LDL subfractions helped to explain the difference 
in oxidation rate and the amount of conjugated dienes formed after 4 h of oxidation 
among LDL subfractions Recently, new information on the conformation of apo 
В and on structural differences among human LDL subfractions have been reported 
(50) A change in the relative protein content among LDL subfractions may lead to 
conformational changes in the core of the subfractions (48,49), which could result 
in a more obvious exposure of arachidonic acid and other PUFAs in LDL3 to free 
radicals formed during the lipid peroxidation process, thus explaining the higher 
rate of oxidation of LDL3 and the higher concentration of conjugated dienes found 
in LDL3 after 4 h of oxidation, respectively 
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In addition to conjugated dienes, presumably more other reactive aldehydes may 
also be present in LDL3 than in LDL2 and LDL1. The aldehydic lipid peroxidation 
products react with the positively charged (-amino groups of lysine residues of apo 
В (28,51,52), resulting in a progressive increase of the negative charge of the 
modified LDL. Also, apo B-100 will be degraded to a certain extent during the 
oxidation process (21,53,54). Our results have shown that the oxidized LDL 
subfractions had an increased electrophoretic mobility on agarose gel and extensive 
degradation of apo B-100. These results confirm that, indeed, we were studying 
the phenomenon known as biologic modification of LDL. 
In summary, the differences in response to oxidation among LDL subfractions in 
one subject and among different subjects can be explained by the large variability 
in the fatty acid and antioxidant contents in the LDL subfractions and in the 
subjects. It is reasonable to assume that this reflects to some extent the different 
dietary conditions of the subjects studied. Also, specific different physicochemical 
and structural properties of the LDL subfractions can contribute to the differences 
in oxidizability among LDL subfractions. 
As reviewed by Steinberg et al. (40), oxidative modification is not likely to occur 
in the circulation. However, it may take place In the vascular wall, which is devoid 
of well-equipped antioxidant mechanisms. The small quantitative differences in the 
susceptibility to oxidation among LDL subfractions In vitro, as shown in this report, 
may have implications for the in vivo situation. In conditions like hyperapo-
betalipoproteinemia, the relatively faster oxidative modification of heavy LDL3 in 
the vessel wall, combined with the elevated plasma LDL3 concentration 
(6,10,11,39), may result in excessive uptake of the modified LDL3 by the 
scavenger receptor, converting macrophages into foam cells, the hallmark of 
atherosclerotic plaques. This hypothesis may explain the higher incidence of CAD 
in patients with hyperapobetalipoproteinemia. 
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METABOLISM OF LDL SUBFRACTIONS BY MACROPHAGES 
ABSTRACT 
The metabolism of three low density lipoprotein (LDL) subfractions by human 
monocyte-denved macrophages (HMDM) through the LDL receptor pathway was 
studied. The three LDL subfractions, very light LDL1, light LDL2, and heavy LDL3, 
were isolated from serum pools of normohpidemic subjects by density gradient 
ultracentrifugation. The LDL subfractions were shown to differ in molecular size 
and chemical composition but not in electrophoretic mobility on agarose gel Cell 
specific association, cell specific degradation, and stimulation of cholesteryl 
estenfication were determined in parallel after incubation of HMDM with increasing 
amounts of LDL protein of the three LDL subfractions The experiments were 
repeated four times with freshly prepared LDL subfractions 
Both the cell specific association and degradation increased more with increasing 
LDL protein concentration for LDL1 than for LDL3 ( p < 0 001). The results for LDL2 
were intermediate between those for LDL1 and LDL3 and differed significantly from 
both ( p < 0 05) For the stimulation of cholesteryl ester formation, the curves for 
LDL1 and LDL2 increased more with increasing LDL protein concentration than that 
for LDL3 ( p < 0 001), the results for LDL1 and LDL2 did not differ significantly from 
each other. These differences between LDL subfractions in cholesteryl 
estenfication were independent of the cholesterol content of the LDL subfractions 
The results show that LDL subfractions have different rates of LDL receptor-
mediated catabolismi by HMDM As HMDM play an important role in the formation 
of atherosclerotic plaques, the differences between the LDL subfractions in 
catabolism by HMDM, may result in differences in atherogenicity between LDL 
subfractions, isolated from normohpidemic subjects. 
INTRODUCTION 
The prominent feature of the early atherosclerotic lesion is the presence of lipid-
loaded foam cells in the subendothelial space of the vessel wall The foam cells are 
derived from human monocyte-denved macrophages (HMDM) Much research has 
been performed to determine the mechanisms that might explain how macrophages 
become lipid-loaded One involves the ability of HMDM to take up chemically or 
biologically modified LDL via the scavenger receptor (1) A suggested alternative 
mechanism leading to foam cell formation is the uptake of native LDL through the 
LDL receptor (apo B/E receptor) (2-7), usually, this receptor is effectively regulated 
to prevent excess cellular cholesterol accumulation (8) However, recently, it has 
been shown that metabolic stimulation of HMDM by microbial and immunological 
products (2,3,6), as well as by platelet and arterial wall cells secretory products 
(4,5), induces a marked stimulation of the LDL receptor activity with excessive 
uptake of native LDL, leading to foam cell formation in vitro. The uptake of native 
LDL through the LDL receptor pathway in activated HMDM therefore provides an 
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alternative mechanism to stimulate cholesteryl ester synthesis, that is, foam cell 
formation, in macrophages. 
LDL, however, is not a homogeneous macromolecule LDL particles differ in terms 
of particle size and composition (9-14) Epidemiological and case-control studies 
have shown that a predominance of small and dense LDL particles is associated 
with an increased risk of coronary heart disease (10,15-18). LDL subfractions also 
differ in their binding to the LDL receptor on both Hep G2 cells (19), fibroblasts 
(20), and U-937 monocyte-like cells (21), suggesting a difference in atherogenic 
potential between LDL subfractions. 
In the present report, the possible difference in atherogenicity between LDL 
subfractions was studied more directly by determining the rates of LDL receptor-
mediated catabolism of LDL subfractions by HMDM, as these cells play a crucial 
role in the development of atherosclerosis 
Single spin density gradient ultracentnfugation was used to isolate three LDL 
subfractions, very light LDL1, light LDL2, and dense LDL3, from sera of 
normolipidemic subjects (14,19). Within a single experiment, the differences in 
effect of the three LDL subfractions, LDL1, LDL2, and LDL3, on cell association, 
cell degradation, and cholesterol estenfication in human monocyte-denved 
macrophages, in response to incubation with increasing amounts of LDL protein 
and LDL cholesterol was determined 
MATERIALS AND METHODS 
Experimental Protocol 
LDL subfractions, isolated from serum pools, were characterized and assayed in 
HMDM in parallel for association, degradation, and cholesterol estenfication In 
total, four experiments were performed For each experiment, three LDL subfrac-
tions were isolated freshly from serum pools (19,20), consisting of sera from 4-5 
healthy normolipidemic subjects, who had fasted overnight Approximately half of 
the sera were obtained from females. All subjects had a family history free from 
hyperlipoproteinemia and premature atherosclerosis, and did not use any 
medication Serum was isolated within 2 h after sampling and pooled Levels of 
total serum cholesterol, serum triglycerides, HDL cholesterol, and LDL cholesterol 
in the four pools studied ranged from 4 75-4.89 mmol/l, 0 86-1 23 mmol/l, 1 3 1 -
1.67 mmol/l and 2.63-3 15 mmol/l, respectively. 
LDL Subfractionation 
Isolation of LDL subfractions was performed by density gradient ultracentnfugation 
(14,19), with some slight modifications to increase the distance between the LDL 
subfractions, in order to facilitate the isolation of the various subfractions by 
aspiration, as described previously (19) To prevent oxidation during 
ultracentnfugation, the density solutions were supplemented wi th 
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ethylenediaminotetraacetic acid (EDTA, 0.1 g/l). After ultracentrifugation, three 
LDL subfractions (LDL1 d = 1.030-1.033 g/ml, LDL2, d = 1.033-1.040 g/ml, LDL3, 
d = 1.040-1.045 g/ml) were visible as distinct bands in the middle of the tubes. 
The LDL subfractions were then carefully isolated, pooled, and concentrated as 
described (19), followed by dialyzing overnight against a saline solution containing 
5 mg/l of gentamycine and 0.1 g/l of EDTA (19). In the in vitro experiments, EDTA 
interference was eliminated for by addition of 10 μ\ of an 1 : 1 (v/v) mixture of 
CaCI2 (5 mmol/l) and MgCI2 (5 mmol/l) per 100 μ\ of the LDL subfraction solution. 
Separation of Cells 
Monocytes were isolated, as descibed previously, with the use of cell scatter 
monitored counterflow centrifugation (22). Briefly, mononuclear cells were 
obtained from buffy coats of healthy volunteers and isolated by centrifugation in 
Percoli (Pharmacia, Uppsala, Sweden) (σ= 1.075 g/ml) at 4°C. Monocytes were 
purified from mononuclear cells with counterflow centrifugation, monitored by 
continuous f low cytometry. Monocyte fractions were over 9 5 % pure (evaluated 
in cytocentrifuge preparations after staining for non-specific esterase and with 
May-Griinwald-Giemsma), and viability was more than 9 8 % , as assessed by trypan 
blue dye exclusion. The isolated monocyte fractions contained between 80 and 
120 χ 10 e cells. 
Cell Culture 
The isolated monocytes were resuspended in RPMI 1640 medium containing 10% 
(v/v) fetal calf serum, penicillin (100 U/ml), streptomycine (100 //g/ml), and L-
glutamine (2 mmol/l) at a final concentration of 1 χ 10 e cells/ml. One ml aliquots 
of the cell suspension were dispersed into each plastic petri dish (10 χ 35mm) and 
then incubated in a humidified C0 2 (5%) incubator at 37°C. After one hour, each 
dish was washed twice with 1 ml of RPMI 1640 medium without serum, to 
remove the last nonadherent lymfocytes. The adhering cells (98-99% monocytes) 
were incubated at 37°C in 1 ml of RPMI 1640 medium, containing 2 0 % whole 
human serum, penicillin (100 U/ml), streptomycine (100 //g/ml), and L-glutamine 
(2 mmol/l). The medium was aspirated and replaced with fresh medium of the 
same composition every other day. On day 6, after washing the dishes twice with 
1 ml of RPMI 1640 without serum, the cells were incubated with 1 ml of fresh 
medium, containing lipoprotein-deficient serum (LPDS) (isolated from the pooled 
serum of healthy subjects by ultracentrifugation at 160,000 g a v , d = 1.225 g/ml for 
46 h, final concentration 5 mg of protein/ml). All four experiments were started on 
day 7, after the cells had grown for 20 h in the presence of LPDS-containing 
medium; the LDL receptor activity is then maximally expressed (23,24). 
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The LDL subfractions were labelled with Na125l (Amersham International 
Amersham, Bucks, UK) using the method of McFarlane (25), essentially a; 
described by Bilheimer et al. (26). The iodinated LDL subfractions were dialyzec 
overnight against 5 I of saline containing 5 mg/l gentamycin and 0.1 g of EDTA pe 
liter at pH 7.5. Specific activities for the iodinated LDL subfractions varied betweer 
75 and 210 cpm/ng of protein. In all preparations, the trichloroacetic acid anc 
isopropanol precipitability of LDL radioactivity were greater than 99% and 90% 
respectively. Less than 5% of the radiolabel was extractable by chloroform 
methanol. All the iodinated and non-iodinated LDL subfraction preparations wen 
sterilized by passage through a 0.45 //m millipore filter and stored at 4°C, unti 
use, within 15 h. 
Assays of Cell Association and Proteolytic Degradation of 125I-LDL Subfractions 
On the day of the experiment (=day 7), the LPDS containing medium wa: 
removed, the cell layer washed with RPMI 1640 without additives, and the cell; 
incubated with increasing amounts of protein (0, 10, 30, and 80¿/g/ml) from eacl 
of the 125l-labelled LDL subfractions in 1 ml LPDS medium. After 5 h of incubation 
the media were harvested and the proteolytic degradation of 125l-native LDl 
subfractions was measured by assaying the amount of 125l-labeled trichloroacetic 
acid soluble (non-iodide) material formed by the cells and excreted into the culture 
medium, as described before (27). After removal of the medium, the cells wert 
cooled to 4°C, extensively washed and dissolved in 0.2 N NaOH. The cell 
associated radioactivity (i.e., bound and internalized radioactivity) was quantitatec 
(27) and the cellular protein was determined by the method of Lowry et al. (28) 
Non-specifically associated and degraded 12SI-LDL were determined in triplicate a 
LDL protein concentration of 10 ¿/g/ml and 30 //g/ml in the presence of 300 anc 
500//g/ml unlabeled LDL subfractions, respectively. In all experiments performed 
each value represents the mean of quadruplicate incubations. The results wen 
expressed as ng of HMDM associated and degraded 125I-LDL per mg of cell protein 
Incorporation of 14C-oleate into Cholesteryl Esters 
The extent of incorporation of 14C-oleate in cholesteryl esters was determined a: 
described by others (19,29). Essentially, cells were incubated for 6 h in the 
presence of increasing amounts of protein (0, 5, 20, and 70 //g/ml) of each of th< 
LDL subfractions in 1 ml LPDS medium with 10 μ\ of a sodiumt^CJoleate-albumii 
stock solution (19). The incorporation of radiolabeled oleate into cholesteryl oleati 
was determined after the separation of lipids by thin layer chromatography (19) 
For the three experiments performed, the recovery of the internal standar« 
averaged 65.1 ± 6.5 %. After extraction of the lipids from the dishes, eel 
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(28). In all three experiments performed, each value represents the mean of 
triplicate incubations. The results were expressed as nmols of 14C-oleate 
incorporated in cholesteryl esters per mg of cell protein. 
Analytical Methods 
Total cholesterol, unestenfied cholesterol, phospholipids, and triglycerides were 
measured by enzymatic, commercially available reagents (Boehrmger-Mannheim, 
FRG, cat.no. 237574, 310328, 691844, and Sera Pak, Miles, Italy cat no 6399, 
respectively) The protein content of the LDL subfractions was determined by the 
method of Lowry et al (28). From these data the mean ratio of cholesterol (free 
cholesterol + cholesterol moiety of cholesteryl ester { » 0.59 χ weight of 
cholesteryl ester}) to protein was calculated. HDL cholesterol was determined in 
whole plasma by the polyethylene glycol 6000 method (30) LDL cholesterol was 
calculated with the Friedewald formula (31). 
Agarose Gel Electrophoresis, Gradient Gel Electrophoresis, and SDS-Polyacrylamide 
Gel Electrophoresis 
Agarose gel electrophoresis was carried out at pH 8.6 in a barbital buffer using the 
Beekman Paragon system (Beekman Instruments, Ine )(32) For gradient gel 
electrophoresis, commercially available 2-16% Polyacrylamide gels were used 
(Pharmacia, Uppsala, Sweden, cat. no. 19-1264-01) (9). To check for possible 
degradation of apo B-100 in the LDL subfractions after the isolation procedure, 
sodium dodecyl sulfate Polyacrylamide gel electrophoresis was performed using 
3%/4% discontinuous Polyacrylamide disc gels (33) 
STATISTICAL ANALYSIS 
Statistical analysis were carried out by methods cited previously (19) In short, the 
values obtained for the cholesteryl estenfication as a function of both LDL protein 
and LDL cholesterol were approximated by response curves modelled as a square 
root function, that is, chol.^ß.j 'VLDL-protein, in which the parameter (Ì,, depends 
on the experiment (ι = 1,2,3,4) and LDL subfractions (j = LDL1, LDL2, LDL3) The 
differences in response curves, depending on LDL subfractions, were tested by 
means of covanance analysis, in which the cholesteryl estenfication was the 
dependent variable, the square root from LDL protein the independent regression 
variable, and the LDL subfraction (3 levels) and the experiment (4 levels) the 
independent class variables. The interaction between experiment and LDL 
subfraction was also included in the model. In the covanance analysis model, no 
intercept was allowed for LDL subfraction. 
The cell specific association and degradation were calculated as described (19). 
The differences between the LDL subfractions, in the response curve of the cell 
75 
CHAPTER 4 
specific association and degradation to the LDL protein, were analyzed with a 
covariance analysis, comparable to the one used for the cholesterol esterification. 
So, the dose-response curves of the LDL subfractions were approximated by curve 
fitting modelling procedures. A square root function appeared to be best in 
modelling the dose-response curves, as this function reflects the fact that HMDM 
have been shown to take up and degrade native LDL, even when the cells have 
been cultured in the presence of levels of lipoprotein cholesterol that would be 
expected to repress fully the LDL receptor in skin fibroblasts (34). So, the 
assumption of being out of saturation on the intervals of LDL protein and LDL 
cholesterol concentration used, is valid for the cell specific association and 
degradation. For the cholesteryl 14C-ester formation the validity of this assumption 
has not been demonstrated experimentally. However, for reasons of uniformity, 
similar analysis were performed for all three metabolic variables. 
The statistical analysis was performed with the GLM-procedure available in the 
Statistical Analysis System software package (SAS Institute Incorporated, Cary, 
NC). 
RESULTS 
LDL Subfraction Pattern 
After density gradient ultracentrifugation, three LDL subfractions could be seen, 
separated by a clear interface, in all four pooled sera: very light LDL1, light LDL2, 
and heavy LDL3. Density ranges (g/ml) and serum concentrations (mg LDL 
protein/dl) of the three LDL subtractions are given in Table 1. The distribution of 
apo В between LDL1, LDL2, and LDL3 was 33.0 ± 4 . 9 % , 38.9 ± 4.4% and 28.1 
± 1.8%, respectively. The subfractions were isolated by aspiration, pooled, and 
used for the in vitro studies with HMDM. 
TABLE 1. Density, relative chemical composition (% of dry massi, cholesterol to protein ratio, and 
serum concentration of LDL1, LDL2, and LDL3, isolated from serum pools of normolipidemic 
subjects. 
LDL1 LDL2 LDL3 
Density range (g/ml) 
Free cholesterol 
Phospholipids 
Protein 
Cholesteryl ester 
Triglycerides 
Ratio chol/prot' 
Serum concentration" 
1.030 - 1.033 
11.4 ± 0.6 
20.9 ± 0.8 
23 0 ± 1.5 
39.7 ± 2.0 
5.0 ± 0.7 
1.52 ± 0.14 
17.9 ± 1.3 
1.033 - 1.040 
11.2 ± 0.9 
20.3 ± 0.8 
24.7 ± 0.9 
39.1 ± 2.4 
4.7 ± 1.6 
1.39 ± 0.07 
23.7 ± 3.1 
1.040 - 1 0 4 5 
10.7 ± 0.9 
18.4 ± 0.9 
30.6 ± 1.2 
35.2 ± 1.5 
5.1 ± 0 5 
1.03 ± 0.06 
18.4 ± 4.2 
Results are given as mean ± SD, η = 4. * In this ratio cholesterol = free cholesterol + cholesterol 
moiety of cholesteryl ester { •> 0.59 χ weight of cholesteryl ester}. "Protein concentrations of the 
subfractions in mg per dl of serum. 
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Physicochemical Characteristics of LDL Subfractions 
The chemical composition data of the LDL subfractions are shown in Table 1. The 
relative content of free cholesterol, cholesteryl esters, and phospholipids decreased 
and that of protein increased with increasing density. The mean ratio choles­
terol/protein was 1.52, 1.39, and 1.03 for LDL1, LDL2, and LDL3, respectively. 
This ratio was used to convert LDL protein concentration to LDL cholesterol 
concentration for each LDL subfraction in the cholesteryl ester formation assay. By 
gradient gel electrophoresis, it was found that LDL3 was smaller than LDL2, and 
LDL2 smaller than LDL1 (Fig. 1). 
No visual differences could be detected in the mobility on agarose gel between the 
three native LDL subfractions. Compared to Cu2 +-oxidized LDL subfractions, the 
native subfractions moved much slower (Fig. 2). Furthermore, in the LDL 
subfractions after the isolation procedure, an intact apo B-100 band was visible in 
SDS Polyacrylamide gels. After oxidative modification of the LDL subfractions, 
extensive degradation of apo B-100 was found (Fig. 3). The results of both agarose 
and SDS gel electrophoresis indicate that the LDL subfractions were not oxidatively 
modified during the isolation procedure. 
FIGURE 1 . Polyacrylamide gradient gel electrophoresis of three LDL 
subfractions, LDL1 (1), LDL2 (2| and LDL3 (3), isolated from a 
serum pool of normolipidemic subjects. 
3 - 2 
FIGURE 2. Agarose gel electrophoresis of 
native and Cu2*-oxidized LDL subfractions 
(0-LDL). Native LDL subfractions were isola­
ted as described in the Method section. LDL 
subfractions were oxidized by incubating the 
LDL subfractions in PBS (0.25 g/l) in the 
presence of 1.66 μΜ CuCI2 as pro-oxidant. 1. 
LDL1; 2. LDL2; 3. LDL3; 4. 0-LDL1; 5.0-
LDL2; 6. 0-LDL3. The application sites are in­
dicated by the arrow. The cathode is at the 
top. 
•M 
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FIGURE 3. SDS-polyacrylamide gel 
electrophoresis of native and 
oxidized LDL1, LDL2, and LDL3. 
Native LDL subfractions were iso-
lated as described in the Method 
section. LDL subfractions were oxi-
dized as described in the legend of 
Fig. 2. The arrow indicates the in-
tact apo B-100 band in the native 
LDL subfractions. 1. LDL1; 2. 
LDL2; 3. LDL3; 4. 0-LDL1; 5. 0-
LDL2; 6. 0-LDL3. 
1 2 3 4 5 6 
Metabolic Studies 
The number of isolated monocytes in one experiment was not always sufficient to 
complete all three metabolic assays. Therefore, in experiment 1 only the 
degradation and cholesteryl ester formation assays were determined, and in 
experiment 3 only the association and degradation assays were performed, 
whereas in both experiment 2 and 4 all three metabolic events were assayed. 
The collected data were subjected to an overall biostatistical analysis, which 
include the interexperimental variation and tests for possible differences between 
the LDL subfractions in the course of the metabolic events. The dose-response 
curves were approximated by curve fitting modelling procedures and possible 
differences between the parameters of these curves were tested, using covariance 
analysis. The covariance analysis model, including only experiment 2 and 4, in 
which all three metabolic events were assayed, revealed that there were statistical 
significant differences for all three metabolic events between the LDL subfractions. 
The differences between the LDL subfractions within experiment 2 did not differ 
significantly from the differences between the subfractions found in experiment 4. 
The covariance analysis model was repeated, now including all four experiments. 
The results of the cell specific association, degradation, and induction of 
78 
METABOLISM OF LDL SUBFRACTIONS BY MACROPHAGES 
cholesteryl ester accumulation, when including all four experiments, did not differ 
significantly from those obtained from experiment 2 and 4 only. Again, a statistical 
significant difference for all three metabolic events between the LDL subfractions 
was found. The influence of the LDL subfractions on the response curve of the cell 
specific association, degradation, and induction of cholesteryl ester accumulation, 
did not differ significantly between the experiments. The results are presented for 
the maximal number of experiments of each metabolic event (Table 2). Represen-
tative estimated curves of the cell specific assocation, degradation, and cholesteryl 
ester formation are shown in Figure 4. 
To give an interpretation of the interaction between experiments and LDL 
subfractions, the differences between the parameters of the curves of the LDL 
subfractions in the four experiments, from the covariance analysis, for the cell 
specific association, cell specific degradation, and induction of cholesteryl ester 
accumulation, as a function of the concentration of LDL protein or LDL cholesterol, 
were also estimated and statistically tested (Table 3). 
Note that in spite of the variations between experiments, we were able to make 
generalizations by the application of the overall biostatistical analysis, in which all 
of the individual experimental data were preserved, while an overall effect is also 
presented. 
Cell Specific Association 
The analysis of covariance, including experiment 2, 3, and 4, revealed that for the 
cell specific association, the estimated curve for LDL1 was situated significantly 
above that for LDL3 (p<0.001) . The estimated curve for LDL2 was intermediate 
between that for LDL1 and LDL3 and differed significantly from both (p<0.01 and 
p<0 .05 , respectively). Thus, LDL1 gives a greater association to HMDM than 
LDL2, and LDL2 gives a greater association than LDL3. The estimated differences 
between the parameters of the curves of LDL1, LDL2, and LDL3 for the cell 
specific association and the levels of significance are indicated in Table 2. The 
differences between the LDL subfractions, within each experiment, are shown in 
Table 3. In all three experiments, LDL1 gives a higher association than LDL2, and 
in experiment 3 and 4, LDL2 gives a higher association than LDL3, reflecting the 
overall differences between the three LDL subfractions. Only the levels of 
significance differed between the experiments. In Fig.4A, the estimated curves for 
the cell specific association of LDL1, LDL2, and LDL3 in experiment 2 are shown. 
Cell Specific Degradation 
From the covariance analysis, including all 4 experiments, the overall curves of cell 
specific degradation for the LDL subfractions were estimated. It appeared that the 
estimated curve of LDL1 was situated significantly above that of LDL2 (p<0.05) 
and LDL3 (p<0.001) . The curve of LDL2 was situated significantly above that of 
LDL3 (p<0.001 ). Thus, LDL1 was degraded faster by HMDM than LDL2, and LDL2 
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was degraded faster than LDL3 (Table 2). In experiment 1, 2, and 4, the same 
differences between LDL subfraction degradation by HMDM was found as in the 
overall analysis, only the levels of significance differed (Table 3). 
Especially experiment 2, shown in Fig. 4B., reflects the overall significant 
differences (Table 3). 
Stimulation of Cholesteryl Ester Formation 
The covariance analysis, including experiment 1, 2, and 4, showed that per LDL 
particle intracellular cholesteryl ester formation was stimulated significantly more 
by LDL1 than by LDL3 (p<0.001) , and by LDL2 significantly more than by LDL3 
(p<0.001 ). LDL1 and LDL2 stimulated the cholesteryl ester formation to the same 
extent (Table 2). All experiments reflect the overall significant differences between 
the LDL subfractions. In addition, LDL1 and LDL2 differ significantly in experiment 
1 (Table 3). To exclude that differences between LDL subfractions were simply the 
result of their differences in cholesterol/protein ratio, cholesteryl ester formation 
was also analyzed as a function of LDL cholesterol concentration. The overall 
differences between the LDL subfractions were again significant (Table 2), and all 
experiments reflect the overall results (Table 3). The curves for the stimulation of 
the cholesterol esterlfication are shown for experiment 1, in Fig. 4C and 4D. 
TABLE 2. The estimated differences between the parameters of the curves of the LDL subfrac-
tions, from the covariance analysis, including the maximal number of experiments, for the cell 
specific association (exp 2, 3, 4), cell specific degradation (exp 1, 2, 3, 4) and cholesteryl ester 
formation (x10 2 , exp 1, 2, 4), in relation to LDL protein and LDL cholesterol concentrations. 
MODEL 1: 
LDL protein 
(//g/ml) 
LDL subfraction 
difference 
LDL1-LDL2 
LDL2-LDL3 
LDL1-LDL3 
Dependent variables 
Cell specific 
association 
4 93 ± 1.53° 
3.17 ± 1.47* 
8.09 ± 1.55= 
Cell specific 
degradation 
2.86 ± 1.36' 
5.42 ± 1.40= 
8.28 ± 1.36= 
Cholesteryl ester 
formation 
0.255 ± 0.151 
1.035 ± 0.150= 
1.290 ± 0.151 = 
MODEL 2 
LDL cholesterol 
(//g/ml) 
Cholesteryl ester 
formation 
0.151 ± 0.128 
0 802 ± 0.140= 
0 954 ± 0.138= 
The curves are parametrized with the function y = aVx, in which y = association (ng/mg cell pro-
tein), degradation (ng/mg cell protein), cholesteryl ester formation (nmol/mg cell protein), respec-
tively, and x = LDL protein (MODEL 1) and LDL cholesterol (MODEL 2), respectively, as described in 
Statistical Methods. LDL1-LDL2, LDL2-LDL3, LDL1-LDL3: differences between the estimated 
parameters of the curves of LDL1 and LDL2, LDL2 and LDL3, LDL1 and LDL3, respectively. 
' , 0.01 < p < 0 . 0 5 ; ", 0 0 0 1 < p < 0 . 0 1 ; =, p < 0 . 0 0 1 . 
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FIGURE 4. Estimated curves for the metabolic variables in the LDL receptor pathway measured in 
HMDM. 
association Ι ης / m g cell protei 
LDL proiem l u g / m l ) 
degradation (ng/mg cell protein) 
molester y I ester (or med [nmol/mg celi protein) • 
0 5 1 D 
0 20 ¿0 80 100 LDL-pro ie in l ,ug /ml 1 
90 100 
LOL cholesterol ι ^ ς / m l ) 
Cell specific association (A), cell specific degradation (B), and induction of cholesteryl ester formation 
(C,D) were assayed after incubation of HMDM with increasing amounts of LDL protein of three LDL 
subfractions, LDL1, LDL2, and LDL3. To preclude that differences between the estimated curves of the 
LDL subfractions are simply the result of their differences in the cholesterol/protein ratio, the estimated 
curves of the cholesteryl ester accumulation are shown both as a function of LDL protein (C), and as 
a function of LDL cholesterol (D). Indicated points represent the means of quadruplicate measurements 
in cell specific association (A, experiment 2), cell specific degradation IB, experiment 2), or triplicate 
measurements in cholesteryl ester formation ( C D , experiment 1). 
o, LDL1; D, LDL2; л, LDL3. Solid-, interrupted-, and dotted lines represent the response curves of 
LDL1, LDL2, and LDL3 to LDL protein or LDL cholesterol concentrations, respectively. The models used 
for estimation of the curves are described in Material and Methods, and in the legend of Table 2. 
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TABLE 3. The estimated differences between the parameters of the curves of the LDL subfractions 
in the four experiments, from the covariance analysis, for the cell specific association, cell specific 
degradation, and cholesteryl ester formation ( x 1 0 2 l , in human monocyte-denved macrophages, in 
relation to LDL protein and LDL cholesterol concentrations. 
Exp. 
1 
2 
3 
4 
MODEL 1: 
LDL protein 
(/yg/ml) 
LDL 
subfraction 
difference 
LDL1-LDL2 
LDL2-LDL3 
LDL1-LDL3 
LDL1-LDL2 
LDL2-LDL3 
LDL1-LDL3 
LDL1-LDL2 
LDL2-LDL3 
LDL1-LDL3 
LDL1-LDL2 
LDL2-LDL3 
LDL1-LDL3 
Cell specific 
association 
7.71 ± 2.60 b 
-0.33 ± 2.37 
7.38 ± 2.59" 
4.22 ± 2.92 
5.25 ± 2.92 
9.47 ± 3.04" 
2.85 ± 2.41 
4.58 ± 2.29' 
7.43 ± 2.39 b 
Dependent variables 
Cell specific 
degradation 
2.06 ± 2.81 
6.14 ± 3.22' 
8.20 ± 3.06" 
8.65 ± 2.35e 
8.70 ± 2 . 3 1 e 
17.35 ± 2 . 3 1 e 
-1.25 ± 3.01 
4.55 ± 2.91 
3.29 ± 3.13 
1.99 ± 2.65 
2.29 ± 2.66 
4.28 ± 2.29 
Cholesteryl ester 
formation 
0.979 ± 0 257= 
0.813 ± 0.257" 
1.792 ± 0.257= 
-0 435 ± 0.262 
1.180 ± 0.262 e 
0.745 ± 0.267" 
0.221 ± 0.263 
1.113 ± 0.262 e 
1.334 ± 0.259 e 
MODEL 2: 
LDL cholesterol 
U/g/ml) 
Cholesteryl ester 
formation 
0.743 ± 0.218" 
0.546 ± 0.240" 
1.290 ± 0.236 e 
-0.418 ± 0 222 
0.960 ± 0.245 e 
0.543 ± 0.245" 
0.129 ± 0.223 
0.901 ± 0 244 e 
1.029 ± 0.237 e 
Units of the concentrations of LDL protein and LDL cholesterol and the dependent variables are the 
same as indicated in Table 2; ",0.01 < p < 0 . 0 5 ; ", 0 001 < p < 0 . 0 1 ; e, p < 0 . 0 0 1 
DISCUSSION 
HMDM play an important role In the development of atherosclerotic plaques (1); 
recently, it has become apparent that macrophage activation may lead to 
accelerated cellular cholesteryl ester accumulation and foam cell formation in vitro, 
by increasing the native LDL uptake through the LDL receptor (2-7). As clinical 
studies have shown that small, dense LDL particles are associated with an 
increased risk of coronary heart disease (10, 15-18), we now determined whether 
the difference in atherogenicity between three discrete LDL subfractions could be 
due to differences in catabolism through the LDL receptor pathway by HMDM. To 
ensure that we indeed studied the interaction of native LDL subfractions with the 
LDL receptor, and not the uptake of modified LDL by the scavenger receptor, 
experiments were performed on day 7 in LPDS-containing medium; reportedly, LDL 
receptor activity is then maximally induced, and scavenger receptor activity 
repressed (23,24). Furthermore, isolated LDL subfractions did not show an 
increased electrophoretic mobility on agarose gel or degradation of apo В on SDS 
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gel, indicating that the LDL subfractions were not oxidatively modified during the 
isolation procedure. 
Our results clearly show that the more dense the LDL subfraction, the less its cell 
specific association, degradation, and stimulation of cholesteryl ester formation in 
HMDM. These conclusions hold when results are expressed as a function of LDL 
cholesterol concentration. 
Knight et al. (35) found that the LDL receptor on HMDM bound and degraded 
similar amounts of heavy and light LDL, with essentially the same affinities. Also 
in fibroblasts, Hep G2 cells, and in freshly isolated hepatocytes, the LDL receptor 
did not appear to distinguish between two LDL subfractions (36). However, further 
subfractionation of LDL in three or more subfractions, apparently enhances the 
discriminatory power of these in vitro tests; recently, differences in metabolic 
characteristics between several LDL subfractions, in different cell lines, were 
reported (19-21). Chapman et al. (21) showed that LDL subspecies, in the density 
range 1.030-1.036 g/ml, bound with higher affinity to the LDL receptor on U-937 
monocyte-like cells, and were degraded at greater rates, than the dense LDL 
subspecies, isolated in the density range 1.036-1.044 g/ml. Jaakola and colleagues 
(20) demonstrated that LDL II (d = 1.037-1.041 g/ml) displayed the highest binding 
affinity and degradation rates in cultured fibroblasts compared to LDL I (1.031-
1.037 g/ml) and LDL III (1.041-1.047 g/ml). The differences in density intervals, 
used to isolate LDL subfractions, complicates comparison between the different 
studies. Nevertheless, the overall conclusion from our findings is in agreement with 
that of Swinkels et al. (19) and Chapman et al. (21) by indicating that the 
association and degradation of the LDL subfractions decreases progressively with 
increasing density, going from 1.030 to 1.044 g/ml. 
In this study, LDL subfractions were isolated from serum pools, in analogy by 
Jaakola et al. (20) and Swinkels et al. (19), in order to obtain high concentrations 
of each LDL subfraction (3.5 mg), to be able to perform all 3 metabolic assays in 
one experiment. Although, reportedly, LDL particles are heterogeneous between 
subjects, we observed consistent results among 4 different serum pools (19), 
which appeared similar to those reported by Chapman et al., who based their 
results on sera isolated from three different subjects (21). 
Our results provide evidence that the greater fractional catabolic rate of light LDL 
in humans (37), can be explained by the preferential catabolism of very light LDL1 
through the LDL receptor pathway. This hypothesis is supported by the study of 
Teng et al., who have shown that antibodies to antigenic sites close to the binding 
region react more strongly with light than with heavy LDL (38). 
The reason for the reduced association and degradation of LDL3 is not clear (19). 
Modification of LDL size and composition by a number of pertubations, both in vivo 
and in vitro (39-43), have been shown to alter the receptor binding properties of 
the lipoprotein in vitro. Analogous to our findings with LDL3, a decreased 
association for the most dense LDL particles to the LDL receptor was found. These 
data suggest that even the small differences in lipid composition and/or diameter 
between the LDL subfractions, isolated from normolipidemic sera, result in 
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conformational changes of the LDL receptor domain of apolipoprotein B-100, 
leading to decreased affinity of LDL3 for the LDL receptor (44). 
When studying the metabolization of the LDL subfractions by cells, usually only 
the cell specific association and degradation assays are determined (20,21,35,36). 
In the present report, we also studied the capacity of the LDL subfractions to 
induce foam cell formation, by measuring their stimulation of the cholesteryl ester 
formation in HMDM, with the goal to investigate possible differences in atherogenic 
potential between LDL subfractions. The light, large LDL particles resulted in a 
greater accumulation of cholesteryl esters compared to the heavy, small LDL 
particles. So, assuming that overexpression of the LDL receptor still results in the 
enhanced uptake of the more buoyant LDL subfractions, LDL1 induces more foam 
cell formation in activated macrophages than LDL3, suggesting an enhanced 
atherogenicity of the light LDL particles. 
These results may seem contradictionary to the epidemiologic data, correlating 
coronary heart diseases with the small, dense LDL subfractions (10,15-18). 
However, for definite conclusions on the atherogenicity of the LDL subfractions, 
based on the in vitro studies, the occurrence of additional processes in vivo should 
be considered. Firstly, in vivo, the light LDL subfractions may be converted to the 
heavy LDL subfractions (45). Secondly, the in vitro decreased association and 
degradation of dense LDL3 by both the LDL receptor on HMDM, as presented in 
this report, and on Hep G2 cells (19), suggest an increased residence time for the 
dense LDL particles in the circulation. Thirdly, in vivo LDL subfractions may be 
modified by lipid peroxidation (1). We have shown that in vitro LDL3 is more 
susceptible to oxidative modification than LDL1 (46), as recently confirmed by 
others (47). This combination of the increased residence time and the enhanced 
oxidizability of LDL3 may render the dense LDL particles more susceptible to the 
uptake by the scavenger receptor, on HMDM, also resulting in foam cell formation 
(1). So, further elucidation of the relevance of the LDL receptor compared to the 
scavenger receptor in the generation of foam cells in vivo, may contribute to the 
unravelling of the mechanisms involved in the different atherogenic potentials 
between LDL subfractions. 
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ORAL CONTRACEPTIVES AND THE LDL SUBFRACTION PROFILE 
ABSTRACT 
To investigate the effect of low dose oral contraceptives on the low density 
lipoprotein (LDL) subfraction profile, the distribution of the LDL subfraction patterns 
in 20 premenopausal women on oral contraceptive (OC) therapy and 41 
premenopausal women not taking gonadal hormones was studied. The LDL 
subfraction patterns were identified by density gradient ultracentrifugation and 
each individual LDL subfraction pattern was characterized by the relative 
contribution of three major LDL subfractions: very light, LDL1; light, LDL2; and 
dense, LDL3 to total LDL. 
Serum lipid and lipoprotein levels were similar in OC users and controls, except for 
significantly higher triglyceride levels in OC users. As for the LDL subfraction 
patterns, among the OC users the mean relative contribution of dense LDL3 to total 
LDL was significantly higher than in the controls (32% ± 8% vs 2 6 % ± 13%, 
p < 0 . 0 5 ) , whereas the relative contribution of very light LDL1 to total LDL was 
significantly lower (27% ± 8% vs 3 4 % ± 10%, p < 0 . 0 1 ) , indicating a higher 
prevalence of the more dense LDL subfraction patterns among OC users. 
Furthermore, the distribution of the LDL subfraction patterns in OC users (27% 
LDL1, 41 % LDL2 and 3 2 % LDL3) resembled that of men (25% LDL1, 4 3 % LDL2, 
and 3 3 % LDL3, η = 59). Statistical analysis revealed that OC use was significantly 
associated with a more dense LDL subfraction pattern, characterized by an 
increased relative contribution of LDL3 ( + 6%, ρ < 0 . 0 5 ) and a decreased relative 
contribution of LDL1 (-6%, p < 0 . 0 1 ), even after correcting for the influence of lipid 
and lipoprotein levels, which in controls were shown to have a significant relation 
to LDL3 and LDL1, respectively. 
So, independent of the lipid and lipoprotein levels, low dose OC alter the 
composition of LDL to a heavy, dense LDL subfraction profile, which reportedly has 
been associated with an increased risk of atherosclerosis. 
INTRODUCTION 
Epidemiological studies have demonstrated a relationship between oral contracep­
tive (OC) use and coronary heart disease (CHD), especially among women over 35 
who smoke (1-3). Primarily the high-dose, progestin-dominant OCs have been 
suggested to be potentially atherogenic as they induce an atherogenic plasma lipid 
and lipoprotein profile, i.e. decreased high density lipoprotein cholesterol (HDL-C) 
levels and increased levels of low density lipoprotein cholesterol (LDL-C) (4-5). 
These alterations in plasma lipids depend on the estrogen (6) and progestin dosage 
and the androgenic activity of the progestins (7,8). With the introduction of the 
low dose OCs, containing lower doses of both estrogens and progestins and 
relatively less androgenic progestins, a reduction in adverse effect of OCs on 
plasma lipids and lipoproteins has been achieved (9), although not completely 
eliminated (9-12; for review, see Ref. 13). Thus, the association of OC use with 
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an atherogenic lipid and lipoprotein profile, and subsequent increased risk of 
atherosclerosis has been questioned for the newer low dose OCs. 
Recently, the risk of CHD has also been associated with low density lipoprotein 
(LDL) heterogeneity (14-17). Human LDL comprise discrete subfractions varying 
in size, density, and chemical composition (14-19), which may be influenced by 
genetic (20,21) and metabolic factors (22). A predominance of the small, more 
dense LDL subfraction has been associated with an increased risk of CHD (14-17). 
So, despite only minor or no changes in LDL cholesterol concentration, OCs may 
alter the composition of LDL to a more atherogenic LDL subfraction profile. The 
purpose of this study was to determine whether low dose OC use was associated 
with this dense, atherogenic LDL subfraction profile. 
MATERIALS AND METHODS 
Subjects 
In a family study, to investigate a possible genetic influence on LDL heterogeneity, 
61 apparently healthy menstruating women without history of CHD were screened. 
They were asked about their way of birth control; 20 women were on low dose OC 
therapy for at least one year; 9 subjects used Marvelon, a monophasic OC 
containing low doses of ethinylestradiol and desogestrel, a progestin with reduced 
androgenicity. Nine subjects used either a triphasic (Trigynon) or a monophasic 
(Microgynon 30, Stederil 30) OC formulation containing ethinylestradiol and 
levonorgestrel, a potent progestin with marked antiestrogenic and androgenic 
properties. Two subjects used OC with the less androgenic progestins 
norethisteron and lynestrenol, respectively (Table 1 ). The other 41 women had not 
used OCs for at least 3 months prior to this study. No other medication was used. 
Two groups of women matched for antropometrie measurements, smoking and 
exercise habits, alcohol use, and educational attainment, environmental factors 
which are known to influence lipid metabolism. After informed consent was 
obtained, overnight fasted blood of the subjects was sampled for determination of 
serum lipid and lipoprotein levels (23) and the LDL subfraction profile. 
Lipid and Lipoprotein Analysis 
The density of 2.9 ml of serum was raised to d = 1.019 g/ml by the addition of 0.5 
ml of a solution containing NaCI (11.42 g/l), KBr (133.48 g/l), and EDTA (0.1 g/l) 
(d = 1.10 g/ml). Very low density lipoprotein (VLDL) + intermediate density 
lipoprotein (IDL) were isolated by ultracentrifugation for 16 h at 40,000 rpm in an 
IEC B-60 fixed angle rotor 468 (Damon/IEC, Needham Heights, MA, USA) (24). 
LDL cholesterol (LDL-C) was calculated by subtraction of VLDL + IDL cholesterol 
and HDL cholesterol (HDL-C) from total serum cholesterol. HDL-C was determined 
in whole plasma by the polyethylene glycol 6000 method (25). Serum total 
cholesterol (TC) and triglycerides (TG) were determined by enzymatic, commercially 
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available reagents (Boehnnger-Mannheim, Mannheim, FRG, cat no 237574 and 
Sera Pak, Miles, Italy cat no. 6639, respectively) Apoprotein В in the d > 1 019 
g/ml fraction was determined in duplicate on two different plates by radial 
immunodiffusion in 0 8% (wt/vol) agarose in barbital buffer, pH 8 6 (26) The 
0 8% (wt/vol) agarose contained 0.3% (vol/vol) anti-apo В antiserum, raised in 
rabbits against human LDL (1.030-1 050 g/ml) When duplicates differed more 
than 10%, radial immunodiffusion was repeated 
Detection and Analysis of Low Density Lipoprotein Subfraction Patterns 
LDL subfractions were detected by single spin density gradient ultracentrifugation 
as described previously (27) After performing densitometric scanning of the slide 
of the tube with the LDL subfractions in triplicate, peak identification was 
performed (28). Usually, three LDL subfractions very light, LDL1 ; light, LDL2, and 
dense, LDL3, were visible as distinct bands in the tube corresponding with the 
three peaks, h i , h2, and h3, respectively, on the scan (Fig 1). Each subject 
showed her own specific LDL subfraction pattern characterized by the relative 
contribution of three major LDL subfractions, LDL1, LDL2, and LDL3, to total LDL 
To describe each of these individual LDL subfraction patterns, the mean peak 
heights ( h i , h2, h3) of the three major LDL subfractions (LDL1, LDL2, LDL3) on 
the three scans were used to calculate the relative contribution of each LDL 
subfraction to total LDL [total LDL (100%) = h i + h 2 + h3] So, the LDL subfrac­
tion patterns were described allowing the contribution of all three main LDL 
subfractions to total LDL to be taken into account, instead of only considering the 
major LDL subfraction (20,29) 
To be able to compare the LDL subfraction pattern distribution among ОС users 
and controls with other groups in the population, the LDL subfraction patterns were 
also determined among 78 men and 19 postmenopausal women, participating in 
the family study. 
STATISTICAL ANALYSIS 
For statistical hypothesis testing, serum TG and VLDL-TG were transformed 
logarithmically due to skewing of the distributions The summary statistics, 
however, were calculated without log transformation 
The two-sample t-test was used to determine differences between ОС users and 
controls with respect to age, body mass index (BMI), serum lipid, and lipoprotein 
levels, and the relative contribution of LDL1, LDL2, and LDL3 to total LDL. 
Pearson correlation coefficients were computed to determine the correlation 
between the variables serum TC, serum TG, LDL-C, HDL-C, VLDL-C, VLDL-TG, LDL 
apo В and the three LDL subfractions [LDL1 (%), LDL2 (%), LDL3 (%)] 
Stepwise multiple linear regression analyses including forward selection and 
backward elimination procedures were used to examine significant contributions 
of the independent variables (age, body mass index, serum TC, serum TG, LDL-C, 
93 
CHAPTER 5 
HDL-C, VLDL-C, VLDL-TG, and LDL apo B) to the prediction of each LDL 
subfraction in the control subjects. 
To examine whether OC use has a significant additional influence on the LDL 
subfraction pattern, independent of the lipid and lipoprotein levels, analyses of 
covariances were applied separately for each LDL subfraction, with the LDL 
subfraction as dependent variable and those lipid and lipoprotein levels relating 
significantly with this LDL subfraction, as found by the stepwise analysis, as 
covariates. Both the stepwise regression analyses and the analyses of covariances 
were performed only for those LDL subfractions which differed significantly 
between OC users and controls. 
Statistical analysis were performed with procedures from the Statistical Analysis 
System (SAS Institute Incorporated, Cary, NC). 
RESULTS 
The population studied included 61 premenopausal women, 20 OC users, and 41 
nonusers. All OC users were taking low dose OCs (Table 1). To exclude that the 
results on lipid, lipoprotein levels, and LDL subfraction patterns were influenced by 
the different OC formulations, the OC users were subdivided in levonorgestrel 
(n = 9) and desogestrel OC users (n = 9) (Table 1). 
TABLE 1. Composition of the oral contraceptives used by the subjects on oral contraceptive 
therapy (n = 20) 
Chemical composition 
Contraceptive Type Estrogen Dose (μς) Progestin Dose (¿ig) 
Marvelon 
Microgynon 30 
Stederil 30 
Trigynon 
Modicon 
Ministat 
9 
4 
2 
3 
1 
1 
Combined 
Combined 
Combined 
Triphasic 
Combined 
Combined 
Ethinyl estradiol 
Ethinyl estradiol 
Ethinyl estradiol 
Ethinyl estradiol 
Ethinyl estradiol 
Ethinyl estradiol 
30 
30 
30 
30,40 
35 
37.5 
Desogestrel 
Levonorgestrel 
Levonorgestrel 
Levonorgestrel 
Norethisteron 
Lynestrenol 
150 
150 
150 
50,75,125 
500 
750 
Lipid and Lipoprotein Levels 
Mean age, BMI, and lipid and lipoprotein levéis among the nonusers, OC users, and 
the two subgroups of OC users are shown in Table 2. Among the OC users the 
two subgroups did not differ in their anthropometric and lipid and lipoprotein 
characteristics (t-test, ρ > 0.05, Table 2). Furthermore, both the levonorgestrel and 
desogestrel OC users showed similar effects on serum lipid and lipoprotein levels 
compared to the control group (Table 2). So, all OC users were analyzed in a single 
group, also including the 2 subjects on Modicon and Ministat. Compared to 
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controls, the OC users were younger and had higher plasma triglyceride levels 
(Table 2). 
TABLE 2. Anthropometric measurements and plasma lipid and lipoprotein concentrations in 
controls (n = 41) and oral contraceptive (OC) users (n = 20), subdivided in desogestrel (n = 9) and 
levonorgestrel (n = 9) OC users 
Age (yrs) 
Body mass index (kg/rn3) 
Total cholesterol6 
Triglycerides" 
VLDL-cholesterolb 
VLDL-triglyceridesb 
HDL-cholesterol" 
LDL-cholesterol" 
LDL apo В (g/l) 
Desogestrel 
In = 9) 
29.3 ± 3.8 
20.7 ± 1.3 
4.98 ± 0.88 
1.08 ± 0.45 
0.53 ± 0.32 
0.59 ± 0.34 
1.66 ± 0.34 
2.79 ± 0.71 
1.28 ± 0.27 
ОС users 
Levonorgestrel 
(n = 9) 
29.7 ± 5.5 
21.8 ± 1.6 
4.61 ± 0.45 
1.04 ± 0.28 
0.45 ± 0.16 
0.53 ± 0.23 
1.66 ± 0.39 
2.50 ± 0.35 
1.16 ± 0.21 
Total 
(n = 20) 
29.4 ± 
21.4 ± 
4.68 ± 
1.03 ± 
0.48 ± 
0.55 ± 
1.64 ± 
2.56 ± 
1.20 ± 
4.7 
1.7 
0.75 
0.36 
0.25 
0.28 
0.34 
0.59 
0.25 
Controls 
(n = 41) 
33.6 ± 7.9" 
21.9 ± 2.4 
4.49 ± 0.61 
0.83 ± 0 . 3 0 ' 
0.40 ± 0.21 
0.45 ± 0.24 
1.57 ± 0.38 
2.53 ± 0.57 
1.10 ± 0.24 
Results are given as mean ± SD. " p < 0 . 0 5 versus total group of OC users (n = 20); 
ь
 Concentrations in mmol/liter. 
LDL Subfraction Pattern 
For each subject the LDL subfraction pattern was determined by the relative 
contribution of the three major LDL subfractions to total LDL, expressed as the 
relative peak heights of the observed LDL subfractions on the scans. A 
predominant heavy, dense LDL subfraction pattern, defined by a major peak of 
dense LDL3, was characterized by a high relative contribution of LDL3 to total LDL 
(Fig. 1, tube I and scan I), whereas in a predominant light LDL subfraction profile, 
with a major peak of very light LDL1, a high relative contribution of LDL1 to total 
LDL was found (Fig. 1, tube II and scan II). So, the more dense LDL subfraction 
profiles were characterized by increased relative contributions of LDL3 and 
decreased relative contributions of LDL1. 
Among OC users, both the levonorgestrel and desogestrel OC users had a LDL 
subfraction profile with a considerably higher mean relative contribution of LDL3 
and a lower mean relative contribution of LDL1 compared to the control group 
(Table 3). So, among both the levonorgestrel and the desogestrel OC users a more 
dense LDL subfraction profile was observed. As both the OC formulations were 
thus associated with a high prevalence of the dense LDL subfraction pattern, all OC 
users were analyzed as a single group, including the 2 subjects on Modicon and 
Ministat. 
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FIGURE 1 . Representative 
examples of a dense and 
buoyant low density lipoprotein 
(LDL) subfraction profile. 
y w 
Α L % 
A. LDL banding patterns after 
density gradient ultracentrif uga-
tion of the serum of one subject 
using oral contraceptives 
(tube I) and one control subject 
(tube II). In tube I, LDL2 and 
LDL3 contribute most to total 
LDL, reflecting a dense LDL 
subfraction pattern whereas in 
tube II, LDL1 and LDL2 are the 
predominant LDL subfractions, 
reflecting a buoyant LDL sub-
fraction pattern. B. Results of 
densitometric scanning of the 
slide of tube I and II shown in 
A. In scan I the highest peak is 
h3, corresponding with the 
main LDL subfraction, LDL3 (A, 
tube I). In scan II the highest 
peak is h i , the major LDL sub-
fraction being LDL1 (A, tube II). 
The peak heights were used to 
determine the relative contribu­
tion of the three LDL subfrac­
tions to total LDL. The dense 
LDL subfraction pattern was 
characterized by a high relative 
contribution of LDL3 to total 
LDL (scan I, 1 8 % LDL1, 3 7 % 
LDL2, and 4 5 % LDL3) whereas 
a more buoyant LDL subfraction 
pattern was represented by a 
high relative contribution of 
LDL1 to total LDL (scan II, 4 2 % 
LDL1, 3 6 % LDL2, and 2 2 % 
LDL3). 
Among the OC users the 
mean relative contribu­
tion of LDL3 to total LDL 
was significantly higher 
whereas the mean relati­
ve contribution of LDL1 LDL 1 
to total LDL was significantly lower compared to nonusers. No significant 
difference in the mean relative contribution of LDL2 to total LDL was found 
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between OC users and controls (Table 3). These results suggest a strong 
association of OC use with the more dense LDL subfraction patterns, independent 
of the OC formulation. 
The distribution of the LDL subfraction patterns was not only related to the use of 
OCs but also differed by gender, age, and in women, depending on hormonal 
status, as shown in Table 3. The prevalence of a more dense LDL subfraction 
pattern increased with age and was higher among men than in women. Strikingly, 
the LDL subfraction profile among OC users resembled that of men (Table 3). 
As the mean relative contribution of LDL2 did not differ significantly between OC 
users and controls, only LDL1 and LDL3 were considered in further statistical 
analyses. 
TABLE 3. Distribution of the low density lipoprotein (LDL) subfraction pattern by gender, age, and 
hormonal status in women. 
LDL subfraction pattern 
Subjects LDL1 |%) LDL2 (%) LDL3 (%) 
Premenopausal 
Controls n = 41 34 ± 10 4 0 ± 9 26 ± 13 
OC users' n = 20 27 ± 8" 41 ± 5 32 ± 8 b 
Levonorgestrel n = 9 27 ± 6 41 ± 5 31 ± 4 
Desogestrel n = 9 26 ± 10 42 ± 6 32 ± 11 
Postmenopausal 
age > 50 yrs η = 19 29 ± 8 45 ± 6 26 ± 6 
Male 
age 20-50 yrs η = 59 25 ± 11 43 ± 12 33 ± 18 
age > 50 yrs η = 19 20 ± 10 38 ± 1 5 41 ± 23 
The relative contribution of the three major LDL subfractions to total LDL is expressed as percenta­
ge of total LDL. ' OC users = oral contraceptive users, subdivided in levonorgestrel and desoges­
trel OC users; ь p < 0 . 0 5 versus controls. 
Interrelations between LDL subfractions and Lipid and Lipoprotein Levels 
Among nonusers, LDL1 was found to be negatively correlated with serum TG, 
VLDL-TG, and VLDL-C and positively correlated with HDL-C, TC, LDL-C, and LDL 
apoB, whereas LDL3 was positively correlated with serum TG, VLDL-TG, and 
VLDL-C and negatively correlated with HDL-C, TC, LDL-C, and LDL apoB (Table 4). 
Similar linear associations between LDL1 and LDL3 with lipid and lipoprotein levels 
were found among OC users but the correlations were not always significant (Table 
4). So, when the relative contribution of LDL1 decreased and that of LDL3 
increased, that is, when a more dense LDL subfraction profile was observed, a 
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more atherogenic lipoprotein profile was found with increased VLDL lipids and 
decreased HDL cholesterol levels. 
TABLE 4. Correlations of serum lipid and lipoprotein levels with LDL1 and LDL3, respectively, in 
oral contraceptive users (n = 20l and controls (n = 41) 
Total cholesterol" 
Triglycerides' 
VLDL cholesterol' 
VLDL-triglycerides' 
HDL cholesterol" 
LDL-cholesterol" 
LDL apoB (g/l) 
OC users 
0 39 
-0 40 
-0 27 
-0 23 
0 35 
0 41 
0 26 
LDL1 
Controls 
0 22 
0 7 1 " 
-0 65" 
0 75 b 
0 40" 
0 21 
0 05 
Both 
0 20 
0 65 b 
0 54" 
0 60" 
0 32" 
0 23 
0 03 
OC users 
0 6 1 " 
0 16 
0 07 
0 03 
0 20 
0 63" 
0 45" 
LDL3 
Controls 
0 24 
0 70" 
0 53" 
0 7 0 b 
0 07 
-0 4 1 " 
0 28 
Both 
-0 27" 
0 57" 
0 3 8 b 
0 53" 
-0 07 
-0 43" 
-0 25 
0C users = oral contraceptive users Pearson's correlation coefficient with LDL1 and LDL3, 
" Concentration in mmol/l, b p<0 05 
Because of the strong interrelations between lipid, lipoprotein levels, and the LDL 
subfractions, stepwise multiple regression analyses were performed in the control 
group to evaluate which lipids or lipoproteins (serum TC, serum TG, LDL-C, HDL-C, 
VLDL-C, VLDL-TG, and LDL apoB) contributed significantly to the prediction of 
LDL1 and LDL3, respectively Age and body mass index were also allowed to enter 
into the models. Both backward and forward stepwise analyses resulted in the 
same model; the best model for prediction of LDL1 appeared to include serum 
VLDL-TG and HDL-C (R2 = 0.66, p < 0 001) and that of LDL3 included VLDL-TG, 
VLDL-C, and LDL apoB (R2 = 0 64, ρ < 0 001 ) No other variables met the 0.05 level 
of significance for entering the models 
Covanance analyses revealed that OC use had a significant additional influence on 
both LDL1 and LDL3: the mean relative contribution of LDL1 (dependent variable) 
among OC users was 6% lower ( p < 0 01) than in controls, after correcting for 
HDL-C and VLDL-TG levels (covanates), whereas the mean relative contribution of 
LDL3 was 6% higher (p<0.01) among OC users compared to controls, after 
correcting for VLDL-C, VLDL-TG, and LDL apoB levels 
DISCUSSION 
The results of the present study show that low dose oral contraceptive use is 
strongly associated with the more dense LDL subfraction patterns, characterized 
by the increased relative contribution of dense LDL3 and decreased relative 
contribution of very light LDL1, independent of the OC formulation (Table 3) In 
fact, the distribution of the LDL subfraction patterns among women using OCs 
appeared to resemble that of men (Table 3), who have a much greater risk of 
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developing CHD than premenopausal women, not using OCs The mechanisms by 
which oral contraceptives apparently affect LDL density, directly or indirectly, 
remain to be elucidated One possible explanation may be that OC use influences 
the activity of several proteins and enzymes involved in LDL heterogeneity (30), 
like cholesteryl ester transfer protein (31 ), lipoprotein lipase and hepatic lipase (32) 
Recently, estrogens have been shown to inhibit hepatic lipase activity (33) The 
apparent contrast that both estrogen deficiency in menopause and estrogen 
administration in OC users are associated with the more dense LDL subfractions 
(34) suggests that the progestins in the OC formulation oppose the effect of 
estrogens with regard to their effect on the LDL subfraction pattern 
The strong association of the dense LDL subfraction profile with OC use may have 
implications for the atherogenic risk profile of OC users, reportedly, subjects with 
high serum concentrations of small and dense LDL particles have an increased risk 
of coronary heart disease (14-17) Austin et al (14) showed that their small, dense 
LDL subfraction pattern В, detected by gradient gel electrophoresis, was 
significantly associated with a threefold increased risk of myocardial infarction In 
two other studies CHD was associated with small LDL (15,17) and higher 
concentrations of small LDL were found in patients with CHD than in matched 
controls (16) There is also a predominance of small dense LDL particles with 
normal LDL concentrations in patients with familial combined hyperlipoproteinemia 
and hyperapobetalipoproteinemia, conditions with increased risk of CHD (35) 
Additionally, several studies have shown that, besides the increased risk of CHD, 
most subjects with a heavy LDL subfraction pattern also tend to have a high-risk 
lipid and lipoprotein profile, that is, relatively increased serum TG and decreased 
HDL-C levels (14,16,28,29). Our present results again show that the more dense 
LDL subfraction patterns in the controls were significantly correlated with 
decreased levels of HDL-C and increased serum VLDL-lipid levels The lipid and 
lipoprotein levels explained approximately 6 5 % of the variation in LDL1 (significant 
contributions of HDL-C and VLDL-TG levels) and LDL3 (significant contributions of 
VLDL-C, VLDL-TG, and LDL apoB) 
Thus, the question arises whether the dense LDL subfraction patterns, induced by 
OC use, will also have an enhanced atherogenic potential and, if so, whether this 
is independent from the associated atherogenic lipid and lipoprotein profile In the 
present study statistical analyses revealed that OC use was significantly associated 
with an increase in LDL3 ( + 6%) and a decrease in LDL1 (-6%), that is, a dense 
LDL subfraction pattern, even after correcting for those lipid and lipoprotein levels 
which have been associated with LDL3 and LDL1 among nonusers These results 
suggest that a dense LDL subfraction pattern is an independent risk factor for CHD 
Recently, the same results were reported for cynomolgus monkeys treated with 
OCs (36) Furthermore, the differing relations of the LDL subfraction pattern with 
lipid and lipoprotein levels between OC users and nonusers (Table 4) suggest that 
the characteristics of the LDL subfraction pattern distribution in OC users may not 
be exclusively determined by the same lipid and lipoproteins as found among 
controls As for the direct, atherogenic potentials of the dense LDL particles, we 
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recently showed that the dense LDL particles in healthy subjects were more 
susceptible to oxidative modification in vitro than very light LDL particles (37). This 
modification process enhances the atherogenic properties of the LDL particles (38). 
Furthermore, the dense LDL particles were shown to have an abnormal interaction 
with the LDL receptor on both Hep G2 cells (39) and human monocyte-derived 
macrophages (40), resulting in abnormal metabolisation of dense LDL, which may 
also render the dense particles more atherogenic (39,40). So, for more definite 
conclusions concerning the direct atherogenic potential of the dense LDL particles 
among OC users, additional information is required on physicochemical, oxidative, 
and metabolic properties of the dense LDL particles in women using OCs. 
In summary, our results indicate that despite only minor changes in lipid and 
lipoprotein levels, use of oral contraceptives is associated with changes in the 
composition of LDL, resulting in a more dense LDL subfraction profile. These 
results support the hypothesis that in OC users an increased risk of CHD could be 
attributable to the more dense LDL subfraction patterns, associated with OC use 
and independent of lipid and lipoprotein levels. 
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THE EFFECT OF SIMVASTATIN ON THE LDL SUBFRACTION PROFILE 
ABSTRACT 
The effect of simvastatin therapy on the LDL subfraction profile, using density 
gradient ultracentrifugation, was studied in 26 patients with familial 
hypercholesterolemia. Among the patients before treatment, the LDL subfraction 
profile consisted of 3 LDL subfractions, LDL1, LDL2, and LDL3, present in a 
relatively narrow density range (d = 1.030-1.045 g/ml), very similar to that reported 
among normolipidemic subjects. Simvastatin did not influence this LDL subfraction 
profile with respect to the number and density range of the LDL subfractions, and 
did not change the relative contribution of the 3 LDL subfractions (% mass) tototal 
LDL. So, simvastatin did not significantly alter LDL density. However, the 
composition of the isolated LDL subfractions did change after simvastatin 
treatment, as evidenced by the reversal towards normal of the increased 
cholesterol to protein ratio (mean 1.51 before vs 1.38 after therapy, p < 0 . 0 1 ; 
mean 1.36 among normolipidemic subjects). 
When the subjects were stratified by their plasma triglyceride levels or their change 
in plasma triglycerides during simvastatin therapy, a strong dependence of the LDL 
subfraction profile and its composition on plasma triglyceride levels was observed; 
increasing plasma triglyceride levels were associated with a more dense LDL 
subfraction profile, characterized by a high relative contribution of dense LDL3 to 
total LDL and changes in LDL composition, reflected by a relatively low cholesterol 
to protein ratio. 
Our results indicate that in patients with familial hypercholesterolemia (1) plasma 
triglyceride levels have an important role in determining the properties of LDL and 
(2) simvastatin therapy results in compositional changes of LDL, which may effect 
the intrinsic metabolic characteristics of LDL and thus Its atherogenic potential. 
INTRODUCTION 
Familial hypercholesterolemia (FH) is a relatively common inherited disorder, 
characterized by hypercholesterolemia with high plasma levels of low density 
lipoprotein (LDL), xanthomatosis, and accelerated atherosclerosis. This disease is 
perhaps the most convincing evidence that the concentration of LDL cholesterol 
in plasma is highly correlated to the incidence of coronary heart disease (CHD)(1 ). 
The 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase inhibitors offer 
an effective means of reducing the levels of plasma LDL in patients with 
hypercholesterolemia (2-4), by suppressing hepatic cholesterol synthesis and 
upregulating the number of hepatic LDL receptors (5,6). The reduction of LDL 
cholesterol has been associated with regression of atherosclerosis (7,8). In addition 
to the elevation of plasma LDL cholesterol levels, patients with FH reportedly have 
an altered LDL in terms of particle size, molecular mass, and chemical composition 
(9-11). 
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Plasma LDL is known to be heterogeneous and comprises discrete subfractions 
with distinct physical and chemical characteristics (12 17). The LDL subfractions 
also differ in their metabolic properties (18-20), indicating that specific LDL 
subfractions may be more atherogenic and contribute significantly more to the 
development of premature CHD than others (21-28) Hence, both LDL 
heterogeneity and LDL concentration are factors that may act together, 
contributing to an increased risk of CHD Therefore, in the present report we 
studied the effect of simvastatin treatment of FH patients on both plasma LDL 
cholesterol concentration and the density distribution and composition of the 
composite LDL subfractions 
PATIENTS AND METHODS 
Patients 
Twenty six patients with familial hypercholesterolemia (10 men and 16 women, 
mean age 42 years (range 17-65 years)), with plasma total cholesterol levels > 
7 00 mmol/l, LDL cholesterol levels > 5 00 mmol/l, and plasma triglyceride levels 
< 3 60 mmol/l, confirmed by repeated measurements, were included in the study 
All patients had a clinical presentation of heterozygous familial hypercholesterole 
mia (e g tendon xanthomas (η = 12), severe hypercholesterolemia (n = 26), and a 
family history of hypercholesterolemia with coronary heart disease (n = 22)) None 
of the patients had diabetes, liver, thyroid, or renal diseases and none took drugs 
known to affect lipid metabolism The participants discontinued all lipid-lowering 
medication at least 2 months before the start of the study, and all patients 
continued their standard lipid-lowering diet throughout the trial Other concomitant 
medication was maintained unchanged during the study Baseline plasma lipid 
values were measured at the end of this wash-out period Thereafter, the subjects 
were treated with simvastatin 40 mg daily during at least 3 months Informed 
consent was obtained. Simvastatin elicited no adverse side-effects and tolerance 
was excellent. Venous blood samples were collected after an overnight fast, in Na 
EDTA-contammg tubes, prior to and 3 months after treatment with simvastatin, for 
determination of lipid and lipoprotein levels, the LDL subfraction pattern, and the 
chemical composition of the isolated LDL subfractions For the evaluation of drug 
safety, serum enzyme activities (aspartate aminotransferase (ASAT), alanine 
aminotransferase (ALAT), creatine kinase (CK), and alkaline phosphatase (AP) were 
determined according to the clinical routine at the hospital All values remained 
within the normal range during treatment with simvastatin (ASAT<25 U/l, 
A L A T O O U/l, CK 24-117 U/l, AP 33-65 U/l) 
Reference values for the LDL subfraction pattern and composition from normo-
lipidemic subjects (n = 28) were obtained from earlier studies in our laboratory 
(15,19,20). 
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Detection and Analysis of Low Density Lipoprotein Subtraction Patterns 
LDL subfractions were detected by single spin density gradient ultracentrifugation 
as described previously (15,20). After ultracentrifugation, the 3 major LDL 
subfractions, very light LDL1 (d = 1.030-1.033 g/ml), light LDL2 (d = 1.033-1.040 
g/ml), and dense LDL3 (d = 1.040-1.045 g/ml) were visible as 3 distinct bands in 
the middle of the ultracentrifuge tube. Each subject showed his/her own LDL 
subfraction pattern, characterized by the relative contributions of the 3 major LDL 
subfractions to total LDL. The tube of each subject was placed in a specially 
designed rack and photographed (24). After densitometric scanning of the slide of 
the tube with the LDL subfractions, peak identification was performed by the LKB 
2190 GelScan program on an Apple Me computer as described (24). The LDL 
subfractions were then accurately isolated by aspiration with a rubber bulb pipet 
and the chemical composition was determined (20). The LDL mass of each 
subfraction was calculated by summing the contents of free and esterified 
cholesterol, triglycerides, phospholipids, and protein (mg/l). 
Plasma Lipid and Lipoprotein Assays 
The density of 2.9 ml of plasma was raised to d = 1.019 g/ml by the addition of 
0.5 ml of a solution containing NaCI (11.42 g/l), KBr (133.48 g/l), and EDTA (0.1 
g/l) (d = 1.10 g/ml). Very low density lipoprotein (VLDL) + intermediate density 
lipoprotein (IDL) were isolated by ultracentrifugation for 16 h at 40,000 rpm 
(165,000g) in an IEC B-60 fixed angle rotor no 468 (Damon/IEC). LDL cholesterol 
was calculated by subtraction of VLDL + IDL cholesterol and high density 
lipoprotein (HDL) cholesterol from total plasma cholesterol. HDL cholesterol was 
determined in whole plasma by the polyethylene glycol 6000 method (29). Total 
cholesterol (TC), unesterified (free) cholesterol (FC), phospholipids (PL) and 
triglycerides (TG) were determined by enzymatic, commercially available reagents 
(Boehringer-Mannheim, FRG, cat.no. 237574, 310328, 691844 and Sera Pak, 
Miles, Italy cat.no. 6639, respectively). The protein content of the LDL 
subfractions was determined by the method of Lowry et al. (30). From these data, 
the mean ratio of cholesterol (FC + cholesterol moiety of cholesteryl ester [CE; 
« 0 . 5 9 χ weight of CE]) to protein was calculated. Total LDL mass was 
approached by summing the LDL mass of the composite LDL subfractions. 
STATISTICAL ANALYSIS 
The Wilcoxon's signed-rank test was used to determine the significance of the 
changes in lipid and lipoprotein values, LDL composition, and distribution, observed 
after simvastatin treatment. Wilcoxon's test was used to assess the significance 
of the differences between different groups. 
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All results are expressed as mean values ± SD, unless otherwise stated Statistical 
analysis was performed with the STATISTIX software package (NH Analytical 
Software, St Paul, MN, USA). 
RESULTS 
Effect of Simvastatin on Lipid and Lipoprotein Levels 
Simvastatin therapy reduced the mean plasma levels of total cholesterol and LDL 
cholesterol by 3 0 % (p<0.001) and 36% (p<0.001) , respectively (Table 1). Mean 
plasma triglyceride levels fell by 12% (p = 0 09) and HDL cholesterol 
concentrations increased by 7% (p<0 05) No consistent effect of simvastatin on 
VLDL cholesterol and VLDL triglyceride levels was found. 
TABLE 1. Plasma lipid and lipoprotein levels in 26 subjects with heterozygous familial hypercholes 
terolemia, before and after simvastatin treatment 
BMI (kg/m2) 
Total cholesterol" 
LDL cholesterol' 
HDL cholesterol' 
Triglycerides' 
VLDL cholesterol' 
VLDL triglycerides" 
Before 
24 5 ± 2 8 
9 64 ± 1 54 
7 84 ± 1 51 
1 10 ± 0 29 
1 69 ± 0 65 
0 72 ± 0 37 
0 88 ± 0 45 
After 
24 8 ± 2 7 
6 77 ± 1 17c 
5 05 ± 1 17 ' 
1 18 ± 0 28" 
1 49 ± 0 81 
0 56 ± 0 61 
0 81 ± 0 68 
Change(%) 
-30% 
-36% 
+ 7% 
-12% 
-22% 
- 8 % 
* concentration in mmol/l, " 0 01 < p < 0 05 , c p < 0 001 versus before simvastatin therapy BMI 
body mass index, LDL = low density lipoprotein, HDL = high density lipoprotein, VLDL = very 
low density lipoprotein 
Effect of Simvastatin on the LDL Subfraction Pattern 
Qualitative changes in the LDL subfraction pattern 
In the plasma of the hypercholesterolemic patients, before therapy, three LDL 
subfraction bands, very light LDL1 (d = 1.030-1 033 g/ml), light LDL2 (1 033-
1.040 g/ml), and dense LDL3 (1 040-1.045 g/ml) were present in a relatively 
narrow density range. Both the number of LDL subfractions and the density range 
of the LDL subfraction profiles appeared similar to those reported previously for 
normohpidemic subjects (15,19,20). In 16 of the 26 patients, a light LDL 
subfraction profile was observed, with LDL2 being the major LDL subfraction, 
whereas in 10 subjects the dense LDL3 was predominant, resulting in a heavy LDL 
subfraction profile (Fig 1). 
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FIGURE 1 . Densitometrie scanning 
patterns of the low density lipoprotein 
(LDL) subfraction distribution based on 
density gradient ultracentrifugation of 
plasma. 
Representative changes in scanning 
patterns are shown for 3 subjects with 
heterozygous familial hypercholesterol-
emia, before (left scan) and after (right 
scan) simvastatin treatment. 
A. In two subjects a heavy LDL sub-
fraction profile, characterized by a pre-
dominant dense LDL3 peak, before 
simvastatin therapy, was replaced by 
a light LDL subfraction profile, with a 
predominant light LDL2 peak, after 
simvastatin therapy. 
B: In eight subjects, the change in ab-
sorbance profile was characterized by 
a relative increase in the LDL3 peak, 
whereas the LDL1 peak remained simi-
lar or diminished, reflecting a change 
to a more dense LDL subfraction pat-
tern. Among these subjects the mean 
plasma triglyceride level increased after 
simvastatin therapy (1.77 ± 0.59 
versus 2.15 ± 0.98, respectively). 
C. In twelve subjects, a relative 
increase of the LDL1 peak was obser-
ved, often associated with a decrease 
of the LDL3 peak, reflecting a lighter 
LDL subfraction pattern. In these sub-
jects, the plasma triglyceride levels 
dropped after simvastatin therapy 
(1 63 ± 0.72 versus 1.17 ± 0.55, 
p < 0 . 0 0 1 , respectively). 
Because of the inter-individual variation in LDL cholesterol levels and the significant reduction in LDL 
cholesterol after simvastatin treatment, the absolute absorbance of the curves was standardized. 
LDL 
Simvastatin therapy did not alter the number or density range of the LDL 
subfractions, whereas in only 2 subjects simvastatin therapy converted the main 
subfraction LDL3 into LDL2 (Fig. 1A). 
Further analysis of the densitometric scans revealed that in 20 subjects (77%) 
simvastatin treatment was associated with a disproportionate reduction of the peak 
heights of the different LDL subspecies, as evidenced by a change in the shape of 
the LDL subfraction profile (Fig. 1B,C). In 8 subjects, simvastatin treatment was 
associated with a shift towards a more dense LDL subfraction profile, reflected by 
an increase in the relative contribution of LDL3 to total LDL (Fig. 1B), whereas 
among 12 subjects the relative contribution of LDL1 and/or LDL2 to total LDL 
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increased, thus contributing to a lighter LDL subfraction profile after simvastatin 
treatment (Fig. 1С). 
Quantitative Changes in the LDL Subfraction Pattern 
To quantify the change in the relative contribution of each LDL subfraction to total 
LDL after simvastatin therapy, the mass of each LDL subfraction was calculated 
from its chemical composition data (mg/l) and expressed as percentage of total LDL 
(Table 2). A high inter-individual variability in the mass change of the various LDL 
subfractions was observed, consistent with the finding that in some subjects 
simvastatin therapy was associated with a shift towards a more dense LDL 
subfraction profile, whereas among other individuals a lighter LDL subfraction 
profile was observed (Fig. 1 ). The mean reduction in total LDL mass was 3 4 % 
(-2200 mg/l, p < 0 001), which appeared mainly due to a decrease in LDL2 mass 
(-1070 mg/l, p < 0 001), whereas the reduction in the mass of LDL1 and LDL3 was 
significantly less (-617 mg/l, p < 0 . 0 0 1 and -511 mg/l, p < 0 0 1 , respectively). 
However, the corresponding percentage reductions from baseline did not differ 
significantly among the subfractions, resulting in a similar distribution (%) of total 
LDL mass over the composite LDL subfractions, both before and after treatment 
(Table 2). 
TABLE 2 Mass of the low density lipoprotein subfractions, expressed in mg/l or as percentage of 
total LDL mass, in 26 subjects with familial heterozygous hypercholesterolemia before and after 
simvastatin treatment 
Before (mg/l) 
After (mg/ll 
Change (mg/l) 
Before (%) 
After (%) 
LDL1 
1863 ± 683 
1246 ± 445" 
-617 ± 475 
1-33%) 
27 4 ± 7 0 
27 5 ± 7 9 
LDL2 
2916 ± 1073 
1846 ± 685" 
1070 ± 8 6 4 ' 
( 37%) 
43 2 ± 12 3 
40 4 ± 10 7 
LDL3 
1792 ± 937 
1281 ± 628" 
511 ± 700 
( 29%) 
29 4 ± 16 1 
32 0 ± 16 2 
total LDL 
6483 ± 1491 
4283 ± 1094" 
-2200 ± 1 1 8 0 
I 34%) 
1 0 0 % 
1 0 0 % 
1
 0 001 < p < 0 0 1 , " p < 0 001 Before versus After, ' p < 0 05 versus LDL1 and LDL3 
Interrelations between Plasma Triglyceride Levels and the LDL Subfraction Pattern 
When the subjects were stratified by their plasma triglyceride levels ( T G < 1 ; 
1 . 0 < T G < 1 . 5 ; 1 . 5 < T G < 2 . 0 , 2 . 0 < T G < 4 . 0 mmol/l), it appeared that the LDL 
subfraction pattern distribution showed a strong dependence on plasma triglyceride 
levels, both before and after simvastatin therapy. As shown in Fig.2, among the 
patients after simvastatin administration, the relative contribution of LDL1 and 
LDL2 to total LDL mass decreased and that of LDL3 increased with increasing 
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plasma triglyceride levels. Similar results were obtained among the patients before 
simvastatin therapy (data not shown). 
FIGURE 2. The mean relative distribution of the three low density lipoprotein (LDL) subfractions over 
total LDL mass (100%) during simvastatin therapy, in relation to the plasma triglyceride levels 
% of total LDL mass 
LDL1 LDL2 LDL3 
^ B n = 10, plasma triglycerides (TG) < 1 mmol/l; И п = 6, 1.0< TG < 1 . 5 mmol/l; 
I | n = 4, 1.5< TG < 2 . 0 mmol/l; Щ Ц n = 6, 2 0 < TG < 4 . 0 mmol/l. 
Because of this marked influence of the plasma triglyceride concentration on the 
LDL subfraction pattern, the results were also analyzed by subgrouping the patients 
according to the plasma triglyceride change during simvastatin therapy (Table 3 
and 4). In 18 subjects, the plasma triglyceride levels decreased after treatment by 
an average of 2 8 % (Table 3). The LDL subfraction profile did not change in 6 
subjects whereas among 12 subjects a slight relative reduction in the LDL3 peak 
and a relative increase in the LDL1 peak was observed (Fig. 1С). However, 
quantitatively, the relative decrease in the mass of LDL3 and the relative increase 
in the mass of LDL1 did not reach statistical significance (Table 4). So, both before 
and after therapy, LDL was composed of approximately 2 9 % LDL1, 4 5 % LDL2, 
and 2 6 % LDL3 (Table 4). 
In those subjects (n = 8) in whom the plasma triglyceride concentration increased 
after treatment ( + 21.5%), the plasma VLDL lipid levels were higher and HDL 
cholesterol levels lower, both before and after therapy, compared to the subjects 
with decreasing plasma triglyceride levels. In addition, the increase in plasma 
triglyceride level was associated with a small but significant increase in the body 
mass index, whereas among the subjects with decreasing plasma triglyceride levels 
a stable body weight was observed (Table 3). Among all subjects with increasing 
plasma triglyceride levels (n = 8), the LDL subfraction profile showed a shift 
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towards a more dense LDL subfraction pattern, reflected by an increased relative 
contribution of LDL3 to total LDL (Fig 1B) Quantitatively, the relative reduction in 
LDL3 mass by 12% (-238 mg/l, ρ > 0.05) was significantly less than that of either 
LDL2(-45%,-1122 mg/l, p < 0 . 0 1 ) or LDL1 (-37%, -636 mg/l, p < 0 05)(Table 4). 
Hence, the relative mass contribution of LDL3 to total LDL increased significantly 
(37% to 4 6 % , ρ < 0 . 0 5 ) . Note that the mass of LDL3 was considerably higher 
among the subjects with increased plasma triglyceride levels, both before and after 
therapy, compared to the subjects with decreasing plasma triglyceride levels (Table 
4) 
TABLE 3 Plasma lipid and lipoprotein levels in subjects with heterozygous familial hypercholes 
terolemia, stratified by the triglyceride response (increase versus decrease), during simvastatin 
treatment 
BMI (kg/m2l 
Total Cholesterol' 
LDL-Cholesterol' 
HDL-Cholesterol" 
Triglyceride' 
VLDL Cholesterol' 
VLDL-Triglycende' 
TG decreased 
Before 
24 5 ± 3 0 4 
9 77 ± 1 70 
7 98 ± 1 58 
1 13 ± 0 31 
1 65 ± 0 69 
0 66 ± 0 32 
0 82 ± 0 48 
(n = 18) 
After 
24 7 ± 2 98 
6 73 ± 1 2 5 ' 
5 18 ± 1 22" 
1 21 ± 0 27 c 
1 19 ± 0 5 2 ' 
0 33 ± 0 2 0 ' 
0 51 ± 0 29" 
TG increased (r 
Before 
24 6 ± 1 86 
9 35 ± 1 13 
7 53 ± 1 37 
1 04 ± 0 24 
1 77 ± 0 59 
0 83 ± 0 47 
1 02 ± 0 39 
i = 8) 
After 
25 1 ± 1 7 7 ' 
6 87 ± 1 0 3 ' 
4 75 ± 1 0 7 ' 
1 13 ± 0 29 
2 15 ± 0 98" 
0 99 ± 0 88 
1 37 ± 0 85" 
' concentration in mmol/l, ' 0 0 5 < p < 0 1, c 0 01 <p<0 05, d 0 001 < p < 0 0 1 , ' p < 0 001 versus 
before therapy, BMI = body mass index 
Effect of Simvastatin Therapy on the Composition of the LDL Subfractions 
In general, going from LDL1 to LDL3, the relative content of free cholesterol (FC), 
cholesteryl ester (CE), and phospholipids (PL) decreased and that of protein (PROT) 
increased, both before and after treatment (Table 5). Consequently, the ratio of 
cholesterol to protein (chol/prot ratio) decreased going from LDL1 to LDL3. Among 
the untreated FH patients, the mean chol/prot ratio of all subfractions was 
approximately 1 0 % higher than in normolipidemic subjects (Table 5), reflecting an 
altered composition of LDL in FH patients The mean percent protein content of 
total LDL among FH patients, before simvastatin treatment, was significantly lower 
than that among normolipidemic controls (15,19,20) (23.9 vs 25.5, p < 0 05), 
reflecting the presence of less dense LDL among untreated FH subjects. 
After simvastatin therapy, the mean percentage CE content of all subfractions 
decreased significantly, whereas the mean percentage triglyceride (TG), PL, and 
PROT content of all subfractions tended to increase, although not always reaching 
statistical significance 
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TABLE 4. Mass of the LDL subfractions (expressed in mg/l or as percentage of total LDL) in 
subjects with heterozygous familial hypercholesterolemia, stratified by the triglyceride response 
(increase versus decrease) during simvastatin treatment 
TG decreased (n 
Before (mg/l) 
After (mg/l) 
Change (mg/l) 
Before |%) 
After (%) 
TG increased (n = 
Before (mg/l) 
After (mg/l) 
Change (mg/l) 
Before (%) 
After (%) 
= 18) 
LDL1 
1911 ± 579 
1301 ± 4 5 1 ' 
-610 ± 408 
(-32%) 
28.4 ± 5.4 
29.2 ± 6.4 
= 8) 
LDL1 
1740 ± 945 
1104 ± 4 2 8 ' 
-636 ± 655 
(-37%) 
25.0 ± 9.7 
23.8 ± 9.9 
LDL2 
3071 ± 1076 
2021 ± 687 c 
-1050 ± 934 
(-34%) 
45.4 ± 1 1 . 5 
45.1 ± 7.4 
LDL2 
2518 ± 1035 
1396 ± 4 6 0 " 
-1122 ± 714 
(-45%) 
38.2 ± 13.1 
29.9 ± 9.7' 
LDL3 
1691 ± 888 
1074 ± 3 4 7 b 
-617 ± 722 
(-36%) 
26.2 ± 13.2 
25.7 ± 10.0 
LDL3 
2052 ± 1080 
1814 ± 8 8 0 
-238 ± 615 
(-12%) 
36.8 ± 20.3 
46.3 ± 1 9 . Г 
total LDL 
6673 ± 1466 
4 3 9 6 ± 1043= 
-2277 ± 1 1 3 3 
(-34%) 
1 0 0 % 
1 0 0 % 
total LDL 
6055 ± 1555 
4 0 2 9 ± 1234 b 
-2026 ± 1 1 3 0 
(-33%) 
1 0 0 % 
1 0 0 % 
• 0.01 < p < 0 . 0 5 ; " 0.001 < p < 0 . 0 1 ; c p < 0 . 0 0 1 Before versus After; LDL = low density lipopro­
tein. 
The FC content did not change consistently in all LDL subfractions. Consequently, 
the chol/prot ratio decreased significantly in all LDL subfractions, after simvastatin 
therapy and even reverted towards normal (Table 5). So, simvastatin therapy 
resulted in compositional changes of the LDL subfractions, reflected by the 
decreased chol/prot ratio of all LDL subfractions. 
By analyzing the subjects according to their change in plasma triglyceride levels, 
after simvastatin therapy, similar results were obtained; after simvastatin therapy, 
a significant decrease of the ratio chol/prot was observed in both groups (Table 5). 
Among the subjects with increasing plasma triglyceride levels, during simvastatin 
therapy, LDL showed a lower chol/prot ratio than the subjects with decreasing 
plasma triglyceride levels, suggesting that the compositional changes in LDL were 
dependent on plasma triglyceride levels. 
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TABLE 5. Chemical composition (percent of dry mass) of the main low density lipoprotein subfrac­
tions present in 26 heterozygous familial hypercholesterolemia sub|ects, before (A) and after (B) 
simvastatin treatment. 
FC (%) 
CE (%) 
TG (%) 
PL (%) 
Prot (%) 
C/P (η = 26) 
C/P (π = 18) 
C/P (η = 8) 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
REF 
A 
В 
A 
В 
LDL1 
10.04 ± 1.22 
9.95 ± 0.92 
44.38 ± 3.96" 
4 0 . 9 0 ± 3.35 
5.26 ± 1.70" 
5.91 ± 2.31 
19.02 ± 4.85 
21.16 ± 2.98 
21.30 ± 3.04" 
22.09 ± 1.65 
1.74 ± 0.35" 
1.55 ± 0.17 
1.60 ± 0.20 
1.80 ± 0.37" 
1.60 ± 0.16 
1.63 ± 0.30" 
1.44 ± 0.14 
LDL2 
8.93 ± 0.70 
9.04 ± 0 68 
45.08 ± 2.84' 
42.61 ± 2.27 
4.48 ± 1.56 
4 70 ± 1 41 
18.44 ± 2.77 b 
20.33 ± 3.13 
23.07 ± 2.20 
23.33 ± 1.85 
1.56 ± 0.20" 
1.48 ± 0.14 
1.41 ± 0.18 
1.57 ± 0.19 
1.52 ± 0 12 
1.52 ± 0.24" 
1.35 ± 0.12 
LDL3 
8.65 ± 0.94 
8.44 ± 0.98 
41.50 ± 3.02 е 
38.88 ± 2.81 
4.22 ± 1.11' 
5.09 ± 1.53 
18.43 ± 3.65 
19.27 ± 1.91 
27 1 9 ± 2 20" 
28.33 ± 2 91 
1.23 ± 0.14 е 
1.12 ± 0.14 
1.06 ± 0.15 
1.24 ± 0.14" 
1.12 ± 0.15 
1.20 ± 0.15 
1.12 ± 0.10 
total LDL 
9.20 ± 1.13 
9.13 ± 1.06 
43.64 ± 3 . 6 1 " 
40.77 ± 3.20 
4.65 ± 1.52" 
5.23 ± 1.84 
18.63 ± 3.80= 
20.24 ± 2.79 
23.89 ± 3.50 
24.63 ± 3.50 
1.51 ± 0 3 2 е 
1.38 ± 0.24 
1.36 ± 0.26 
1.53 ± 0.34 е 
1.42 ± 0.25 
1.45 ± 0.30 е 
1.29 ± 0 18 
A = before and В = after simvastatin treatment, including all subjects In = 26), or only the subjects 
with decreasing ( n = 1 8 ) or increasing In = 8) plasma triglyceride levels, during simvastatin therapy, 
respectively. REF = reference value for normolipidemic subjects (n = 28)|ref 15,19,20). C/P = 
cholesterol to protein ratio. * 0 . 0 5 < P < 0 . 1 0 ; " 0 . 0 1 < P < 0 . 0 5 ; ' 0.001 < P < 0 . 0 1 ; " P < 0 . 0 0 1 ver­
sus after therapy. LDL= low density lipoprotein; FC= free cholesterol; CE= cholesteryl ester; 
TG = triglyceride, PL= phospholipid; Prot = protein; Chol/Prot = cholesterol (FC + cholesterol 
moiety of cholesteryl ester ICE; - 0 . 5 9 χ weight of CE]) to protein ratio. 
DISCUSSION 
It is well established that HMG-CoA reductase inhibitors effectively reduce plasma 
LDL cholesterol levels in hypercholesterolemic patients (2-4). Although LDL 
reduction is essential to reduce CHD risk, changes in composition, size, and 
hydrated density of LDL particles are potentially important, because LDL 
heterogeneity has also been linked to CHD (21-28). In the present report, we show 
that simvastatin, an HMG-CoA reductase inhibitor, does not only lower plasma LDL 
concentrations in patients with familial hypercholesterolemia (FH), but also modifies 
LDL composition. 
Among the untreated FH subjects, the LDL subfraction pattern comprised 3 LDL 
subfractions, LDL1, LDL2, and LDL3, present in a relatively narrow density range 
(1.030-1.045 g/ml), very similar to that among normolipidemic subjects 
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(15,19,20,24,25). Simvastatin treatment did not change the number of LDL 
subfractions, the density range of the LDL subfraction profiles, or the relative 
contribution of each LDL subfraction to total LDL (% mass). So, simvastatin did not 
induce significant changes in LDL density 
However, simvastatin therapy was associated with compositional changes in the 
isolated LDL subfractions. Among the untreated subjects, a high mean cholesterol 
to protein ratio (1 51) of the LDL subfractions was observed (9-11), which reverted 
towards normal after simvastatin treatment (1 38 versus 1.36 among normolipide-
mic subjects, see ref 15,19,20) 
The relative mass distribution of total LDL over the 3 LDL subfractions appeared 
dependent on plasma triglyceride levels. When the subjects were stratified by their 
plasma triglyceride levels, or their change in plasma triglyceride levels during 
simvastatin treatment, a major influence of plasma triglyceride levels on the LDL 
subfraction profile and its composition was observed, with increasing plasma 
triglyceride levels a more dense LDL subfraction profile was found, characterized 
by a high relative contribution of dense LDL3 to total LDL (Fig 2 and Table 4) and 
the cholesterol to protein ratio decreased (Table 5), in agreement with previous 
reports (23-28,31,32). Recently, similar results were reported among non-familial 
hypercholesterolemic patients treated with lovastatin (33) These results indicate 
that plasma triglyceride levels determine, at least in part, the changes in LDL 
subfraction profile and composition observed during simvastatin treatment. Several 
studies have shown that reductase inhibitors cause an average reduction in total 
plasma triglyceride levels, but considerable inter-individual variation in triglyceride 
response has been reported (33) In the present study, a majority of 18 patients 
showed a decrease in plasma triglyceride levels, during simvastatin therapy, 
whereas in 8 patients the plasma triglyceride levels increased (Table 3) This 
increase in plasma triglyceride levels was associated with both a significant 
increase in body weight, and a more dense LDL subfraction profile Similarly, 
Williams et al. (34) reported that changes in body weight primarily affected LDL 
mass distribution through changes in metabolic processes associated with HDL and 
triglycerides. Although the reason for the increase in plasma triglyceride levels is 
not clear, the differential response in plasma triglyceride levels allowed us to 
reconfirm the strong dependence of the LDL subfraction profile on plasma 
triglyceride levels. 
The relative increase in LDL3 mass with increasing plasma triglyceride levels 
resulted from the significantly diminished absolute reduction of the mass of LDL3 
compared to that of LDL1 and LDL2 (Table 4) Similar results were reported among 
patients with FH (35,36) and primary hypercholesterolemia (37), treated with either 
simvastatin (35,37) or lovastatin (35,36) However, the changes in LDL subfraction 
pattern in these reports were not related to plasma triglyceride levels (35 37) 
Furthermore, no significant change in the lipid to protein ratio was observed among 
the primary hypercholesterolemic subjects (37), whereas the cholesterol to protein 
ratio of FH LDL decreased (35,36), confirming our results. Other studies have 
revealed apparently conflicting results on the ability of reductase inhibitors to 
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modify composition of LDL. For example, among subjects with primary moderate 
hypercholesterolemia, both lovastatin (38) and pravastatin (39) produced no 
consistent changes in LDL particle size, composition, or LDL subfraction pattern, 
whereas after fluvastatin therapy, LDL in most individuals became larger and less 
dense (40) These conflicting results reported are most likely due to a combination 
of factors, including the patient populations studied, their differences in plasma 
triglyceride levels, the various HMG-CoA reductase inhibitors provided, and the 
methods used for detecting LDL heterogeneity 
Several mechanisms could contribute to the compositional changes in LDL 
observed during simvastatin treatment of FH patients, when considering the fact 
that the composition and plasma LDL level is the outcome of (1) the VLDL 
dehpidation cascade in plasma, (2) the VLDL and LDL uptake by common high 
affinity liver LDL (apoB.E) receptors and (3) direct production of LDL-sized particles 
by the liver All these metabolic processes could be independently influenced by 
reductase inhibitors, contributing to the compositional changes in the LDL 
subfractions For example, LDL isolated from guinea pigs (41) or humans (42), 
undergoing lovastatin therapy, were shown to have altered composition and 
decreased ability to bind to the LDL receptor Affirmatively, several other reports 
have shown that especially the abnormally small and dense LDL particles, which 
have a reduced cholesterol to protein ratio, have a reduced affinity for the LDL 
receptor (43-45). This mechanism may explain the diminished reduction in the 
mass of LDL3 compared to LDL1 and LDL2, during simvastatin treatment, reported 
in this study This effect appears to partially oppose the enhanced hepatic LDL 
receptor activity during simvastatin therapy and may independently affect overall 
LDL clearance rates So, the preferential removal of larger, cholesterol-rich LDL 
particles could explain the decrease in cholesterol to protein ratio Especially, in 
subjects with relatively high plasma triglyceride levels, the concentration of dense 
LDL3 may further increase due to the enhanced exchange of VLDL triglyceride for 
LDL cholesteryl esters, mediated by cholesteryl ester transfer protein, which 
contributes to a more dense LDL particle, with decreased cholesteryl ester to 
triglyceride ratio (44,46) Finally, since the different LDL subfractions arise from 
triglyceride-nch lipoproteins, a change in composition (47) or metabolism (39) of 
VLDL, due to the use of HMG-CoA reductase inhibitors, may also contribute to the 
changes in the LDL subfraction profile 
In conclusion, we report that in subjects with heterozygous familial 
hypercholesterolemia, treatment with 40 mg of simvastatin daily, was associated 
with significant changes in the composition of LDL, reflected by the decrease in the 
cholesterol to protein ratio of all LDL subfractions In addition, our results indicate 
that the plasma triglyceride levels contribute, at least in part, to the observed 
changes in LDL subfraction profile, with increasing plasma triglyceride levels a 
more dense LDL subfraction profile was observed The small, dense LDL particles 
have been associated with an atherogenic lipid and lipoprotein profile and an 
increased risk of atherosclerosis (21-28) An enhanced oxidizability of these LDL 
particles, resulting in its increased uptake by the scavenger receptor on 
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macrophages, followed by foam cell formation, may contribute to this increased 
risk of atherosclerosis (20,27,48,49). As reducing the level of serum cholesterol 
has been shown to reduce the risk of atherosclerosis (7), we postulate that the 
quantitative decrease in LDL mass is apparently more important than the qualitative 
changes observed in LDL, after simvastatin treatment. Further elucidation of the 
effect of simvastatin on the oxidizability of the LDL subfractions could contribute 
to the significance of the presence of relatively dense LDL in treated FH patients. 
REFERENCES 
1. Goldstein JL, Brown MS: Familial hypercholesterolemia, in Stanbury, JB, Wijngaarden, JB, 
Fredrickson, DS, Goldstein, JL, Brown MS, eds: The metabolic basis of inherited disease. New 
York, McGraw-Hill Book Company, 1983;pp 672-712 
2. Mol MJTM, Erkelens DW, Gevers Leuven JA, et al: Effects of synvinolin (MK-733) on plasma 
lipids in familial hypercholesterolemia. Lancet 1986;2:936-939 
3. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 
1988;319:24-33 
4. Mol MJTM, Erkelens DW, Gevers Leuven JA, et al: Simvastatin (MK-733): a potent cholesterol 
synthesis inhibitor in heterozygous familial hypercholesterolemia Atherosclerosis 
1988;69:131-137 
5. Bilheimer DW, Grundy SM, Brown MS, et al: Mevinolin and colestipol stimulate receptor-mediated 
clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. 
Proc Natl Acad Sci USA 1983;80:4124-4128 
6. Grundy SM, Bilheimer DW: Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin 
in familial hypercholesterolemia heterozygotes: effects on cholesterol balance. Proc Natl Acad Sci 
USA 1984;81:2538-2543 
7. Yamamoto A: Regression of atherosclerosis in humans by lowering serum cholesterol. 
Atherosclerosis 1991;89:1-10 
8 Brown G, Albers JJ, Fisher LD, et al: Regression of coronary artery disease as a result of 
intensive hpid-lowenng therapy in men with high levels of apohpoprotein Β. N Eng J Med 1990; 
323:1289-1298 
9 Patsch W, Ostlund R, Kuisk I, et al: Characterization of lipoprotein in a kindred with familial 
hypercholesterolemia. J Lipid Res 1982;23:1196-1205 
10. Teng B, Thompson GR, Sniderman AD, et al. Composition and distribution of low density 
lipoprotein fractions in hyperapobetahpoproteinemia, normohpidemia, and familial 
hypercholesterolemia. Proc Natl Acad Sci USA 1983;80:6662-6666 
11 Dachet С, Motta С, Neufcour D, etal: Fluidity changes and chemical composition of lipoproteins 
in type MA hyperlipoproteinemia Biochim Biophys Acta 1046:64-72, 1990 
12. Shen MMS, Krauss RM, Lmdgren FT, et al: Heterogeneity of serum low density lipoproteins in 
normal human subiects J Lipid Res 1981;22:236-244 
13. Krauss RM, Burke DJ Identification of multiple subclasses of plasma low density lipoproteins in 
normal humans. J Lipid Res 1982;23:97-104 
14 Fisher WR: Heterogeneity of plasma low density lipoproteins manifestations of the physiologic 
phenomenon in man. Metabolism 1983:32-283-291 
15 Swinkels DW, Hak-Lemmers HLM, Demacker PNM Single spin density gradient 
ultracentrifugation method for the detection and isolation of light and heavy low density 
lipoprotein subfractions. J Lipid Res 1987;28:1233-1239 
16. La Belle M, Krauss RM: Differences in carbohydrate content of low density lipoproteins associated 
with low density lipoprotein subclass patterns. J Lipid Res 1990;31.1577-1588 
117 
CHAPTER 6 
17 Dormans TPJ, Swmkels DW, de Graaf J , et al Single spin density gradient ultracentrifugation vs 
gradient gel electrophoresis two methods for detecting low density lipoprotein heterogeneity 
compared Clin Chem 1991,37 853 858 
18 Swmkels DW, Demacker PNM, Hak Lemmers HLM, et al Some metabolic characteristics of 
low density lipoprotein subfractions, LDL 1 and LDL-2 In vitro and in vivo studies Biochim 
Biophys Acta 1988,960 1-9 
19 Swmkels DW, Hendriks JCM, Demacker PNM, et al Differences in metabolism of three low 
density lipoprotein subfractions in Hep G2 cells Biochim Biophys Acta 1990,1047 212 222 
20 de Graaf J , Hak Lemmers HLM, Hectors MPC, et al Enhanced susceptibility to in vitro 
oxidation of the dense low density lipoprotein subfraction in healthy subjects 
Arteriosclerosis 1991,11 2 9 8 3 0 6 
21 Sniderman A, Shapiro S, Marpole D, et al Association of coronary atherosclerosis wi th 
hyperapobetahpoproteinemia (increased protein but normal cholesterol levels in human plasma 
low density (ß) lipoproteins) Proc Natl Acad Sci USA 1980,77 604 608 
22 Crouse JR, Parks JS, Schey HM, et al Studies of low density lipoprotein molecular weight in 
human beings with coronary artery disease J Lipid Res 1985,26 566 574 
23 Austin MA, Breslow JL, Hennekes CH, et al Low density lipoprotein subclass patterns and risk 
of myocardial infarction J Am Med Assoc 1988,260 1917 1921 
24 Swmkels DW, Demacker PNM, Hendriks JCM, et al Low density lipoprotein subfractions and 
relationship to other risk factors for coronary artery disease in healthy individuals Arteriosclerosis 
1989,9 604 613 
25 Swmkels DW, Demacker PNM, Hendriks JCM et al The relevance of a protein enriched low 
density lipoprotein and a risk for coronary heart disease m relation to other known risk factors 
Atherosclerosis 1989,77 59 67 
26 Tornvall P, Karpe F, Carlson LA, et al Relationships of low density lipoprotein subfractions to 
angiographically defined coronary artery disease m young survivors of myocardial infarction 
Atherosclerosis 1991,90 67 80 
27 Krauss RM Low density lipoprotein subclasses and risk of coronary artery disease Current 
Opmon in Lipidology 1991,2 248 252 
28 Campos H, Genest Jr JJ , Blijlevens E, et al Low density lipoprotein particle size and coronary 
artery disease Artenoscl Thromb 1992 12 187 195 
29 Demacker PNM, Hijmans AG, Vos Janssen HE, et al A study of the use of polyethylene glycol 
in estimating cholesterol in high density lipoprotein Clin Chem 1980,26 1775 1779 
30 Lowry OH, Rosebrough NJ, Farr AL, et al Protein measurement with the Folin phenol reagent 
J Biol Chem 1951,193 265 275 
31 Sniderman AD, Wolfson C, Teng B, et al Association of hyperapobeta lipoproteinemia with 
endogenous hypertriglyceridemia and atherosclerosis Ann Intern Med 1982,97 833 839 
32 Eisenberg S, Gavish D, Oschry Y, et al Abnormalities in very low, low and high density 
lipoproteins in hypertriglyceridemia Reversal toward normal with bezafibrate treatment J CLm 
Invest 1984,74 470 482 
33 Tilly Kiesi M The effect of lovastatin treatment on low density lipoprotein hydrated density 
distribution and composition in patients with intermittent claudication and primary 
hypercholesterolemia Metabolism 1991,40 623 628 
34 Williams PT, Krauss RM, Vranizan KM, et al Effects of exercise induced weight loss on low 
density lipoprotein subfractions in healthy men Arteriosclerosis 1989,9 623 632 
35 Tilly-Kiesi M, Tikkanen MJ Low density liporotein density and composition in 
hypercholesterolaemic men treated wi th HMG CoA reductase inhibitors and gemfibrozil J Int Med 
1991,229 427 434 
36 Nozaki S, Vega GL, Haddox RJ, et al Influence of lovastatin on concentrations and composition 
of lipoprotein subfractions Atherosclerosis 1990,W84 101 110 
37 Nakandakare E, Garcia RC, Rocha JC, et al Effects of simvastatin, bezafibrate and gemfibrozil 
on the quantity and composition of plasma lipoproteins Atherosclerosis 1990,85 211 217 
118 
THE EFFECT OF SIMVASTATIN ON THE LDL SUBFRACTION PROFILE 
38. Grundy SM Vega GL: Influence of mevinolin on metabolism of low density lipoproteins in primary 
moderate hypercholesterolemia. J Lipid Res 1985;26:1464-1475 
39 Vega GL, Krauss RM, Grundy SM: Pravastatin therapy in primary moderate 
hypercholesterolemia. Changes in metabolism of apohpoprotem B-containing lipoproteins. J Int 
Med 1990;227:81-94 
40. Yuan J , Tsai MY, Hegland J , et al: Effects of fluvastatm (XU 62-320), an HMG-CoA reductase 
inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. 
Atherosclerosis 1991;87:147-157 
4 1 . Berglund L, Sharkey MF, Elam RL, et al: Effects of lovastatin therapy on guinea pig low density 
lipoprotein composition and metabolism. J Lipid Res 1989;30.1591 -1600 
42. Ginsberg H, Chandreshekar P, Berglund L, et al: Lovastatin therapy appears to reduce the in vivo 
affinity of low density lipoproteins (LDL) for the LDL receptor. Arteriosclerosis 1989;9:708 
43. Aviram M, Lund-Katz S, Phillips MC, et al: The influence of the triglyceride content of low density 
lipoprotein on the interaction of apohpoprotem B-100 with cells. J Biol Chem 
1988;263:16842-16848 
44. Deckelbaum RJ, Granot Y, Oschry Y, et al· Plasma triglyceride determines structure-composition 
in low and high density lipoproteins. Arteriosclerosis 1984;4:225-231 
45 Klemman Y, Eisenberg S, Oschry Y, et al: Defective metabolism of hypertriglyceridemic low 
density lipoprotein in cultured human skin fibroblasts. J Clin Invest 1985;75:1796-1803 
46. Gambert P, Bouzerand-Gambert C, Athias A, et al: Human low density lipoprotein subfractions 
separated by gradient gel electrophoresis: Comparison, distribution, and alterations induced by 
cholesteryl ester transfer lipoproteins. J Lipid Res 1990;31:1199-1210 
47. Mol MJTM, Stuyt PMJ, Demacker PNM, et al: The effects of simvastatin on serum lipoproteins 
in severe hypercholesterolemia. Neth J Med 1990;36:182-190 
48. Steinberg D, Parthasarathy S, Carew TE, et al: Beyond cholesterol. Modifications of low-density 
lipoprotein that increase its atherogenicity. N Eng J Med 1989 ;32091 5-924 
49. Palinski W, Rosenfeld ME, Yla-Herttuala S, et al: Low density lipoprotein undergoes oxidative 
modification in vivo. Proc Natl Acad Sci USA 1989,86:1372-1376 
119 

CHAPTER 7 
Identification of Multiple Dense Low 
Density Lipoprotein Subfractions with 
Enhanced Susceptibility to In Vitro 
Oxidation among Hypertriglyceridemic 
Subjects: Normalisation after Clofibrate 
Treatment 
Jacqueline de Graaf, Jan CM Hendriks, Pierre NM Demacker, 
Anton FH Stalenhoef 
Lancet 1992;340:123-124 (letter to the editor) 
Arteriosclerosis and Thrombosis 1993, 
accepted for publication 

THE EFFECT OF CLOFIBRATE ON THE LDL SUBFRACTION PROFILE 
ABSTRACT 
The influence of different plasma triglyceride concentrations on the 
heterogeneity of low density lipoprotein (LDL) and on the susceptibility of LDL 
to Cu 2 + oxidation was investigated LDL subfractions were isolated from plasma 
of 10 normolipidemic control subjects and 12 hypertriglycendemic patients, 
both before and after Clofibrate treatment, using density gradient 
ultracentrifugation In plasma of control subjects, three LDL subfractions were 
present - ι e , LDL1 (d = 1 030 1 033 g/ml), LDL2 (d = 1 033 1 040 g/ml), and 
LDL3 (d = 1 040-1 045 g/ml) In plasma of 9 moderately hypertriglycendemic 
subjects up to five LDL subfractions (LDL1-LDL5) could be detected, with the 
main LDL subfractions being abnormally small and dense ι e , LDL3, LDL4 
(d = 1 045-1 049 g/ml), and LDL5 (d = 1 049-1 054 g/ml) This polydispersity of 
LDL was replaced by monodispersity with further increasing plasma triglyceride 
concentrations, in 3 subjects with chylomicronemia, in whom LDL was con­
centrated in the narrow LDL5 density range Clofibrate treatment of the 
moderately hypertriglycendemic subjects restored the abnormal composition of 
LDL, resulting in a lighter LDL subfraction pattern (LDL1-LDL4) 
In both the control and the moderately hypertriglycendemic subjects, the small 
dense LDL subfractions appeared more prone to oxidative modification in vitro 
than the light LDL subfractions, as measured by the decreased lag time, 
preceding the onset of the lipid peroxidation Furthermore, the dense LDL 
subfractions were more extensively modified in time, as evidenced by an 
increased oxidation rate and a greater amount of dienes formed after 6 hrs of 
oxidation These results suggest an enhanced atherogenic potential of the small, 
dense LDL subfractions within each LDL subfraction profile The hypertri­
glycendemic LDL subfractions before therapy (LDL3-LDL5) were less resistant to 
in vitro oxidation than the light, control LDL subfractions (LDL1 LDL3), probably 
related to the decrease in vitamin E content going from LDL1 to LDL5 After 
Clofibrate treatment, the vitamin E content of the LDL subfractions and the lag 
time increased, indicating an enhanced resistance against oxidation 
INTRODUCTION 
Heterogeneity in composition and size of plasma low density lipoprotein (LDL) 
particles has been well established (1-6) In patients with hypertriglyceridemia, 
LDL has been described as "polydisperse", defined by the presence of more 
than one species of LDL over a broad density range (d = 1 019 1 063 g/ml) 
(3,4). However, the presence of only one major band of small sized LDL 
particles has also been described in hypertriglycendemic sera with use of 
gradient gel electrophoresis (2,6) To address this apparent controversy, we 
applied a density gradient ultracentrifugation method (1) to identify and isolate 
LDL subfractions among subjects with varying degrees of hypertriglyceridemia 
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Their physicochemical characteristics were compared with LDL subfractions, 
isolated from matched normolipidemic controls. 
Previously, we have demonstrated that LDL subfractions in plasma from normo-
lipidemic subjects differ in their tendency to undergo oxidative modification in 
vitro (7). We have now also investigated the susceptibility of the 
hypertriglyceridemic LDL subfractions to oxidation and related this to the 
content of antioxidants as well as fatty acid pattern of LDL, in search of a 
possible mechanism involved in the suggested increased atherogenicity of these 
lipoproteins (8,9). Furthermore, the influence of plasma triglyceride (TG) 
reduction by Clofibrate treatment of the hypertriglyceridemic subjects, on both 
the physicochemical properties as well as the susceptibility to oxidation of the 
isolated LDL subfractions was determined. 
SUBJECTS AND METHODS 
Subjects 
Twelve patients (eleven males and one female) with various degrees of primary 
hypertriglyceridemia (TG levels between 2.5 - 30.0 mmol/1, LDL cholesterol 
levels < 5 . 0 mmol/l, confirmed by repeated measurements) were studied, both 
before and after Clofibrate administration. Secondary causes of hyper-
lipoproteinemia including liver diseases, renal impairment, hypothyroidism, 
diabetes mellitus, gross obesity, and a history of excess alcohol intake were 
excluded. Six patients suffered from coronary heart disease (CHD) or had a 
family history of CHD. The patients were classified as either moderately 
hypertriglyceridemic (n = 9), with plasma TG levels between 2.5 and 7.0 mmol/l 
(phenotype IV), or chylomicronemic (n = 3) with plasma TG levels between 11.5 
and 30.0 mmol/l, and chylomicrons present in fasting plasma (phenotype V). 
The subjects had not been on lipid lowering drugs for at least three months prior 
to this study. Clofibrate was administered in a dosage regimen of 1.0 gram 
twice daily for 2 months. All patients continued their usual moderately fat-
restricted diet (30-35% of total calories, with a ratio of polyunsaturated to 
saturated fat of approximately 1:1) before and during the period of treatment 
with Clofibrate, which resulted in stable body weight (Table 1). All patients 
completed the study. At the beginning of treatment, two patients reported 
transient gastrointestinal discomfort. Continuation of the drug resulted in 
gradual decrease of the complaints. Otherwise, Clofibrate was tolerated well. A 
control group of 10 healthy volunteers (nine males and one female) was 
selected, matched for sex and age; their relative body weight was slightly lower 
(-10%) compared to the hypertriglyceridemic subjects (Table 1). They consumed 
a diet comparable to that of the patients and did not use any medication. 
Informed consent was obtained from all subjects. 
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Low Density Lipoprotein Subfractionation 
Blood samples were obtained after an overnight fast The blood was collected 
into ethylenediammotetraacetic acid (EDTA 1 mg/ml) containing tubes Plasma 
was isolated immediately and supplemented with butylated hydroxytoluene 
(BHT, 4 4 ¿/g/ml). 
Detection and isolation of LDL subfractions was performed by density gradient 
ultracentrifugation, as described previously (1,7) After ultracentrifugation the 
LDL subfractions were visible as distinct bands in the middle of the tube 
Depending on the degree of hypertriglyceridemia, one to five LDL subfractions 
could be detected, concentrated in the following density ranges- LDL1 (1 030-
1 033 g/ml), LDL2 (1 033-1 040 g/ml), LDL3 (1 040 1 045 g/ml), LDL4 (1 045-
1 049 g/ml), and LDL5 (1 049-1 054 g/ml) The ultracentrifugation tube 
containing the LDL subfractions stained with Coomassie Brilliant Blue R (the 
reference tube) of each subject was placed in a specially designed rack and 
photographed (10) Accurate documentation of the different LDL subfraction 
patterns was obtained by scanning the slides in triplicate on a LKB 2202 
ultrascan laser densitometer (10) The mean peak heights (h1-h5) of the LDL 
subfractions (LDL1-LDL5) on the 3 scans were used to calculate the relative 
distribution of each LDL subfraction over total LDL (total LDL [100%] = 
h i + h 2 + h3 + h4 + h5). By using the reference tube for each subject, LDL 
subfractions were accurately isolated by aspiration with a rubber bulb pipet from 
the tubes to which no stain had been added The non-stained LDL subfractions 
of each subject were pooled and concentrated by a second ultracentrifugation 
run (7) The EDTA/BHT-containing LDL subfractions from each subject were 
dialyzed separately in the dark for 48 h at 4°C against 3 liter 0 01 M phosphate 
buffer (pH 7 4) containing 0 16 M NaCI and 0 1 //g/ml chloramphenicol The 
buffer was made oxygen free by vacuum degassing followed by purging with 
nitrogen, the buffer was changed after 24 hrs (7) The EDTA/BHT-free LDL 
subfractions were filtered through a 0 45-//m filter and used for the oxidation 
study immediately The density of the LDL subfractions was determined as 
described (7). 
Oxidation of the Low Density Lipoprotein Subfractions 
The oxidation experiments were performed essentially as described previously 
(7,11) with all subfractions of the same subject run in parallel The EDTA/BHT-
free dialyzed LDL subfractions were diluted with the dialysis buffer to a final 
concentration of 0.25 mg LDL protein/ml Oxidation was initiated by addition of 
freshly prepared 1.66 μΜ CuCI2 solution The kinetics of the oxidation process 
of the LDL subfractions were determined by monitoring the change in the 234 
nm absorbance at room temperature on a Perkin Elmer Lambda 5 UV 
spectrophotometer equipped with a six-position automatic sample changer The 
absorbance curves of the LDL subfractions from each subject were determined 
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in parallel. The baseline values of the absorbance at 234 nm ranged between 
0.1 and 0.3, indicating that the LDL subfractions were not oxidized in vivo or 
during the isolation procedure. After the initial absorbance at 234 nm was set to 
zero, the increase in absorbance was recorded every 3 minutes, for ap-
proximately 6 hrs. The change in absorbance at 234 nm versus time was 
divided into three consecutive phases: a lag phase, a propagation phase, and a 
decomposition phase. From this absorbance curve, the lag time (min), the 
maximal rate of oxidation (nmol of dienes formed per minute per milligram of 
LDL protein subfraction), and the maximal amount of conjugated dienes formed 
per milligram of LDL protein subfraction were calculated (7). In 4 additional 
subjects (serum TG 0.74 - 5.65 mmol/l), LDL subfractions were isolated without 
the use of BHT and oxidation measurements were performed with a modified 
method as described (12). 
Assay of Fatty Acids and Vitamin E in Native LDL Subfractions 
Fatty acids and vitamin E concentrations in the native LDL subfractions of the 
moderately hypertriglyceridemic and control subjects were measured on a high-
performance liquid Chromatograph (Model 8800, Spectra Physics, Eindhoven, 
The Netherlands), with spectrophotometric and fluorescence detection, respec-
tively, essentially as described previously (7). The native LDL subfractions were 
supplemented with BHT (4.4 //g/ml) and EDTA (1 mg/ml) to prevent oxidation 
during storage, at -80°C for up to 4 weeks. The measurements of the vitamin E 
and fatty acid concentrations appeared reproducible on repeated analysis; the 
coefficient of variation was < 5 % (n = 20) for the concentrations of both vitamin 
E and the various fatty acids. 
Analytical Methods 
VLDL and IDL (d<1.019 g/ml) were isolated by ultracentrifugation for 16 hrs at 
40,000 rpm in a fixed angle rotor (13). HDL cholesterol was determined in 
whole plasma by the polyethylene glycol 6000 method (13). LDL cholesterol 
was calculated by subtracting VLDL 4- IDL cholesterol and HDL cholesterol from 
total plasma cholesterol. Total cholesterol (TC), unesterified (free) cholesterol 
(FC), phospholipids (PL) and triglycerides (TG) were determined by enzymatic, 
commercially available reagents (Boehringer-Mannheim, Mannheim, FRG, cat. 
no. 237574, 310328, 691844, and no. 6639, Sera Pak, Miles, Italy, respec-
tively). The protein content of the LDL subfractions was determined by the 
method of Lowry et al. (14). 
For comparison of the relative size of the various isolated LDL subfractions, 
gradient gel electrophoresis was performed using 2-16% Polyacrylamide gels 
(Pharmacia, Uppsala, Sweden, cat. no. 19-1264-01) (5). Agarose gel 
electrophoresis was performed at pH 8.6 in a barbital buffer using the Beekman 
Paragon System (15). Possible degradation of apoB-100 in the LDL subfractions 
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was studied by sodium dodecyl sulfate-polyacrylamide-gel electrophoresis, using 
3%/4% discontinuous Polyacrylamide disc gels (16). 
STATISTICAL ANALYSIS 
Prior to statistical analysis the data were logarithmical transformed in order to 
homogenize the variances. Due to the small number of subjects with 
chylomicronemia (n = 3), they were excluded from the statistical analysis. 
Differences in the mean values of age, BMI, and plasma lipid, lipoprotein levels 
between the control and moderately hypertriglyceridemic subjects, respectively, 
before and after therapy, were tested for significance by t-test procedures. 
Paired t-test procedures were used to assess the effect of Clofibrate treatment 
on plasma lipid and lipoprotein levels in the moderately hypertriglyceridemic 
subjects. 
Only the main LDL subfractions present in the moderately hypertriglyceridemic 
group, - i.e., LDL3, LDL4, and LDL5 before therapy and LDL1, LDL2, and LDL3 
after therapy - were included in the analysis of the variables measured in the 
isolated LDL subtractions. 
A two-way analysis of variance (two-way ANOVA) was used to analyze the 
differences between the three main LDL subfractions of the moderately 
hypertriglyceridemic group before therapy. A three-way analysis of variance 
(three-way ANOVA) was used to analyze simultaneously the differences 
between the control and the moderately hypertriglyceridemic group after 
therapy, as well as the differences between their three main LDL subfractions. 
The differences in mean values were tested for significance by Scheffe's 
multiple comparison tests. 
For all analyses, the retransformed (antilog) values of the mean with 95% 
(symmetrical) confidence intervals are presented as the median with 95% 
(asymmetrical) confidence intervals. 
Statistical analyses were performed with procedures available in the Statistical 
Analysis System soft ware package (SAS Institute Inc., Cary, N.C.). 
RESULTS 
The Effect of Clofibrate on Plasma Lipid and Lipoprotein Levels 
The lipid and lipoprotein profiles of the control subjects and the patients with 
hypertriglyceridemia, before and after Clofibrate treatment, are summarized in 
Table 1. 
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THE EFFECT OF CLOFIBRATE ON THE LDL SUBFRACTION PROFILE 
Effect of Plasma Triglyceride 
concentration on the LDL 
Subfraction Pattern 
Clear differences in number, 
intensity, and density range 
of the distinct LDL subfrac-
tions, visible as colored bands 
along the density gradient, 
were present between the 
controls and the subjects with 
various degrees of hypertrigly-
ceridemia, respectively. 
Analysis of the densitometric 
scans revealed that the com-
position of the LDL subfrac-
tion patterns differed for the 
control and hypertriglyceride-
mic subjects and changed af-
ter Clofibrate therapy (Fig. 1). 
FIGURE 1 . Densitometrie scanning 
patterns of the low density lipo-
protein (LDL) subfraction distri-
butions, based on density gradient 
ultracentrifugation of plasma. 
Representative scanning patterns are shown for 3 normohpidemic controls (C, top i , 3 moderately 
hypertriglycendemic (phenotype IV, middle!, and 2 chylomicronemic subjects (phenotype V, 
bottom), before ( 1 and after (—-) Clofibrate treatment. 
In the plasma of the normotriglyceridemic control subjects, mostly three LDL 
subfractions, LDL1, LDL2, and LDL3, were present in a relatively narrow density 
range, with LDL2 and LDL3 as the predominant fractions (Table 2). In plasma of 
the moderately hypertriglyceridemic subjects, the LDL subfractions were more 
dense, i.e., LDL3, LDL4, and/or LDL5, but in some LDL1 and LDL2 were also 
present. The moderately hypertriglyceridemic LDL thus tended to be 
polydisperse, consisting of multiple subfractions over a broad density range, 
with the dense LDL subfractions (LDL3-LDL5) contributing most to total LDL 
(Table 2). Clofibrate treatment of the moderately hypertriglyceridemic subjects 
induced a lighter LDL subfraction pattern, consisting of LDL1, LDL2, LDL3, and 
LDL4, with LDL1, LDL2 or LDL3 as the main LDL subfraction (Table 2). 
In the subjects with chylomicronemia, a very dense LDL subfraction pattern was 
found, consisting of only one LDL5 subfraction band of very low intensity and 
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high density (1.049-1.054 g/ml). After treatment, the LDL subfraction pattern 
was composed of two dense LDL subfractions, LDL4 and LDL5, with LDL4 
being predominant (Table 2). 
TABLE 2 The characteristics of the LDL subfraction profiles among 10 normolipidemic, 9 
moderately hypertriglyceridemia, and 3 chylomicronemic subjects, before and after Clofibrate 
treatment, described by the relative distribution of the LDL subfractions over total LDL 
Controls Moderately HTG Chylomicronemic 
before therapy after therapy before therapy after therapy 
LDL1 О 13 ± 0 16 0 0 2 ± 0 0 5 0 12 ± 0 12 
LDL2 0 41 ± 0 12 0 0 4 ± 0 0 9 0 25 ± 0 19 
LDL3 0 45 ± 0 19 0 24 ± 0 33 0 52 ± 0 24 
LDL4 0 59 ± 0 39 0 11 ± 0 30 0 61 ± 0 34 
LDL5 0 12 ± 0 21 1 0 39 ± 0 34 
HTG= hypertriglyceridemia, LDL= low density lipoprotein, LDL1 d = 1 0 3 0 1 0 3 3 g/ml LDL2 
d = 1 033-1 0 4 0 g/ml, LDL3 d = 1 0 4 0 1 0 4 5 g/ml, LDL4 d = 1 0 4 5 1 0 4 9 g/ml LDL5 d - 1 0 4 9 
1 0 5 4 g/ml 
Physicochemical Characteristics of the LDL Subfractions 
Chemical Composition and Size 
The LDL subfractions were isolated as discrete bands and their physicochemical 
characteristics analyzed Table 3 shows the relative FC, CE, TG, PL, and protein 
content of the main LDL subfractions present in the control group and the 
moderately hypertriglycendemic group, both before and after therapy In LDL5, 
the relative content of FC, CE, and PL was significantly less and the TG and 
protein content significantly greater than in both LDL3 and LDL4 (Scheffe, 
p < 0 05) The main differences in composition (i.e. the relative FC, TG, and 
protein content) in LDL1, LDL2, and LDL3, were found between LDL1 and LDL3 
(Scheffe, ρ < 0.05) in both the control and the hypertriglycendemic group after 
therapy, whereas the CE and PL content differed significantly in the control 
group only (Scheffe, p < 0 05, Table 3) 
Fig 2 shows that the migration distance of the LDL subfraction particles in 
gradient gel electrophoresis increased going from LDL1 to LDL5, indicating a 
gradual decrease in particle size with increasing density of the LDL subfractions 
The migration distance of the LDL subfractions in the hypertriglycendemic group 
before therapy increased significantly going from LDL3 to LDL4 to LDL5 
(Scheffe, p < 0 . 0 5 ) . Furthermore, LDL3 moved significantly further than LDL2, 
and LDL2 significantly further than LDL1 (Scheffe, ρ < 0.05) The migration 
distance of the LDL subfractions was similar for the control and 
hypertriglycendemic group after therapy 
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FIGURE 2. Migration distance (mm) in gradient gel 
electrophoresis of the main low density lipoprotein 
(LDL) subfractions present in 10 normohpidemic 
( ) and 9 moderately hypertriglycendemic 
subjects, before ( ) and after (—) 
Clofibrate treatment. 
Each point represents the median value with 95% 
confidence interval. The footnotes indicate dif-
ferences between LDL subfractions within each 
group, according to Schef fe (p<0.05) . * = LDL1 
versus LDL2; 4= LDL2 versus LDL3; i LDL3 
versus LDL1; || LDL3 versus LDL4; 1 LDL4 
versus LDL5; * * LDL5 versus LDL3. 
Migratori distance [mm] 
LDL1 LDL2 LDL3 LDL4 LDL5 
Fatty Acid Composition 
The major fatty acids in the main LDL subfractions were linoleic acid (18:2), 
palmitic acid (16:0), and oleic acid (18:1), followed by arachidonic acid (20:4) 
and stearic acid (18:0). Between LDL3, LDL4, and LDL5 no significant dif-
ference in the concentration (¿/mol/g LDL protein) of each of these individual 
fatty acids was found (data not shown). For LDL1, LDL2, and LDL3, the 
concentration of each individual fatty acid decreased with increasing density, 
mainly due to significant differences between LDL1 and LDL3 (Scheffe, 
p<0.05) . Consequently, the total fatty acid and PUFA content decreased 
significantly going from LDL1 to LDL2 to LDL3 (Scheffe, ρ < 0 . 0 5 ) , whereas the 
percentage of PUFAs did not differ significantly (Table 3). 
After Clofibrate treatment, the total fatty acid concentration increased con­
siderably; in the LDL subfractions of the treated hypertriglycendemic group the 
concentration of the fatty acids was significantly greater than in the control 
group (three-way ANOVA, p < 0 . 0 5 ) , except for linoleic acid; the concentration 
of this fatty acid in the LDL subfractions of the treated hypertriglycendemic 
group was significantly lower than in the controls (LDL1 771.8 vs 964.0; LDL2 
711.7 vs 856.2; LDL3 592.7 vs 740.7, respectively, three-way ANOVA, p < 
0.05). 
Vitamin E Concentration 
In the untreated hypertriglyceridemic group, the vitamin E content (//mol/g LDL 
protein) was significantly less in LDL5 than in both LDL3 and LDL4 (Table 3, 
Scheffe, p < 0 . 0 5 ) . In LDL1, LDL2, and LDL3, the vitamin E content also 
decreased with increasing density, due to significant differences between LDL1 
and LDL3 (Scheffe, ρ < 0 . 0 5 ) . The vitamin E content of the LDL subfractions in 
the treated hypertriglyceridemic group was significantly greater than in the 
control group, despite the similar LDL subfraction pattern (three-way ANOVA, 
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p < 0 . 0 5 , Table 3). No detectable amounts of vitamin E were present in the LDL 
subfractions after the oxidation experiments. 
TABLE 3. Chemical composition (percent of dry mass), vitamin E concentration, and fatty acid 
content (μιηοΙ/ο LDL protein) of the main low density lipoprotein subfractions present in 10 normo-
hpidemic and 9 moderately hypertnglyceridemic subjects, before and after Clofibrate treatment. 
Before 
Clofibrate 
FC (%) 
CE (%) 
TG (%) 
PL (%) 
Prot (%) 
PUFA (%| 
Vit E 
After 
Clofibrate 
FC (%) 
CE (%)' 
TG (%)' 
PL (%)' 
Prot (%) 
Total FA' 
Total PUFA1 
PUFA |%|' 
Vit E1 
Control 
subjects 
FC (%) 
CE (%) 
TG |%) 
PL (%| 
Prot (%) 
Total FA 
Total PUFA 
PUFA (%) 
Vit E 
LDL3 (η = 8) 
7.9 (7.0;8.9) 
34.1 (29.7;39.2) 
6.9 (5.1;9.2) 
18.8 (17.0;20.7) 
31.3 (26.5;36.8) 
44.7 (41.8:47.7) 
10.2 |8.9;11.6) 
LDL1 (n = 8) 
10.4 (9.3;11.7) 
36.7 (33.0;40.7) 
8.2 (5.6;12.1) 
21.3 (19.8;22.9) 
22.7 (21.1;24.4) 
2963.2 (2421.0:3626.8) 
1231.6 (1068.4:1419.8) 
41.6 (34.9;49.5I 
15.7 (11.5:21.5) 
LDL1 (n = 9) 
10.8 (9.8:11.9) 
39.3 (36.4;42.4) 
5.7 (4.0;7.9) 
21.2 (20.1;22.2| 
22.4 (20.2;24.8) 
2847 4 (2512 0;3227.6| 
1331.7 (1199.6:1478.4) 
46.8 (44.0:49.7) 
13.3 (10.3;17.1) 
LDL4 (n = 7) 
7.1 (6.3:8.1) 
38.5 (33.1:44.6) 
6.3 (4.6:8.5) 
18.8 (16.9:20.8) 
27.6 (23.2;32.9) 
45.8 142.6:49.1) 
10.4 |9.1;12.0I 
LDL2 (n = 9) 
9.6 (8.7;10.6) 
37.2 (33.9:40.8) 
6.7 (4.8;9.5| 
21.8 (20.5:23.2) 
24.0 (22.4;25.6) 
2807.9 (2415.3:3264.4) 
1136.9 (1022.6:1264.0) 
40.5 (35.5:46.2) 
14.7 (11.6;18.5| 
LDL2 (n = 10) 
9.7 (8.8:10.61 
41.7 (38 8;44.9) 
4.8 (3.5:6.6) 
20 8 (19 9;21.8) 
22.5 (20.4;24.8I 
2577.5 (2304.2:2883.2) 
1205.0 (1097.6:1323.0) 
46.8 (44.3:49.3) 
11.5 (9.3:14.2) 
LDL5 (n = 7| 
5.8 (5.1:6.6)" 
24.1 (20.7;27.9P 
9.9 (7.2;13.5)" 
15.0 (13.5,16.7)' 
43.0 (36.1,51.2)" 
47.5 (43.7;51.7| 
7.5 (6 4,8 7)" 
LDL3 In = 9) 
8.7 (7.9;9.7|b 
38.3 (34.9:42.0) 
5.5 (3.9;7.7)d 
20 9 (19 7:22.3) 
26.2 (24.5;28.0I C 
2477.2 (2130.8:2879.9)" 
988.9 (889.5:1099.4)" 
39.9 (35.0:45.5) 
13.6 (10.7:17.1)' 
LDL3 (n = 10) 
9.1 (8.3;10.0) b 
37.4 (34.8;40.2)" 
4.5 (3.3:6 2)" 
19.1 (18.2;20.0) c 
29.4 (26.7;32 41e 
2204.9 (1971.1;2466.4) b 
1052.4 (958.5:1155 4)b 
47.7 |45.2;50.4) 
10.4 (8.4;12.9)' 
Values are presented as median with 9 5 % confidence interval between brackets. The footnotes 
indicate differences between LDL subfractions within each group, according to Scheffe ( p < 0 . 0 5 ) . 
" = LDL5 versus LDL4 and LDL3; " LDL1 versus LDL2 and LDL2 versus LDL3 and LDL3 versus 
LDL1; c LDL3 versus LDL1 and LDL2; " LDL1 versus LDL2 and LDL3; " LDL2 versus LDL3; ' LDL3 
versus LDL1. The superscript 1 indicates that the hypertriglycendemic group after therapy and the 
control group differ significantly for the presented variable (three-way ANOVA, p < 0 . 0 5 ) . 
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FIGURE 3. Oxidizability of the mam low density 
lipoprotein subfractions in 10 normolipidemic 
( ) and 9 moderately hypertriglyceridemic 
subjects, before ( ) and after I—) 
Clofibrate treatment. The oxidizability is described 
by the lag time, the oxidation rate, and the 
maximal amount of dienes formed at the end of 
the oxidation process, calculated from the absor-
bance curves of the LDL subfractions, obtained 
during oxidation. Footnotes indicate significant 
differences between LDL subfractions, as 
described in the legend of Figure 2. Brackets link 
the hypertriglyceridemia group after therapy with 
the control group, indicating that the groups differ 
significantly for the presented variable (three-way 
ANOVA, p < 0 . 0 5 ) . 
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The lag time of the LDL subfractions tended to decrease with increasing density 
(Fig. 3). Among the subfractions of the hypertriglyceridemic group before 
therapy, the lag time of LDL5 was significantly shorter than that of LDL3 
(Scheffe, p < 0 . 0 5 ) . Considering LDL1, LDL2, and LDL3, the lag time of LDL3 
was significantly shorter than that of LDL1 (Scheffe, p < 0 . 0 5 ) . The lag time of 
the LDL subfractions in the treated hypertriglyceridemic group did not differ 
significantly from that in the control group (three-way ANOVA, ρ > 0 . 0 5 ) . 
The maximal rate of oxidation and the maximal amount of dienes formed per 
milligram of LDL protein subfraction tended to increase going from LDL3 to 
LDL5 (Fig. 3); the values of both parameters were significantly greater in LDL5 
than in LDL3 or LDL4 (Scheffe, ρ < 0 . 0 5 ) . A similar trend was found going from 
LDL1 to LDL3 with significantly greater values for oxidation rate and maximal 
amount of diene formation in LDL3 than in both LDL1 and LDL2 (Scheffe, 
133 
CHAPTER 7 
ρ < 0 . 0 5 ) . Among the LDL subfractions of the treated hypertriglyceridemia 
group, both the oxidation rate and the maximal amount of dienes formed were 
significantly less than in the control group, despite the similar LDL subfraction 
pattern (three-way ANOVA, p < 0 05). 
In the experiments, in which no BHT was used during the isolation of the LDL 
subfractions, the same qualitative differences were obtained as described here 
(results not shown). 
DISCUSSION 
The density distribution of LDL in our moderately hypertriglyceridemia patients 
covered, with our method of isolation, a wide density range from 1 030 to 
1.054 g/ml, concentrated in five discrete LDL subfractions, LDL1 to LDL5 The 
mam LDL subfractions were abnormally small and dense (LDL3-LDL5), whereas 
for the normohpidemic subjects three distinct LDL subfractions, LDL1, LDL2, 
and LDL3, in a relatively narrow, light density range (1 030 1 045 g/ml) could 
be detected In the subjects with chylomicronemia (TG levels > 1 1 mmol/l) this 
polydispersity of LDL was absent and only one LDL subfraction (LDL5) in a 
narrow density range (1 049-1 054 g/ml), defined as monodisperse LDL, was 
present So, in contrast with Fisher et al (3,4), we found that polydispersity of 
LDL is not a simple function of plasma triglycerides Our data indicate that both 
the number and the relative distribution of the LDL subfractions over total LDL 
are dependent on the extent of hypertriglyceridemia 
Subjects with moderate hypertriglyceridemia are considered to be at increased 
risk for CHD, especially men over aged 50 with low HDL cholesterol levels (17) 
An enhanced atherogenic potential of the hypertriglycendemic LDL subfractions 
could contribute to this phenomenon Reportedly, alterations in composition of 
LDL particles were associated with changes in LDL metabolism in cultured cells 
(18-21), which may render the hypertriglycendemic LDL particle more 
atherogenic 
An other potential mechanism which may increase the atherogemcity of LDL 
particles includes the oxidative modification of LDL (22,23) This oxidative 
modification converts LDL to a form recognized by the scavenger receptor and 
uptake of oxidized LDL induces foam cell formation in vitro, the hall mark of 
atherosclerotic plaques (22). 
Recently, we showed that the more dense LDL subfractions in normohpidemic 
subjects, LDL2 and LDL3, were more susceptible to oxidative modification (7), 
as confirmed by others (21,24) The more dense LDL2 and LDL3 may therefore 
contribute more to foam cell formation per particle than the less dense LDL 
subfraction, LDL1, explaining the association of dense LDL with an increased 
risk of CHD (10,24-26) 
In addition, we now report that the dense LDL subfractions present in the 
hypertriglycendemic subjects (LDL3-LDL5) also differ in their susceptibility to 
lipid peroxidation in vitro The heavy LDL5 was less well protected against 
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oxidative modification than LDL3, as measured by the significantly shorter lag 
time. Once the lipid peroxidation process started, LDL5 was more extensively 
modified in time than LDL3, as evidenced by the increased rate of oxidation and 
the greater amount of dienes formed. 
In trying to explain the difference in lag time among LDL subfractions, vitamin E 
appeared to be an important factor, as suggested previously (11,27-29); the 
decrease in lag time with increasing density of the LDL subfractions was 
associated with a decrease in vitamin E content (Table 3). When LDL is more or 
less depleted of antioxidants, the lipid peroxidation process starts with the 
peroxidation of the PUFAs in LDL lipids and their degradation to, among other 
things, conjugated dienes (27). The major PUFAs in LDL that can undergo lipid 
peroxidation are 18:2 and 20:4, which are mainly bound to phospholipids, 
cholesterol, and to a lesser extent to triglycerides (28). Our results indicate that 
in the more dense LDL subfractions within each group, more PUFAs were 
degraded during the oxidation process. However, the PUFA content did not 
differ significantly among LDL3-LDL5 in the hypertriglyceridemic group and even 
decreased going from LDL1 to LDL3 among the normolipidemic subjects. 
Apparently, other factors including LDL particle size, conformational changes of 
apo В (9,18,19) and location of fatty acids (e.g., on surface phospholipids or in 
core triglycerides or cholesteryl esters) are important as well in determining the 
rate of oxidation and diene formation. 
It appeared that the rate of oxidation and diene formation of the LDL subfrac­
tions in the hypertriglyceridemic subjects were less than in the control subjects 
(Fig.3). These results do not appear to be in line with an increased susceptibility 
to lipid peroxidation as suggested above; we found, however, that after the lag 
phase had ended, extensive physicochemical alterations in all LDL subfractions 
were present on agarose and SDS gel, suggesting biological modification of all 
LDL subfractions (30-32). Therefore, we suggest that more value should be set 
on the duration of the lag time. 
After 2 months of Clofibrate treatment the dense LDL subfraction pattern was 
replaced by a light LDL subfraction pattern (LDL1-LDL3); again, the most dense 
LDL subfraction (LDL3) showed an enhanced oxidizability compared to light 
LDL1 (Fig.3). 
The light LDL subfractions in the treated hypertriglyceridemic group (LDL1-
LDL3) appeared more resistant against oxidation than before therapy (LDL3-
LDL5), as measured by the increase in lag time, which reverted to normal. The 
increase in lag time of the LDL subfractions after Clofibrate treatment was 
associated with an increase in vitamin E content going from LDL5 to LDL1. 
These results stress the role of vitamin E in retarding or preventing the oxidative 
modification of LDL subfractions, although other additional antioxidants may 
also contribute to the difference in lag time among LDL subfractions (28,33,34). 
Furthermore, the extent of oxidation, as determined by the oxidation rate and 
the amount of dienes formed, did not change after treatment; this is consistent 
with the similar absolute linoleic acid and PUFA content of the LDL subfractions 
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after Clofibrate treatment, ¡η agreement with results obtained with other fibrates 
(35-37). 
The LDL subfractions after Clofibrate administration, were still less extensively 
modified in time than the control LDL subfractions, which was apparently 
related to the significantly lower concentration of PUFAs (per μπηοΙ vitamin E or 
per g LDL protein), available for oxidation in the treated hypertriglyceridemic 
LDL subfractions. 
In summary, our results show that LDL isolated from hypertriglyceridemic 
subjects are more prone to in vitro oxidative modification than LDL from control 
subjects. Clofibrate treatment reduced the susceptibility of LDL to oxidation. 
Hence, if the oxidative modification hypothesis in the development of 
atherosclerotic plaques is relevant (21), LDL in hypertriglyceridemic subjects 
have an enhanced atherogenic potential, which reverts toward normal after 
Clofibrate treatment. 
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GENETIC INFLUENCES ON THE LDL SUBFRACTION PROFILE 
ABSTRACT 
A lipoprotein profile characterized by a predominance of small, dense, low density 
lipoprotein (LDL) particles has been associated with an increased risk of 
atherosclerosis To investigate whether genetic factors are involved in determining 
this heavy LDL subfraction pattern, this study was undertaken with the aim of 
resolving the effects that major genes, multifactorial hentability, and environmental 
exposures have on the LDL subfraction pattern In a random sample of 19 healthy 
Dutch families including 162 individuals, the distribution of the LDL subfraction 
pattern was determined by density gradient ultracentrifugation For each subject 
a specific LDL subfraction profile was observed, characterized by the relative 
contribution of the three major LDL subfractions, LDL1 (d = 1 030-1.033 g/ml), 
LDL2 (d = 1 033-1 040 g/ml), and LDL3 (d = 1 040 1 045 g/ml), to total LDL A 
continuous variable, parameter K, was defined to characterize each individual LDL 
subfraction pattern Complex segregation analysis of this quantitative trait, under 
a model which includes a major locus, polygenes, and both common and random 
environment, was applied to analyze the distribution of the LDL subfraction pattern 
in these families 
The results indicate that the LDL subfraction pattern, described by parameter K, is 
controlled by a major autosomal, highly penetrant, recessive allele with a 
population frequency of 0 19 and an additional multifactorial inheritance 
component The penetrance of the more dense LDL subfraction patterns, 
characterized by values of K < 0 , was dependent on age, gender, and, in women, 
on oral contraceptive use and postmenopausal status Furthermore, multiple 
regression analysis revealed that approximately 60% of the variation in the LDL 
subfraction pattern could be accounted for by alterations in age, gender, relative 
body weight, smoking habits, hormonal status in women, and lipid and lipoprotein 
levels 
In conclusion, our results indicate that genetic influences as well as environmental 
exposure, sex, age, and hormonal status in women are important in determining 
the distribution of the LDL subfraction patterns in this population, and that these 
influences may contribute to the explanation of familial clustering of coronary heart 
disease 
INTRODUCTION 
Several studies have shown that low density lipoproteins (LDL) are heterogeneous 
macromolecules, consisting of discrete subfractions which differ in 
physicochemical composition (1-6), metabolic behavior (7-9), and atherogenic 
potential (10). Recently, the risk of coronary heart disease (CHD) has been 
associated with a high prevalence of small, dense LDL particles (11-16) It has 
been shown that LDL heterogeneity is markedly influenced by age, gender, relative 
body weight, smoking habits, and lipid and lipoprotein levels, together predicting 
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3 7 % (17) to 6 1 % (18) of the variability in LDL subfraction patterns The remainder 
of the variability has been suggested to be genetically determined Possible genetic 
control of LDL heterogeneity was first reported by Fisher et al (19), on the basis 
of molecular-weight measurements of LDL in five families. Also, among patients 
with hyperapobetalipoprotememiaand familial combined hyperlipoproteinemia, both 
characterized by a predominance of small, dense LDL particles and an increased 
risk of atherosclerosis, genetic influences in the etiology have been proposed 
(20,21). Recently, Austin et al (22-24) provided new evidence that the distribution 
of the LDL subfraction pattern in a community-based healthy population has a 
genetic base; they distinguished two discrete phenotypes, based on LDL particle 
size, which were denoted "A" and "B" and which were characterized by a 
predominance of large and small LDL particles, respectively Phenotype В appeared 
to be inherited as a single-gene trait with a dominant mode of inheritance 
However, as the distribution of LDL particles, by size, within the LDL density range 
shows a continuity, the dichotomization of the LDL subfraction patterns into two 
discrete phenotypes (23) may result in considerable overlap between patterns A 
and В and in a high intermdividual variability, in LDL particle size, among subjects 
with either pattern A or B. In a recent study, we confirmed that a dichotomous 
classification of the LDL subfraction profile into patterns A and В could indeed not 
fully reflect the great intermdividual variation in LDL subfraction patterns that was 
observed among 131 healthy subjects when LDL subfractions were detected by 
density gradient ultracentrifugation ( 17), a specific LDL subfraction distribution was 
found for each subject and was characterized by the relative contribution of the 
three major LDL subfractions, LDL1, LDL2 and LDL3, to total LDL Moreover, when 
family data are useful for genetic counseling, quantitative traits of relatives are 
often more informative than their affection status So, the LDL subfraction pattern 
can be considered a quantitative rather than a qualitative trait When a quantitative 
trait such as the LDL subfraction pattern is reduced to a dichotomy (LDL 
subfraction patterns A and B), relevant information is lost Hence, in the present 
report we introduced a continuous variable, parameter K, to describe each 
individual LDL subfraction pattern 
The primary aim of this study was to examine in healthy Dutch families the mode 
of inheritance of the dense LDL subfraction pattern, on the basis of LDL particle 
density and by means of the quantitative parameter К LDL subfraction patterns 
were determined among 162 individuals from 19 large kindreds of two generations 
by density gradient ultracentrifugation Complex segregation analysis (25-29) was 
then used to investigate the inheritance of the LDL subfraction patterns To 
examine possible differences in the information provided by a continuous parameter 
and a dichotomous classification, complex segregation analysis was carried out 
using both parameter К and a pattern A/pattern В classification, based on 
parameter К 
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SUBJECTS AND METHODS 
Families 
The recruitment of nuclear families took place in The Netherlands. The families 
were obtained through probands in both first and second generations and were 
ascertained by survey among healthy individuals in our department. For families to 
participate in the study, the inclusion criterion was a minimal family size of 6 
individuals with a minimal age of 16 years. 
Nineteen nuclear families with an average of seven or eight children per family 
were screened, for a total of 179 individuals. For most families, all family members 
were visited on the same day. All parents lived in the southern and eastern areas 
of The Netherlands. The children were living all over The Netherlands, within a 2.5 
h drive from the city of Nijmegen. Each subject completed a medical history 
questionnaire used to collect information on those factors that have been 
associated with variations in lipid and lipoprotein levels, including life style (e.g., 
profession, alcohol use, cigarette smoking, and physical activity) and hormonal 
status (pre- or postmenopausal status in women, postmenopausal hormone users, 
and oral contraceptive [OC] use), medical status (e.g., diabetes, renal impairment, 
and liver diseases) and medication use. Subjects who were pregnant, had lipid 
disorders (total cholesterol > 6.5 mmol/l and triglycerides > 2.5 mmol/l) or 
cardiovascular or other serious diseases, or used medications which are known to 
influence serum lipids and lipoproteins levels were excluded from the study. Eight 
children were abroad at the time of the study. In total, 162 subjects were left, 
including all parents, who gave their informed consent to participate in this study. 
From each subject, blood was sampled in evacuated collection tubes (Corvac) after 
an overnight fast. Serum was isolated within 2 h, for determination of the LDL 
subfraction pattern and the lipid, lipoprotein, and apolipoprotein levels. Nonlocal 
participants were visited at their homes, and blood was transported on ice to the 
laboratory within 3 hours. All participants were Caucasian, and random mating was 
assumed. 
Detection and Analysis of Low Density Lipoprotein Subfraction Patterns 
LDL subfractions were detected by single spin density gradient ultracentrifugation 
according to a method described elsewhere (30). After ultracentrifugation the three 
major LDL subfractions - very light LDL1 (d = 1.030-1.033 g/ml), light LDL2 
(d = 1.033-1.040 g/ml), and dense LDL3 (d = 1.040-1.045 g/ml) - were visible as 
3 distinct bands in the middle of the ultracentrifugation tube. The tube of each 
subject was placed in a specially designed rack and photographed (17). After 
densitometric scanning of the slide of the tube with the LDL subfraction patterns 
in triplicate, different aspects of the densitometric curves, including peak height, 
peak width, peak area, and distances between peaks, were examined for their 
ability to describe an individual LDL subfraction pattern (Fig. 1). Analysis of the 
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densitometric scans was performed by the LKB 2190 GelScan program on an 
Apple lie computer, according to a method described elsewhere (17). As each 
subject showed her or his own LDL subfraction pattern, characterized by the 
relative contribution of the three major LDL subfractions to total LDL, all three LDL 
subfractions were considered in the search to define of a continuous variable to 
quantify the LDL subfraction profile. It appeared that both the relative peak height 
and relative peak area were most informative in expressing the relative contribution 
of each subfraction to total LDL. So, initially, two different continuous variables, 
based on peak heights and peak area (17) were introduced, to quantify the LDL 
subfraction patterns. Since similar results were obtained when the distribution of 
the LDL subfraction pattern quantified by either peak heights or peak area was 
analyzed, and since both continuous variables showed a strong significant 
correlation (r = -0.85, ρ <0.001), in the present report the results will be presented 
for the continuous variable based on peak heights and defined as parameter K. 
FIGURE 1 . Densitometrie scanning patterns of the low density lipoprotein (LDL) subfraction 
distributions, based on density gradient ultracentnfugation of sera. 
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Representative examples of a dense and buoyant LDL subfraction profile are shown. In scan I the 
highest peak is h3 ( = LDL3), reflecting a dense LDL subfraction pattern. In scan II the highest peak is 
hi ( = LDL1|, i.e., a buoyant LDL subfraction pattern. The relative peak heights were used to determine 
the relative contribution of the three LDL subfractions to total LDL, expressed in the quantitative 
parameter K. The dense LDL subfraction pattern (h1-h3<0) was characterized by a negative value of 
К (scan I; K = -0.22, calculated by K = (%h1-%h3]/(%h2-%h1 +1)|, whereas a more buoyant LDL 
subfraction pattern (h1-h3>0) was represented by a positive value of К (scan II; K = 0.18, calculated 
by K = (%h1-%h3)/(%h2-%h3 + 1)]. 
To express the relative contribution of each LDL subfraction to total LDL, the mean 
relative peak heights of the major LDL subfractions on the three scans (total LDL 
[100%] = LDL1 [%h1] + LDL2 [%h2] + LDL3 [%h3]) (Figs.1 and 2) were used 
to define parameter К as a continuous variable, to describe each individual LDL 
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subfraction pattern When a subfraction pattern was characterized by a 
predominance of buoyant LDL particles (h1-h3>0), К was calculated by 
K = (%h1-%h3)/(%h2-%h3 + 1) So the more buoyant LDL subfraction patterns, 
mainly consisting of LDL1 and LDL2, were characterized by positive values of К 
( 0 < K < 1 ) In the case of a predominancy of heavy, dense LDL particles 
(h1-h3<0), К was calculated by K = (%h1-%h3)/(%h2-%h1 + 1 ) , resulting in 
negative values of К (-1 < K < 0 ) for the more dense patterns, predominated by 
LDL2 and LDL3 (Figs.1 and 2) So the values of К varied between -1 and + 1, the 
value of -1 reflects a very heavy LDL subfraction profile consisting of one LDL 
subfraction, - i e , dense LDL3 -, whereas the value of + 1 reflects a very light LDL 
subfraction profile characterized by the presence of only very light LDL1 Although 
some of the information is lost in the calculation of parameter K, this quantitative 
measure provides an approximation of each individual LDL subfraction profile, 
reflecting the great intermdividual variety in LDL subfraction patterns Furthermore, 
parameter К allows the contribution of all three main LDL subfractions to total LDL 
to be taken into account, instead of only the major LDL subfraction, when the LDL 
subfraction pattern is defined (14,18,23,31) 
To compare the information provided by the continuous parameter К with the 
dichotomous classification as reported in the literature, the LDL subfraction 
patterns were also subdivided into a light ( = A ) or heavy (=B) LDL subfraction 
pattern, by introducing a threshold for parameter К We considered the LDL 
subfraction profile with a predominant LDL2 peak (h2) and with equal contributions 
of LDL1 and LDL3 (hi =h3) as to be the intermediate LDL subfraction profile, with 
the value of К being 0 (%h1-%h3 = 0) (Fig 2) With increasing relative contributions 
of LDL1, a light LDL subfraction profile was observed, with LDL1 and LDL2 
contributing most to total LDL (K = (%h1-%h3)/(%h2-%h3 +1)) The light LDL 
subfraction pattern A was defined by K > 0 With increasing relative contributions 
of LDL3, a more heavy LDL subfraction pattern was found, with LDL2 and LDL3 
contributing most to total LDL (К = (%h1-%h3)/(%h2-%h1 + 1 )) So the heavy LDL 
subfraction pattern В was defined by K < 0 (Fig.2). 
Plasma Lipid and Lipoprotein Assays 
The density of 2 9 ml of serum was raised to d = 1 019 g/ml by the addition of 0 5 
ml of a solution containing NaCI (11 42 g/l), KBr (133 48 g/l), and EDTA (0 1 g/l) 
(d = 1 10 g/ml). Very low density lipoprotein (VLDL) + intermediate density 
lipoprotein (IDL) were isolated by ultracentrifugation for 16 h at 40,000 rpm 
( 165,000g) in an IEC B-60 fixed-angle rotor 468 (Damon/IEC) ( 17) LDL cholesterol 
was calculated by subtraction of VLDL + IDL cholesterol and high density 
lipoprotein (HDL) cholesterol from total serum cholesterol HDL cholesterol was 
determined in whole plasma by the polyethylene glycol 6000 method (32) Serum 
total cholesterol and triglycerides were determined by enzymatic, commercially 
available reagents (Boehnnger Mannheim, FRG, cat no 237574 and Sera Pak, 
Miles, Italy cat no 6639, respectively). 
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Apoprotein В in the d > 1 . 0 1 9 g/ml fraction was determined in duplicate on two 
different plates by radial immunodiffusion in 0.8% (w/v) agarose in barbital buffer, 
pH 8.6. The 0.8% (w/v) agarose contained 0.3% (v/v) anti-apoB antiserum, raised 
in rabbits against human LDL (1.030-1.050 g/ml). When duplicates differed more 
than 10%, radial immunodiffusion was repeated (17). 
FIGURE 2. Pedigree of family 19, showing the densitometry scanning patterns of the LDL subfraction 
profiles obtained after density gradient ultracentnfugation of sera. 
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Each LDL subfraction profile is characterized by a specific value of parameter K, calculated as described 
in the legend of Figure 1. In addition, each LDL subfraction profile is classified as pattern A ( K > 0 ) , 
pattern В ( K < 0 | or the intermediate LDL subfraction pattern (K = 0 l . For each individual the age is 
indicated. OC= oral contraceptive user. 1 =LDL1 (1 030-1 033 g/ml); 2 = LDL2 (1.033-1.040 g/ml|, 
3 = LDL3 (1 040-1 045 g/ml). 
Complex Segregation Analysis 
The segregation of the LDL subfraction pattern in the families was studied using 
the mixed genetic model for nuclear families, as developed by Morton and MacLean 
(25-29). The main purpose of this model is to discriminate a major locus from 
polygenic and environmental effects. The mixed model assumes that the 
phenotype, i.e., the LDL subfraction pattern, results from the independent 
contribution of (1) a major locus, (2) a multifactorial transmissible component 
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(including polygenes and/or common environment), and (3) residual random 
environmental effects. The major locus effect results, under a genetic hypothesis, 
from segregation at a single locus of two alleles, С and c, leading to three 
genotypic classes (CC, Cc, and cc). The model does not include multiple alleles and 
two or more major loci (25). The mixed model allows analysis of both quantitative 
measurements (parameter K) and dichotomous variables (light (A) or heavy (B) LDL 
subfraction pattern). 
To increase the power of the segregation analysis to reveal genetic influences on 
the LDL subfraction profile, the LDL subfraction profile (i.e., parameter K) variation 
due to age, sex, and hormonal status was taken into account by introducing 
liability classes; each individual was assigned to one of five subgroups which were 
based on age, sex, and hormonal status in women (Table 1) and which were 
introduced into the model as discrete liablity classes (27). The values of parameter 
К were standardized within each liability class (mean=0; and SD = 1), to control 
for the parameter К variation due to age, sex, and hormonal status. The 
segregation analysis was performed on the standardized values of K. 
To be able to compare our results on the inheritance of the LDL subfraction pattern 
(parameter K) with those in the literature, the dichotomous classification in patterns 
A and B, based on parameter K, was also applied in the segregation analysis, in 
analogy with the study by Austin et al. (23). Again, in the distribution of patterns 
A and B, the variation dependent on age, sex, and hormonal status (Table 1 ) was 
controlled for by introducing discrete liability classes. 
The working method of the segregation analysis is to compare the likelihood of 
different modes of inheritance, both genetic and environmental. This requires the 
estimation of parameters appropriate to the different models tested. The 
parameters specifying the major locus include D, the degree of dominance at the 
major locus; T, the difference in means between opposite homozygous genotypes, 
expressed in SD units on the scale of parameter K; Q, the gene frequency of the 
major locus; and T 1 , T2, and T3, the respective probabilities that genotypes CC, 
Cc, and cc transmit the allele C. Recently, Iselius and Morton reported that only the 
use of Mendelian transmission probabilities (T2 = 0.5) were valid in the POINTER 
computer program (33). So, if the major locus is assumed to be Mendelian, T2 is 
fixed at 0.5 ( T 1 = 1 ; and T3 = 0). Parameter H represents the multifactorial 
(polygenic and/or cultural) heritability. Maximum-likelihood estimation was used 
and the -2 log likelihood values for the corresponding models were compared by 
a likelihood-ratio (X2) test. The results presented are confined to analyses of 
nuclear families. All calculations were performed using the computer program 
POINTER (27). 
STATISTICAL ANALYSIS 
Serum triglycerides and VLDL triglycerides were transformed logarithmically 
because of skewing of the distributions. Means and SDs of these variables are, 
however, reported in antilog units, for ease of interpretation. 
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To determine the difference in lipid and lipoprotein values, between LDL subfraction 
patterns A and B, these values were corrected for the influence of gender, age, 
body mass index (BMI), smoking habits, and OC use and were tested by analysis 
of covariance. All two variable interaction terms with the LDL subfraction pattern 
were included in the model. The nonsignificant interactions were deleted. This 
resulted in the inclusion of the interaction term between OC use and subfraction 
pattern for VLDL triglycerides. With the final model, adjusted lipid and lipoprotein 
values were estimated for 50-year-old, nonsmoking men with a BMI of 24, and the 
difference between LDL subfraction patterns A and B, in lipid and lipoprotein 
values, were tested by using analysis of covariance. 
Pearson correlation coefficients were computed to determine correlations between 
parameter К and the variables age, BMI, and smoking. Partial correlation 
coefficients, controlling for the effect of age, BMI, smoking, and OC use, were 
computed to determine correlations between parameter К and the variables serum 
cholesterol, serum triglycerides, LDL cholesterol, HDL cholesterol, VLDL 
cholesterol, VLDL triglycerides, and LDL apoB. 
Multiple linear-regression analysis was performed to determine the influence of 
gender, age, BMI, smoking habits, and OC use (independent variables) on 
parameter К (dependent variable). 
Stepwise multiple linear-regression including forward-selection and backward-
elimination procedures were used to examine significant contributions of the 
independent variables (serum cholesterol, serum triglycerides, LDL cholesterol, HDL 
cholesterol, LDL apoB, VLDL cholesterol, VLDL triglycerides) to the prediction of 
the parameter K. Any influence of gender, age, smoking habits, BMI, and OC use 
was taken into account by forcing them in each model. 
Statistical analysis involved procedures from the Statistical Analysis System 
computer programs (SAS Institute Incorporated, Cary, NC). 
RESULTS 
Characteristics of the Families 
In total, 162 subjects (80 men and 82 women) participated in the study. Because 
of a technical error, the LDL subfraction patterns of 3 subjects (second generation) 
were not determined. So, in total, 159 subjects (78 men and 81 women) were 
included in the analysis. The first generation included 19 men and 19 
postmenopausal women. None of the postmenopausal women used hormones. The 
mean age of this first generation was 65.4 ± 7.0 years; the women were 
significantly younger than the men (63.1 ± 6.4 versus 67.7 ± 7.0 years, 
respectively; t-test, p < 0 . 0 5 ) . The second generation included 121 subjects (59 
men and 62 women). These 62 women were all premenopausal, and 20 subjects 
(32%) were using low dose oral contraceptives. The mean age of the second 
generation was 31.5 ± 7.3 years, with no significant age difference between men 
and women (30.7 ± 7.3 versus 32.2 ± 7.2, respectively). For all subjects 
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(η = 159), the mean BMI was 22.8 ± 2.3, the men being heavier than women 
(23.2 ± 2.0 versus 22.3 ± 2.5, respectively; t-test, ρ < 0 . 0 5 ) . Of all subjects, 
24.5% (n = 39) were smokers (1-50 sigarettes per day). Among men there were 
significantly more smokers than there were among women (32.1 % versus 17.3%; 
X2-test, p < 0 . 0 5 ) . All subjects were normolipidemic; none of the subjects reported 
diseases or use of medications which are known to influence lipid metabolism. 
Analysis of the LDL Subfraction Patterns 
In all sera, mostly three distinct LDL subfraction bands could be distinguished in 
the LDL density range; they were separated by a clear interface. For each subject 
the LDL subfraction pattern was characterized by the relative contribution of the 
3 major LDL subfractions to total LDL, approached by the quantitative parameter 
K. So the light LDL subfraction patterns were characterized by a major peak of 
large, buoyant LDL1 or LDL2 and by a minor peak of smaller, denser LDL3, 
resulting in a positive value of К ( 0 < K < 1 ) , whereas the heavier, dense LDL 
subfraction patterns had both a major peak of small, dense LDL3 or LDL2 and 
skewing of the curve toward the lighter subfractions LDL1, resulting in a negative 
value of К ( - 1 < K < 0 ) (Figs.1 and 2). 
For the subjects studied, the values of К varied between -1 and + 1 . Among the 
studied subjects, the frequency distribution of К showed a normal distribution, as 
presented in Figure 3. 
Furthermore, the distribution of the LDL subfraction patterns appeared to be related 
to gender, age, and (in women) on hormonal status (Table 1). The median value 
of parameter К was significantly lower in men than in women (p< 0 . 0 0 1 , by 
Wilcoxon's test) and decreased with age, in both sexes. In addition, compared with 
premenopausal women not using OCs, women using OCs had a lower median 
value of K; the LDL subfraction pattern distribution among premenopausal women 
using OCs resembled that of men and postmenopausal women (Table 1). To be 
able to relate our results on the LDL subfraction pattern distribution, defined by 
parameter K, to those in the literature, we used parameter К to define patterns A 
and B, in analogy with other studies (18,23). Our distribution of LDL subfraction 
patterns A and B, based on parameter K, was strikingly consistent with previously 
reported results (18,23,31), even though a different isolation procedure and 
classification for the LDL subfraction patterns was applied (Table 1 ). These results 
indicate a strong relationship between parameter К and the previously reported 
classification in patterns A and B. 
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FIGURE 3. Frequency distribution of parameter К among 159 subjects. The heavy LDL subfraction 
pattern В was defined by K < 0 , whereas the light LDL subfraction pattern A was represented by values 
of K ï O . 
60 
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10 
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Reproducibility of the Quantification of the LDL Subfraction Profile 
Each LDL subfraction profile was scanned in triplicate. Within all triplicates the 
shape of the densitometric curves, including the number of peaks, the peak height, 
the peak width, and the distances between peaks, were similar. The mean value 
of К for the triplicates was -0.035 ( ± 0.234), -0.023 ( ± 0.211), and -0.030 
( ± 0.227), respectively (n = 159). 
The variation between triplicates (i.e., between subject within the population) was 
0.223, whereas the variation within triplicates (measurement error) was estimated 
to be 0.020. Between the triplicates, no systematic deviation in parameter К was 
found (one-way ANOVA, ρ = 0.41). 
The sera of 10 subjects were ultracentrifuged in duplicate at the same time, in two 
different tubes placed in two different ultracentifuges. Both tubes were photo­
graphed separately, and the LDL subfractions were quantitated by densitometric 
scanning as described. The mean values of parameter К for the duplicates were 
-0.077 ( ± 0.185) and -0.079 ( ± 0.179), respectively. The between- and within-
subject variation was 0.182 and 0.008, respectively. 
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To establish the intramdividual variation in the LDL subfraction profile in time, - i e , 
the variation in the value of parameter К during the year -, we determined the LDL 
subfraction profile of five different subjects on five different occasions (t = 0, t = 1 
month, t = 3 months, t = 6 months, and t = 1 year). The mean values of К on the 
five different occasions were -0.104 ( ± 0.242), -0 048 ( ± 0 173), -0 088 
( ± 0 200), -0.043 ( ± 0 233) and -0 033 ( ± 0 237), respectively Among the 
subjects, the variation of К was 0 210, whereas the variation within subjects was 
0 037. No significant change in the value of parameter К during the year was 
found (two-way ANOVA, ρ = 0.23) 
So the LDL subfraction profile, reflected in the densitometric curve and m the value 
of parameter K, appeared reproducible on repeated analysis of freshly isolated sera 
TABLE 1 Distribution of LDL subfraction pattern by gender, age and hormonal status 
Subjects 
FEMALE 
Premenopausal 
OC users 
control 
Postmenopausal 
age > 50 yrs 
MALE 
age 20 50 yrs 
age > 50 yrs 
η 
81 
20 
42 
19 
78 
59 
19 
Parameter K* 
0 047 ( 0 136, 0 1791 
0 038 ( 0 192, 0 130) 
0 083 ( 0 0 3 5 , 0 192) 
0 042 ( 0 143 0 207) 
0 041 ( 0 304 0 109) 
-0 009 ( 0 287 0 142) 
0 126 I-1 0 0 0 0 106) 
LDL subfraction pattern I 
Present 
study' 
3 1 % 
5 5 % 
1 7 % 
3 7 % 
5 8 % 
5 1 % 
7 9 % 
Austin et al 
1988 d 
2 5 % (η = 1 5 4 ) 
1 3 % (π = 1031 
4 9 % (n = 51) 
3 7 % (η = 147) 
4 4 % (n = 112) 
3 Determined By" 
McNamara et al 
1987 and Campos 
et al 1988 d 
1 5 % (n = 142) 
3 0 % (n = 43) 
4 4 % In = 138) 
η = number of subjects, " Expressed as median |50 l h percentile) Data in parentheses are the 10'" 
and 90'" percentiles " LDL subfraction pattern A (%) = 1 0 0 % - LDL subfraction pattern В |%) 
ς
 By density gradient ultracentnfugation, ' By gradient gel electrophoresis 
Interrelation of the LDL Subfraction Pattern with Anthropometric Measurements 
In Table 2 the mean age, BMI, and percentage of smokers among all subjects are 
indicated. The values of parameter К (n = 159) correlated significantly with age and 
BMI, indicating that, with increasing age and relative body weight, a more dense 
LDL subfraction pattern was present (Table 2). Parameter К did not correlate 
significantly with smoking habits (Table 2) Multiple linear regression analysis of 
parameter К revealed that age, gender, BMI, smoking habits, and OC use together 
contributed 2 2 % to the variation of parameter Κ, ι e , the LDL subfraction pattern 
These results indicate that the prevalence of relatively more dense LDL subfraction 
profiles was high among male subjects, smokers, and women using OCs and that 
it increased with age and BMI 
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Similar results were obtained when the pattern A/B classification was used; among 
subjects with a heavy LDL subfraction pattern В, a significantly higher BMI was 
noticed, compared with subjects with pattern A. In addition, among subjects with 
pattern B, there were significantly more smokers than there were among subjects 
with pattern A (Table 2). 
TABLE 2. Adjusted lipid, lipoprotein, and apolipoprotem levels, for all subjects and as stratified by 
light ( = A, K a O l and heavy LDL ( = B, K < O I subfraction patterns. 
All subjects Pattern A Pattern В Correlation coef. 
( n = 1 5 9 ) (n = 92) (n = 67) ( η = 1 5 9 Γ ρ value 
Afle (parents) 65.4 ± 7.0 63.1 ± 7.3 67.0 ± 6.5 
Age (children) 31.5 ± 7 . 3 31.3 ± 7 . 2 31.7 ± 7 . 4 -0.20 < 0 . 0 1 
BMI (kg/m2) 22.8 ± 2.3 22.4 ± 2.3b 23 3 ± 2.2 -0 30 < 0 . 0 0 1 
Smoking 2 4 . 5 % 1 6 . 9 % b 3 4 . 3 % -0.09 ns 
Total cholesterol' . . . 5.07 ± 0.12 5.26 ± 0 . 1 5 4.94 ± 0 . 1 3 0.01 ns 
Triglycerides" 1.12 ± 0 . 0 5 0.98 ± 0.06" 1.22 ± 0 . 0 5 -0.68 < 0 001 
LDL cholesterol* 3.19 ± 0.10 3 33 ± 0 . 1 3 3.10 ± 0 . 1 1 0.01 ns 
HDL cholesterol" . . . . 1.18 ± 0 . 0 4 1.34 ± 0.05" 1.07 ± 0.04 0.37 < 0 . 0 0 1 
VLDL cholesterol . . . . 0.70 ± 0.04 0.59 ± 0.04 b 0.77 ± 0.04 -0.49 < 0 001 
VLDL triglycerides" . . . 0.69 ± 0.06 0.57 ± 0.08" 0.77 ± 0.07 -0.70 < 0 001 
Apo В (g/l) 1.38 ± 0.05 1.34 ± 0 . 0 6 1.41 ± 0 . 0 5 -0.15 ns 
For age and BMI data are mean ± SD; for the lipid and lipoprotein levels data are mean ± SE. 
Mean values of lipid and lipoprotein levels are adjusted, with analysis of covanance, to those of 
50-year-old, nonsmoking men with BMI = 24 kg/m J . " concentration in mmol/l; ь p < 0 001 versus 
pattern B; c For age, BMI, and smoking habits, Pearson correlation coefficients with parameter К 
are shown; for the lipid and lipoprotein levels, partial correlation coefficients with parameter К (to 
control for the effect of age, BMI, and smoking habits) are shown. B M I = body mass index; LDL = 
low density lipoprotein; HDL= high density lipoprotein; VLDL= very low density lipoprotein; apo = 
apoprotein; n s = not significant. 
Interrelation between the LDL Subfraction Pattern and Lipid and Lipoprotein Levels 
The lipid and lipoprotein levels were within the normal range in all subjects (Table 
2). After correction for age, BMI, and smoking, the values of parameter К were 
found to be negatively correlated with serum triglycerides, VLDL triglycerides, and 
VLDL cholesterol levels and to be positively correlated with HDL cholesterol levels. 
So, with decreasing values of parameter K, - i.e., among the more dense LDL 
subfraction profiles - a more atherogenic lipoprotein profile was observed, 
characterized by higher serum triglyceride levels and lower HDL cholesterol levels. 
It was confirmed that, the heavy LDL subfraction pattern В was associated with 
a more atherogenic lipoprotein profile characterized by significantly higher levels 
of serum triglycerides, VLDL triglycerides, and VLDL cholesterol and with lower 
levels of HDL cholesterol (Table 2). As previously reported (17), all lipid and 
lipoprotein levels showed strong intercorrelations, except for total cholesterol and 
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LDL cholesterol levels, which did not correlate with HDL cholesterol levels (data not 
shown). Furthermore, all lipid and lipoprotein levels were positively correlated 
(p<0.001) with age and BMI; only age did not correlate with HDL cholesterol 
levels. Because of these interrelations between lipids and lipoproteins, stepwise 
multiple regression analysis was performed to evaluate which lipids or lipoproteins 
contributed significantly to the prediction of the LDL subfraction pattern. In most 
studies, in the literature, values of LDL cholesterol, VLDL cholesterol and VLDL 
triglycerides either were not available or were not considered. So, to be able to 
compare our results with those in the literature, the stepwise multiple regression 
analysis was performed twice, once excluding LDL and VLDL concentrations 
(model I) and once including values of LDL and VLDL (model II). 
TABLE 3. Regression coefficients and levels of significance for variables in models most appro­
priate for predicting low density lipoprotein density pattern, i.e., parameter K. 
Regression Coefficient ± SE (ρ), under 
Variable' Model I Model II 
(-VLDL and -LDL) ( + VLDL and + LDL) 
Intercept 0.086 ± 0.142 0.55 0.104 ± 0.141 0.46 
Sex 
group 1 0.043 ± 0.032 0.18 0 0 3 5 ± 0.031 0 26 
group 2 0 . 0 1 0 ± 0.032 0.76 -0.007 ± 0.032 0 82 
group 3 -0.033 ± 0.036 0.36 -0.042 ± 0.035 0.23 
Age (years) -0.002 ± 0.001 0.05 -0.002 ± 0 001 0.02 
BMI (kg/m2) -0.001 ± 0.006 0.91 -0.002 ± 0 0 0 6 0.70 
Smoking 0.002 ± 0.002 0.34 0.001 ± 0 0 0 2 0.49 
Total cholesterol 0.082 ± 0.015 0.00 0.072 ± 0 0 1 5 0 0 0 
LDL cholesterolb ....' ....d 
HDL cholesterol" ...." . .." 
Triglycerides" -0.431 ± 0.034 0.00 -0.218 ± 0.105 0 04 
VLDL cholesterol" ....' 0.177 ± 0 0 8 7 0 04 
VLDL triglycerides" ....' -0.366 ± 0 . 1 1 8 0 0 0 
ApoB(g/l) ...." ...." 
R' 0.60 0 6 3 
Group 1 = women not taking oral contraceptives versus men; Group 2 = women on oral contracep­
tives versus men; Group 3 = women on oral contraceptives versus women not taking oral contra­
ceptives. * The first five variables are forced into the model; " concentration in mmol/l; e This 
variable is not included m the model; " This variable does not contribute significantly to the model 
(P>0.05). BMI= body mass index; LDL= low density lipoprotein; HDL= high density lipoprotein, 
VLDL= very low density lipoprotein, apo= apoprotein 
Table 3 shows the results of the two different models that included gender, age, 
BMI, smoking habits, and OC use as covariates. Both backward and forward 
stepwise analysis revealed similar results. In model I, excluding LDL cholesterol, 
VLDL cholesterol, and VLDL triglycerides levels, the best model for prediction of 
parameter К included total cholesterol and serum triglycerides. No other lipid or 
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lipoprotein level reached the ρ = 0 05 level of significance When serum LDL 
cholesterol, VLDL triglycerides, and VLDL cholesterol levels were included in the 
model (model II), total cholesterol, VLDL cholesterol, VLDL triglycerides, and serum 
triglycerides appeared to make a significant contribution to the prediction of 
parameter K. Both models were similar in predicting parameter К (R2 = 0.60). So, 
including VLDL and LDL lipid levels in the model did not provide additional 
information in the prediction of the LDL subfraction pattern 
Complex Segregation Analysis 
An example for the segregation of the LDL subfraction patterns in one family is 
shown in Figure 2 In agreement with the results presented in Table 1, a high 
prevalence of the more dense LDL subfraction profiles (pattern B, or K < 0 ) was 
found among the male family members, whereas in most women a more light LDL 
subfraction pattern (pattern A, or K > 0 ) was observed, only one woman, who used 
oral contraceptives, had a very dense LDL subfraction profile. 
Complex segregation analysis was carried out using both the continuous variable, 
parameter К (Table 4), and the dichotomous classification in LDL subfraction 
patterns A and В (Table 5) To increase the power of the segregation analysis to 
reveal genetic influences on the LDL subfraction profile, the LDL subfraction 
pattern variation due to age, sex, and hormonal status, as reported above, was 
taken into account by introducing 5 liability classes (Table 1), the values of 
parameter К were standardized within each liability class, to control for age, sex, 
and hormonal status The segregation of parameter К in the families was tested on 
the standardized values of K. Similarly, when the dichotomous classification 
pattern A/B was applied in the segregation analysis, discrete liability classes were 
included in the POINTER computer program to control for age, sex, and hormonal 
status. 
Several hypotheses for genetic transmission of the LDL subfraction pattern in these 
Dutch families were tested by the POINTER computer program, postulating no 
familial clustering of the dense LDL subfraction profile beyond that occurring by 
chance (model 2), familial clustering without the influence of a major gene (model 
3), or genetic transmission by various modes of inheritance (models 4-7) The 
different models (models 1-7) and corresponding maximum likelihood parameter 
estimates are presented in Tables 4 and 5. The values in parenthesis were fixed in 
accordance with the model being tested The lower the value of -2 In L + C, the 
greater the likelihood, the better the fit of the model 
Results of the complex segregation analysis using parameter К 
When the standardized values of parameter К were used as a continuous variable 
in the POINTER program, the hypothesis that clustering of low values of Κ (ι e , 
heavy LDL subfraction patterns) in families does not exceed that expected to occur 
by chance (model 2) could be rejected, suggesting a genetic influence on the LDL 
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subfraction pattern (Table 4). The transmission models postulating either a 
multifactorial inheritance component only (model 3) or a general single locus 
(model 4) were also strongly rejected. So, both a multifactorial component and 
amajor gene must be included in the model of inheritance, explaining the 
distribution of the value of K, i.e., the LDL subfraction pattern distribution in our 
families. 
TABLE 4. Results of complex segregation analysis based on five liability classes and the standar­
dized continuous parameter K. 
Model H D Τ Q - 2 l n L + C Comparison X2(df] 
1. General mixed model 0.11 0.06 4.49 0.18 248.2 
2. No inheritance of susceptibility (0) (0) 340.3 2 vs 1 9 2 . 1 ( 2 ) " 
3. Multifactorial inheritance only . 0.38 (0) (0) (0) 328.9 3 vs 1 80.7 (3)" 
4. General single locus (Ol 0.11 4.67 0.17 264 9 4 vs 1 1 6 . 7 ( 1 ) " 
5. Dominant mixed model 0.09 (1.0) 3.63 0.02 269.5 5 vs 1 2 1 . 3 ( 1 ) " 
6. Additive mixed model 0.09 (0.5) 7.25 0.02 269.5 6 vs 1 21.3 (1)" 
7. Recessive mixed model 0.12 (0) 4.31 0.19 249.3 7 vs 1 1.1 (1) 
" p < 0 . 0 0 1 
TABLE 5. Results of complex segregation analysis based on four liability classes and a light (Pat­
tern A, K Ä O ) or heavy (Pattern B, K<0) low density lipoprotein subfraction pattern. 
Model Η D Τ Q - 2 l n L + C Comparison X2(df) 
1. General mixed model 0.001 0.48 2 59 0.37 130 4 
2. No inheritance of susceptibility (0) (0) 148.4 2 vs 1 1 8 . 0 ( 2 ) " 
3. Multifactorial inheritance only 0.77 (0) (0) (0) 131.1 3 vs 1 0 7 ( 3 ) 
4. General single locus (0) 0.49 2.59 0.37 130.4 4 vs 1 0 0 ( 1 ) 
5. Dominant single locus (0) (1.0) 1.64 0.37 130.7 5 vs 4 0 3 ( 1 ) 
6. Additive single locus (0) (0 51 2.56 0.37 130.4 6 vs 4 0 . 0 ( 1 ) 
7. Recessive single locus (0) (0) 1.69 0.82 130.8 7 vs 4 0.4 (1) 
" p < 0 . 0 5 
Indeed, the general mixed model (model 1), which includes both the multifactorial 
component Η and a major gene, had the lowest -2 In L + С value, - i.e., the 
greatest likelihood -thus supporting the data best. For the major locus, both the 
dominant (model 5) and additive (model 6) mode of inheritance were rejected. 
When a recessive mode of inheritance was set for the major locus (model 7), the 
results were consistent with the general mixed model (model 1). So the value of 
parameter К in our families appeared to be controlled by both a major autosomal 
recessive gene and a significant multifactorial inheritance component. The 
frequency of the proposed allele at the major locus that controls the values of 
parameter К was estimated to be 0.19. 
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In the general mixed model, approximately 6 4 % of the transmission variance could 
be accounted for by the major locus, 11 % by multifactorial inheritance, and the 
rest (25%) by random environmental exposures 
The general mixed model and the recessive mixed model (Table 4) were used to 
estimate the genotype-specific penetrance of the more dense LDL subfraction 
patterns, characterized by values of K < 0 Both the general and the recessive 
mixed model revealed similar results (Table 6). For subjects with genotype cc, in 
which с represents the presence of the defective gene causing dense LDL 
subfraction patterns (К < 0), the penetrance was 100%, indicating that all subjects 
with genotype cc will have a value of K < 0 For subjects with genotype Cc or CC, 
the probability of expressing a more dense LDL subfraction pattern was dependent 
on gender, age, and (in women) hormonal status, the risk of having a value of K < 0 
tended to increase with age, for both sexes, and was higher for men than for 
women. 
TABLE 6 
of K < 0 , 
Penetrance of dense 
by liability class 
low den sity lipoprotein 
cc 
subfraction pro) 
Penetrance, 
îles. characterized 
for genotype' 
Cc 
by values 
CC 
0 61 
0 86 
0 65 
0 21 
0 44 
0 75 
0 48 
0 11 
General mixed model 
Male 
age 20 50 years 1 0 
age > 50 years 1 0 
Female 
Premenopausal 
ОС users 1 0 
non ОС users 1 0 
Postmenopausal 
age > 50 years 1 0 0 46 0 30 
Recessive mixed model 
Male 
age 20-50 years 1 0 
age > 50 years 1 0 
Female 
Premenopausal 
ОС users 1 0 
non ОС users 1 0 
Postmenopausal 
age > 50 years 1 0 0 35 0 35 
* Allele с represents the defective allele causing the dense LDL subfraction patterns with values of 
K < 0 O C = oral contraceptive users 
Furthermore, it appeared that OC use was associated with a high penetrance of the 
more dense LDL subfraction patterns For example, in the general mixed model, 
0 4 9 
0 78 
0 53 
0 14 
0 49 
0 78 
0 53 
0 14 
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6 5 % of the women with genotype Cc and using OCs had a dense LDL subfraction 
profile ( K < 0 ) , compared with only 2 1 % of the premenopausal women not using 
OCs (Table 6). Note that, even in the absence of the defective с allele (genotype 
CC), there was still a high probability of values of K < 0 (Table 6). In the general 
mixed model, subjects with genotype Cc showed a slightly higher penetrance of 
the dense LDL subfraction patterns, compared with those with genotype CC, 
whereas, in the recessive mixed model, genotypes CC and Cc had, by definition, 
an identical risk of expressing a dense LDL subfraction pattern. 
TABLE 7. Frequency distribution of genotype present in subjects with light or heavy low density 
lipoprotein subfraction patterns, characterized by values of KaO and K < 0 , respectively 
Frequency, for genotype 
Pattern cc Cc CC 
General mixed model: 
Male: 
age 20-50 years K < 0 0.07 0.36 0.58 
KaO 0.00 0.24 0.76 
age > 50 years K < 0 0.04 0.33 0.63 
K;»0 0.00 0.20 0.80 
Female: 
Premenopausal 
ОС users K < 0 0 20 0.37 0.43 
K;>0 0.00 0.23 0.77 
non ОС users K < 0 0.06 0.35 0 59 
KâO 0.00 0.28 0.72 
Postmenopausal 
age > 50 years K < 0 0.09 0.37 0.54 
KaO 0.00 0.26 0.74 
Recessive mixed model: 
Male: 
age 20-50 years K < 0 0.07 0.29 0.64 
Кг>0 0.00 0.32 0.68 
age > 50 years K < 0 0.04 0.30 0.65 
KaO 0.00 0.32 0.68 
Female: 
Premenopausal 
ОС users K < 0 0.21 0.25 0 54 
KsO 0.00 0.32 0.68 
non ОС users K < 0 0.06 0.30 0.64 
KaO 0.00 0.32 0.68 
Postmenopausal 
age > 50 years K < 0 0.10 0.29 0.62 
KaO 0.00 0.32 0.68 
Allele с represents the defective allele causing the dense LDL subfraction patterns, characterized 
by values of K < 0 . OC= Oral contraceptive users 
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In Table 7, the frequency distribution of the genotypes present in subjects with 
light (K>0) or heavy (K<0) LDL subfraction patterns are shown for both the 
general and recessive mixed model (Table 4) For both models, similar results were 
obtained Among all subjects with light LDL subfraction patterns ( K > 0 ) , 
approximately 7 5 % (range 6 8 % - 80%) were expected to have genotype CC, and 
2 5 % (range 2 0 % - 32%) had genotype Cc, whereas genotype cc was not 
observed (Table 7) All subjects with heavy LDL subfraction patterns (K<0) had 
estimated frequencies of genotypes cc, Cc, and CC of approximately 7%, 3 0 % , 
and 6 3 % , respectively. Only among OC users with heavy LDL subfraction patterns 
(K<0), did the expected frequency of genotypes cc, Cc, and CC differ (20%, 
3 7 % , and 4 3 % , respectively, in the general mixed model) 
TABLE 8 Observed segregation ratios of low density lipoprotein subclass patterns A (KaOl and 
patterns В (K<0) 
Mating type 
(no of matmgs) 
A χ A (2| 
Α χ В (12) 
Β χ В (5) 
Pattern А 
17 194%) 
42 162%) 
14 (40%) 
Number of offspring 
Pattern В 
1 (6%) 
26 (38%) 
21 (60%) 
(%l 
Total 
18 (100%) 
68 (100%) 
35 (100%) 
Results of the segregation analysis using the pattern A /pattern В classification 
In Table 8, the observed segregation ratios for LDL subfraction patterns A and B, 
based on parameter K, among the 19 families are shown 
In order to be able to compare our results on the inheritance of the LDL subfraction 
profile (parameter K) with those in the literature, we also applied the pattern A / 
pattern В classification, based on parameter K, and 4 liability classes (men and 
three groups of women - ι e , premenopausal women using OCs, premenopausal 
women not using OCs, and postmenopausal women -, in the segregation analysis, 
in analogy to the procedure of Austin et al. (23) The results are shown in Table 
5 Whereas the model of no inheritance (model 2) could be firmly rejected, 
discrimination among the other models was not possible at the ρ < 0 05 level Most 
likely, since there is less power in using a dichotomous trait for the segregation 
analysis, the sample size in the present study was not large enough to discriminate 
between complex models of inheritance (ι e , models 3-7) 
DISCUSSION 
The results of the present study show that the distribution of the LDL subfraction 
pattern in a random sample of Dutch families has a genetic base, a common, highly 
penetrant, major autosomal recessive gene, with a population frequency of 0 19, 
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and an additional multifactorial inheritance component best explain the clustering 
of the dense LDL subfraction patterns in this population 
Several studies have suggested a possible genetic control of LDL heterogeneity, 
using a variety of techniques to detect LDL heterogeneity and to analyze its genetic 
susceptibility (19-24) Recent results from Austin et al's study of Mormons living 
in California are similar to our findings among Dutch families, in indicating that a 
ma|or locus is involved in determining the LDL subfraction pattern distribution (23) 
However, our data suggest that the inherited major gene was more likely to be 
recessive than dominant, whereas among the Mormon families a dominant mode 
of inheritance for the major locus was reported It should be noted, however, that 
both the recessive and additive major locus models could not be strongly rejected 
by Austin et al (0 0 5 < p < 0 1)(23) 
In addition, we now report a significant multifactorial inheritance component in the 
distribution of the LDL subfraction profile among the Dutch families, whereas no 
multifactorial hentability was found in the Mormon data Possibly, differences in 
prevalences of nongenetic risk factors e g , smoking and drinking habits, diet, 
relative body weight, and oral contraceptive use - may in part explain the apparent 
differences in genetic models, as these environmental influences have been 
associated with the LDL subfraction pattern (17,34,35) The presence, in the 
present study, of several of these environmental risk factors, along with the high 
prevalence of a dense LDL subfraction pattern, provided an opportunity to assess 
both environmental and genetic influences in the etiology of the LDL subfraction 
pattern distribution in the Dutch population The exclusion of most environmental 
risk factors among the Mormons, because of to their life style, may explain why 
no multifactorial inheritance component was found in data on them (23) 
Furthermore, the inheritance of the LDL subfraction patterns in the present report 
is based on the density distribution of the LDL particles, as LDL subfractions were 
detected by a density gradient ultracentnfugation method Austin et al (23) 
detected LDL subfractions by gradient gel electrophoresis, which separates the LDL 
particles on the basis of the difference in their sizes These two properties of the 
LDL subfractions, - i e , the size and the density - could differ in their susceptibility 
to genetic influences, contributing to a different mode of inheritance 
The differences in genetic models also raises the question whether the same alleles 
for inherited susceptibility occur in the two populations and whether gene dosage 
and gene environment interaction differ between Mormons and the Dutch 
population However, among American Caucasian subjects with familial combined 
hyperhpidemia, the LDL subfraction pattern, isolated by gradient gel 
electrophoresis, appeared to be influenced also by a major locus with an additive 
mode of inheritance and a significant multifactorial component (21), suggesting 
that the pattern of inheritance of the LDL subfraction profile is similar among 
different populations. 
In the present study, using density gradient ultracentnfugation, it appeared that 
each subject showed his or her own specific LDL subfraction pattern (17) To 
reflect the great intenndividual variability in LDL subfraction profile, the LDL 
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subfraction pattern was considered a quantitative trait and was approached by the 
continuous parameter K, which allows the contribution of all three major LDL 
subfractions to be taken into account. Most reports on LDL subfractions distinguish 
only 2 distinct LDL subfraction patterns, denoted "A" and "B", on the basis of the 
size of the LDL particle of only the major LDL subfraction (14,18,23,31). To be 
able to compare our results with those in the literature, we also defined a pattern 
A / pattern В classification by defining a threshold for parameter K. The distribution 
of LDL subfraction pattern А/В, determined on the basis of parameter K, was 
similar to that described by Austin et al. and McNamara et al., who defined their 
pattern A/B classification on the basis of the size of the major LDL subfraction 
(Table 1 ). These close similarities in the distribution of pattern A/B, under different 
definitions, indicate a strong relationship between К and the A/B classification, as 
reported by others. 
When a quantitative trait such as the LDL subfraction pattern is reduced to a 
dichotomy - i.e., LDL subfraction patterns A and В - much information is lost, since 
we do not know whether an individual is close to or far from the threshold. 
Moreover, where familial data are useful, quantitative traits of relatives are often 
more informative than their affection status (25). In addition, the mixed model is 
originally formulated in terms of quantitative traits. When, under a dichotomous 
classification, the mixed model is applied, - by defining, on an underlying 
continuous-liability scale, a threshold whose crossing results in affection - several 
difficulties have been reported (36); for example, there can be flatness of the 
likelihood surface, which complicates maximization of the likelihood, or local 
maxima obscuring true maximum likelihood. Indeed, in the present report, when the 
dichotomous classification of the LDL subfraction pattern - i.e., into patterns A and 
В - was used, the results of the segregation analysis suggested inheritance of the 
LDL subfraction pattern, but a more specific model of inheritance could not be 
defined. Most likely, since there is less power in using a dichotomous trait for 
segregation analysis, the sample size in the present study was not sufficiently large 
to discriminate among complex models of inheritance. Similarly, the discrimination 
among the Mendelian single-locus models reported by Austin et al. (23) was not 
strong. However, application of the quantitative parameter К in the segregation 
analysis resulted in a higher power to discriminate among complex hypotheses, 
compared with the pattern A and В classification; when using parameter K, a clear 
model of inheritance, the general mixed model was the only model that fitted the 
data; all the other models tested were strongly rejected ( p < 0.001). 
Our results thus suggest that the quantitative variable, parameter K, provides more 
information, resulting in the segregation analysis having a higher power to 
discriminate between complex models of inheritance. For the putative major locus, 
the penetrance of the more dense LDL subfraction profiles (К < 0) for subjects with 
genotype Cc was remarkably high and dependent on gender, age, and (in women) 
on hormonal status. Even in the absence of the defective с allele (genotype CC), 
expression of dense LDL subfraction patterns (K<0) was expected (Table 6). 
These results indicate that the phenotypic expression of the major locus respon-
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sible for dense LDL subfraction patterns (K<0) is strongly modulated by 
environmental, behavioral, and/or genetic background. In the general mixed model, 
6 4 % of the total variance in transmission of the heavy LDL subfraction patterns 
was represented by the major locus, whereas 11 % was accounted for by 
multifactorial inheritance and 25% by random environmental influences. These 
results support the hypothesis of etiological (i.e., transmission) heterogeneity, 
whereby in some families the dense LDL subfractions are primarily due to a major 
gene, whereas in other families the disease could be accounted for mainly by the 
multifactorial inheritance component This implies that both a major gene and 
environmental influences are operating, to variable extents, in the families studied. 
In an attempt to differentiate between genetically determined and environmental 
influences, the effects of smoking, body weight, OC use, and lipid and lipoprotein 
levels on the variability in LDL subfraction pattern were evaluated. In the present 
report, it appeared that 6 0 % of the variation in parameter K, - ι e , the LDL 
subfraction pattern - could be explained by gender, age, BMI, smoking habits, 
hormonal status in women (20%), and lipid and lipoprotein levels (40%), 
confirming the results of previous reports (17,18). Also, other biochemical 
influences that may be involved in the generation of LDL subfractions, such as the 
activity of several enzymes (cholesteryl ester transfer protein (37), hepatic lipase 
(38), and lipoprotein lipase (39) must be considered to account for some of the 
variability in the LDL subfraction distribution 
A dense LDL subfraction pattern, characterized by a high prevalence of small, 
dense LDL particles, has been associated with a high-risk lipoprotein profile, 
reflected by increased levels of serum triglycerides and decreased HDL cholesterol 
levels (16-18,24). This strong association between a dense LDL subfraction pattern 
and an atherogenic lipid profile raises the question whether the proposed gene for 
the dense LDL subfraction pattern is also responsible for the associated lipid and 
lipoprotein levels Alternatively, other genetic and environmental factors could 
influence the lipid and lipoprotein levels (40), which in turn may contribute to a 
heavy LDL subfraction pattern. Further elucidation of the genes involved in the 
expression of the LDL subfraction pattern and in lipid and lipoprotein levels could 
help us to understand these complex interrelationships. 
In summary, we conclude that the LDL subfraction pattern is a quantitative trait 
that can be described using the continuous parameter К Application of parameter 
К in the segregation analysis resulted in a higher power to discriminate between 
complex modes of inheritance, compared with the dichotomous classification into 
a light or heavy LDL subfraction pattern. The results indicate that the distribution 
of parameter K, - ι е., the LDL subfraction pattern in Dutch families - is the result 
of a combination of underlying genetic traits and environmental or behavioral traits 
Mapping and molecular characterization of this inherited susceptibility could both 
substantially aid the understanding of the prevalence of the dense LDL subfraction 
profile and contribute to the explanation of familial aggregation of coronary heart 
disease. 
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LINKAGE ANALYSIS AND THE LDL SUBFRACTION PROFILE 
ABSTRACT 
Low density lipoproteins (LDL) are heterogeneous and comprise discrete 
subfractions By density gradient ultracentrifugation of plasma of healthy 
individuals, 3 major LDL subfractions-LDL1 (d = 1 030-1 033 g/ml), LDL2 (1 033-
1 040 g/ml), and LDL3 (1 040-1 045 g/ml) - could be distinguished For each 
subject a specific LDL subfraction profile was observed, characterized by the 
relative contribution of the 3 major LDL subfractions to total LDL A continuous 
variable, parameter K, was defined to characterize each individual LDL subfraction 
pattern Complex segregation analysis of this quantitative trait demonstrated that 
the LDL subfraction pattern, described by parameter K, was controlled by a single 
major genetic locus and an additional significant multifactorial inheritance 
component As a small dense LDL subfraction profile has been associated with 
atherosclerosis, the elucidation of the molecular basis of this trait is important 
Since the LDL subfraction profile shows strong interrelationships with lipid and 
lipoprotein levels, we have investigated the impact of 7 candidate genes - ι e , the 
АРОВ gene, the AP0A1-C3-A4 gene cluster, the APOE-C1 C2 gene cluster, the 
APOA2 gene, the hepatic lipase (HL) gene, the lipoprotein lipase (LPL) gene, and 
the LDL receptor (LDLR) gene - on the LDL subfraction profile, by performing 
linkage analysis in 18 nuclear families No co-segregation was observed between 
the haplotypes of the 7 candidate genes and the phenotype of the LDL subfraction 
profile ( = parameter K) The peak LOD scores ranged between -7 999 and 0 166, 
at a recombination fraction (0) of zero, suggesting that these genes do not 
contribute to the LDL subfraction pattern phenotype in these families, under the 
assumption of a major genetic locus, influencing the LDL subfraction profile 
Although heterogeneity in the genetic basis for the LDL subfraction profile cannot 
be excluded, our results indicate that it is unlikely that the genetic abnormality, 
resulting in a small dense LDL subfraction profile, is in the 7 genes investigated in 
this study 
INTRODUCTION 
Several studies have shown that low density lipoproteins (LDL) comprise discrete 
subfractions (1-5), which differ in physicochemical composition (4-8), metabolic 
behavior (9-15), and atherogenic potential (16-24) A high prevalence of small, 
dense LDL particles has been associated with an increased risk of coronary heart 
disease and an atherogenic lipoprotein profile, consisting of relatively increased 
plasma triglyceride and apoprotein В levels, and decreased high density lipoprotein 
(HDL) levels (17-24) Most likely, LDL heterogeneity results from a large variety of 
genetic as well as environmental factors. It has been shown that the LDL 
subfraction profile is markedly influenced by age, gender, smoking habits, 
medication use, and lipid and lipoprotein levels (25-28) Since 1975, a possible 
genetic control of LDL heterogeneity has been suggested, using a variety of 
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techniques to detect LDL heterogeneity and to analyze its genetic susceptibility 
(29-35). Austin et al. (19,32) distinguished two LDL subfraction patterns, that is, 
a light (A) or heavy (B) pattern, determined by the particle size of the major LDL 
subfraction. Using complex segregation analysis, the inheritance of LDL subclass 
pattern B, in both primarily healthy families (32) and in families with familial 
combined hyperlipidemia (FCH) (34), was consistent with the presence of a single 
major genetic locus, whereas among the FCH families an additional significant 
multifactorial inheritance component was found (34). 
When using density gradient ultracentrifugation to detect LDL subfractions (4), we 
found that each subject showed his or her own LDL subfraction profile, 
characterized by the relative contribution of the 3 major LDL subfractions (LDL1, 
LDL2, LDL3) to total LDL (21). To reflect this great interindividual variability, we 
considered the LDL subfraction profile a quantitative trait and introduced a 
continuous variable, parameter K, to characterize each individual LDL subfraction 
profile (35). In a random sample of Dutch families, the small, dense LDL 
subfraction pattern, described by parameter K, appeared to be inherited as a single 
gene trait with a recessive mode of inheritance and a significant multifactorial 
inheritance component (35). 
To verify whether a major locus is implicated in determining the LDL subfraction 
profile, linkage analysis was performed. As the LDL subfraction profile shows 
strong interrelations with other lipid and lipoprotein levels (19,24,33), the 
candidate gene approach was applied to study the impact of 7 genes, that is, the 
АРОВ gene, the APOA1-C3-A4 gene cluster, the APOE-C1-C2 gene cluster, the 
APOA2 gene, the hepatic lipase (HL) gene, the lipoprotein lipase (LPL) gene, and 
the LDL receptor (LDLR) gene, on the LDL subfraction profile. The role of these 
candidate genes - genes at which allelic variations are likely to affect the LDL 
subfraction profile - was evaluated by seeking linkage between haplotypes of 
these candidate genes and the LDL subfraction profile. Eighteen nuclear families, 
in total 153 subjects, were included in the analysis. Linkage analysis was 
performed by considering the LDL subfraction profile as either a quantitatively or 
a qualitatively inherited trait. 
SUBJECTS AND METHODS 
Families 
Eighteen nuclear families, consisting of both parents and their children, in total 153 
individuals, gave their informed consent to participate in this study. All subjects 
were normolipidemic and no cardiovascular or other serious diseases were 
reported. The families have recently been described in detail elsewhere (35). 
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LDL Subfractionation 
From each subject blood samples were obtained, after an overnight fast, in 
evacuated collection tubes (Corvac) for the LDL subfraction analysis and in EDTA-
containing tubes for DNA analysis. Plasma was separated from the cells by 
centrifugation at 500 g for 10 min at room temperature. The cells were stored at 
-80°C and used to isolate genomic DNA. The LDL subfraction analyses were 
performed on fresh, unfrozen sera. The LDL subfractions were detected by single 
spin density gradient ultracentrifugation, as described previously (4). After 
ultracentrifugation, the 3 major LDL subfractions - very light LDL1 (d = 1.030-1.033 
g/ml), light LDL2 (d = 1.033-1.040 g/ml), and dense LDL3 (d = 1.040-1.045 g/ml) -
were visible as 3 distinct bands in the middle of the ultracentrifuge tube. Each 
subject showed his/her own LDL subfraction pattern, characterized by the relative 
contributions of the 3 major LDL subfractions to total LDL. The tube of each 
subject was placed in a specially designed rack and photographed. After 
densitometric scanning of the slide of the tube with the LDL subfraction pattern in 
triplicate, peak identification was performed by the LKB 2190 GelScan program on 
an Apple lie computer, as described elsewhere (21). To express the relative 
contribution of each LDL subfraction to total LDL, the mean relative peak heights 
(%h) of the 3 major LDL subfractions on the three scans (total LDL [100%] = 
LDL1 [%h1] + LDL2 [%h2] + LDL3 [%h3]) were used to define parameter К as 
a continuous variable, to characterize each individual LDL subfraction pattern (35). 
When a subfraction pattern was characterized by a predominance of buoyant LDL 
particles, that is, LDL1 and LDL2 (h1-h3>0), К was calculated by 
К = (%h1-%h3)/(%h2-%h3 + 1 ), resulting in positive values of К ( 0 < К < 1 ) for the 
more light, buoyant LDL subfraction profiles. In the case of a predominancy of 
heavy, dense LDL particles ( h 1 - h 3 < 0 ) , К was calculated by 
К = (%h1-%h3)/(%h2-%h1 + 1 ) , resulting in negative values of К (-1 < K < 0 ) for 
the more dense patterns, predominated by LDL2 and LDL3 (35). To compare the 
information provided by the continuous parameter К with the dichotomous 
classification, as reported in the literature (19,32), the LDL subfraction patterns 
were also arbitrarely subdivided into a light ( = A) or heavy ( = B) LDL subfraction 
pattern, by introducing a threshold for parameter K. The light LDL subfraction 
pattern A was defined by K^O and the heavy LDL subfraction pattern В was 
defined by K < 0 , as described in detail elsewhere (35). 
DNA Extraction and Polymorphisms 
Genomic DNA was prepared from white blood cells by standard methods (36). For 
genotyping conventional, mostly two-allele RFLPs (restriction fragment length 
polymorphisms), highly informative VNTR (variable numbers of tandem repeat) and 
MS (microsatellite) polymorphisms were analyzed. The DNA polymorphisms were 
detected by Southern blot analysis (SBA) (37) or polymerase chain reaction (PCR) 
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based techniques (38) The polymorphisms of the 7 candidate genes and their 
chromosomal location are listed in Table 1 
TABLE 1 The polymorphisms of 7 candidate genes used in the linkage analysis 
Gene 
АРОВ 
APOA2 
APOEC1-C2 
APOA1 C3 A4 
Lipoprotein lipase 
LDL receptor 
Hepatic lipase 
Chromosome 
2p24 p23 
1q21 q23 
1 9 q 1 3 2 
11q23 qter 
6p22 
19p13 3 
15q21 q23 
Polymorphism 
SBA/Xöal 
SBA/fcoRI 
PCR/VNTR 
PCR/MS 
PCR/APOC2/MS 
PCR/APOC3/MS 
SBA/W/лсІІ 
SBA/SamHI 
SBA/Pvu\ 
PCn/Taq\ 
PCR/AvaU 
PCRWcol 
PCRIHmcU 
PCR/Sful 
SBA/Mspl 
SBA/flff/ll 
SBA/W/nrflll 
Reference 
Priestley et al 19Θ5 (39) 
" 
Boerwinkle et al 1988(401 
Weber é ta l 1989 (41) 
Weber é ta l 1989 (41) 
Zuhani é ta l 1990 (42) 
Heinzman et al 1987 (43) 
" 
• 
Top et al 1991 (44) 
" 
" 
" 
" 
Datta et al 1988 (45) 
" 
" 
SBA= Southern blot analysis PCR= polymerase chain reaction VNTR= variable number of tan 
dem repeat marker, MS = microsatellite marker LDL low density lipoprotein APO apoprotein 
Southern blot analysis Genomic DNA was digested with restriction enzymes, using 
2-10 units of enzyme per /vg of DNA, under conditions recommended by the 
manufacturer (Pharmacia) The DNA fragments were subjected to agarose gel 
electrophoresis and transferred to nitrocellulose filters by Southern blotting 
techniques, as previously described (37) Thereafter, the DNA was hybridized with 
32P-dCTP labeled probes to detect the RFLPs The labelling of probes, hybridization, 
and washing conditions were performed, as reported previously (37) 
Polymerase chain reaction. To amplify the VNTR region at the З'-end of the АРОВ 
gene, the polymerase chain reaction (PCR) was performed with tailored 
oligonucleotides and thermostable Taq polymerase The amplification products 
were separated by agarose gel electrophoresis and visualized by staining the gel 
with ethidium bromide (40) For the LDL receptor gene, five pairs of oligonucleotide 
primers, derived from the sequence flanking the polymorphic AvaW, Nco\, Taq\, 
HmcW, and Stu\ sites, were used to amplify the respective regions (44) The PCR 
products were digested with the respective enzymes at 37°C for 16 h, according 
to recommendations of the supplier (Pharmacia) Thereafter, the digestion products 
were separated on gel, stained with ethidium bromide, and photographed The MS 
polymorphisms in AP0A2, APOC2, and APOC3 were analyzed with a PCR based 
protocol (41,42) (Table 1) 
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Segregation and Linkage Analysis 
The segregation of the LDL subfraction profiles in the Dutch families was studied 
using the mixed genetic model for nuclear families, as developed by Morton and 
MacLean (46-50). The results indicated that the distribution of the LDL subfraction 
profiles ( = parameter K) in these families was controlled by both a common, highly 
penetrant, major autosomal recessive gene, with a population frequency of 0 19, 
and a significant multifactorial inheritance component, as described previously (35) 
As the heavy, dense LDL subfraction profile may thus be inherited as a single gene, 
linkage of that hypothetical susceptibility gene and several marker genes were 
evaluated statistically by the LINKAGE computer program (Linkage 5 03), 
developed by Lathrop and Lalouel (51-54) 
Eighteen nuclear families, including 153 subjects, were tested for cosegregation 
of allelic variations of 7 candidate genes with the LDL subfraction profile The odds 
that the heavy, dense LDL subfraction pattern and a specific marker gene were 
inherited together by chance (no linkage), were compared with the odds that the 
dense LDL subfraction pattern and the marker gene were coinhented more often 
(linkage). The strength of evidence for or against linkage was expressed by the lod 
score (LOD), which is the log 1 0 of the ratio of these two odds Lod scores were 
calculated at various recombination fractions, where the lod score for each 
recombination fraction is the base-ten logarithm of the odds in favor of linkage 
versus non-linkage. Lod scores of + 3 . 0 or more were taken as very strong 
evidence for linkage; a lod score of -2 0 or less was taken as strong evidence 
against linkage. A lod score close to zero reflects little information for linkage of 
the dense LDL subfraction profile to the marker 
The linkage analysis was performed twice by introducing the LDL subfraction 
profile as either (1) a qualitative trait, defined by an affected (heavy LDL 
subfraction pattern В) or non-affected (light LDL subfraction profile A) status, or 
(2) a quantitative trait, expressed by parameter К The variation in the distribution 
of patterns A and B, dependent on age, sex, and - in women - hormonal status, 
was taken into account by introducing liability classes; each individual was 
assigned to one of 5 subgroups (Table 2), which were based on age, sex, and 
hormonal status (35), and which were introduced into the model as discrete liability 
classes. For each genotype (CC, Cc and cc, in which allele с represents the 
defective allele causing the heavy LDL subfraction profile В), the associated 
penetrance, dependent on the liability class (Table 2, ref. 35), was introduced into 
the LINKAGE program Similarly, when using the quantitative parameter K, the 
values of parameter К were standardized within each liability class (mean = 0; and 
SD = 1 ) to control for parameter К variation due to age, sex, and hormonal status. 
The linkage analysis was performed on the standardized values of parameter K. The 
penetrance values were replaced by mean values (μ) and variances (σ) of parameter 
К by genotype; for the genotypes CC, Cc, and cc, the mean value of parameter К 
was estimated μ
ζζ
 = 0.225, μ
Ζο
 = -0.044 and μ00 = -4.265, respectively, with 
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σ = 0.624. No difference in variance between homozygotes and heterozygotes 
was assumed. 
TABLE 2. Penetrance of the dense low density lipoprotein subfraction profiles, characterized by 
values of K<0, by liability class. 
Penetrance, for genotype 
ce Ce CC 
General Mixed Model 
Male 
age 20-50 years 1.0 0.61 0.44 
age > 50 years 1.0 0.86 0.75 
Premenopausal 
OC users 1.0 0.65 0.48 
non OC users 1.0 0.21 0.11 
Postmenopausal 
age > 50 years 1.0 0.46 0.30 
Allele с represents the defective allele causing the dense LDL subfraction patterns, characterized 
by values of K<0. OC= oral contraceptive users. 
RESULTS 
Analysis of the LDL Subfraction Patterns 
In all sera, mostly three distinct LDL subfraction bands could be distinguished in 
the LDL density range. For each subject, the LDL subfraction pattern was 
characterized by the relative contribution of the 3 major LDL subfractions to total 
LDL, approached by the quantitative parameter К (35). The values of parameter К 
varied between -1 and + 1; a positive value of К ( 0 < K < 1) represented a light LDL 
subfraction pattern, characterized by a high relative contribution of buoyant LDL1 
and LDL2 to total LDL, whereas the more heavy LDL subfraction patterns, in which 
LDL2 and LDL3 contribute most to total LDL, were characterized by a negative 
value of К ( - 1 < K < 0 ) . The frequency distribution of parameter К among the 
studied subjects showed a normal distribution (35). 
To be able to relate our results on the LDL subfraction pattern distribution, defined 
by parameter K, to those in the literature, we used parameter К to define patterns 
A and B, in analogy with other studies (19,32). Our distribution of patterns A and 
B, based on parameter K, was strikingly consistent with previously reported results, 
even though a different isolation procedure and classification for the LDL 
subfraction patterns was applied (35). The distribution of the LDL subfraction 
patterns appeared to be related to gender, age, and in women depending on 
hormonal status; the prevalence of the heavy pattern В was higher in men than in 
women and increased with age in all subjects. Furthermore, women using oral 
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contraceptives had a very high prevalence of pattern В compared to women not 
using hormones. Among subjects with a heavy LDL subfraction profile a more 
atherogenic lipoprotein profile was found, consisting of relatively increased VLDL 
lipids and decreased HDL cholesterol levels (35). These results have been described 
in detail previously (35). 
Definition of the Haplotypes for the 7 Candidate Genes 
For the АРОВ gene, 15 of the 18 families were informative with the 3'-VNTR 
marker (Table 1). Linkage disequilibrium between the fcoRI, Xba\, and VNTR sites 
was such that Xba\ and fcoRI did not contribute additional genotypic information 
over the VNTR genotypes, except for one family, in which only the fcoRI 
polymorphism was informative, allowing the definition of the haplotypes necessary 
to track the inheritance of the АРОВ gene in this family. In the 2 remaining families 
one parent appeared to be homozygous by haplotype analysis with all 3 markers. 
For the APOA2 gene, the APOE-C1-C2, and the AP0A1-C3-A4 gene clusters, the 
MS markers (Table 1) were informative in 12, 6, and 8 families, respectively, out 
of the total number of 18 families tested. For the HL, LPL, and LDLR gene the 
haplotypes were formed by 3, 3, and 5 RFLPs, respectively (Table 1). Out of 18 
families, only 3 families appeared to be informative for the HL and LDLR genes and 
4 families were informative for the LPL gene. In the remaining families either one 
of the parents was homozygous or both parents were heterozygous, decreasing the 
linkage information in the pedigrees. 
Linkage Analysis 
Linkage analysis was performed to test for cosegregation of the haplotypes of the 
7 candidate genes with the LDL subfraction profile. The number of families tested 
for АРОВ, APOA2, AP0E-C1-C2, APOA1-C3-A4, HL, LPL, and LDLR were 18 (2), 
12 (0), 8 (2), 9 (1), 12 (9), 5 (1), 3 (0), respectively, where the numbers between 
brackets indicate the number of families in which one parent appeared to be 
homozygous. The remaining families were not included in the linkage analysis, as 
both parents were heterozygous, providing no additional information on linkage. 
In Table 3, the results of the linkage analysis are shown when using the 
dichotomous classification into a heavy (pattern B, K < 0 ) or light (pattern A, K > 0 ) 
LDL subfraction profile. The total lod score for all markers ranged between -0.311 
and 0.312 at a recombination fraction (Θ) of zero, providing no information for 
linkage of the heavy, dense LDL subfraction pattern В to one of these markers. For 
each family a nonsignificant lod score (values close to zero) was obtained for all 
markers at recombination fractions between 0 and 0.5 (data not shown). 
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TABLE 3. Total lod scores between the haplotypes of 7 candidate genes with the heavy, dense 
LDL subfraction patterns |K<0), using the dichotomous classification for the LDL subfraction 
profile 
Recombination fraction (Θ) 
АРОВ 
APOE-C1 
APOA2 
LDLR 
LPL 
HL 
-C2 
APOA1-C3-A4 
0 00 
-0 311 
0 267 
-0 206 
-0 044 
-0 017 
0 312 
-0 137 
0 01 
-0 305 
0 260 
-0 200 
-0 042 
-0 016 
0 306 
-0 129 
0 05 
-0 245 
0 234 
-0 175 
-0 033 
0014 
0 277 
-0 101 
0 10 
-0 182 
0 199 
0 138 
0 024 
-0 011 
0 237 
-0 073 
0 20 
-0 095 
0 128 
-0 079 
-0 012 
-0 006 
0 152 
-0 035 
0 30 
-0 040 
0 063 
0 035 
0 005 
-0 003 
0 075 
-0 014 
0 40 
0 010 
0017 
0 009 
0 001 
-0 001 
0 020 
-0 003 
APO, apoprotein, LPL, lipoprotein lipase, HL, hepatic lipase, LDLR, LDL receptor 
The linkage analysis was repeated, now introducing the standardized values of 
parameter K, to describe each individual LDL subfraction pattern. The lod score for 
each marker at various recombination fractions was calculated for each individual 
family (data not shown). Depending on the computed lod score value, the families 
were categorized arbitrarily as class I, II, or III. Families with negative lod scores 
were defined as class I families, suggesting that the dense LDL subfraction profile 
is not linked to the marker; only those families with a lod score <-2 provide strong 
evidence against linkage. Class II families, characterized by a lod score close to 
zero (-0 1 0 0 < lod score < 0 . 1 0 0 ) , provided little information for linkage of the 
dense LDL subfraction pattern to that marker, whereas class III families had more 
positive lod scores, indicating increasing evidence for linkage of that marker to the 
hypothetical susceptibility allele (Table 4). 
For the АРОВ gene, 2 class I families were found, with lod values of -6 091 and 
-2.499. The sum of the lod scores from these two class I families was -8 590 at 
0 = 0, which strongly indicated exclusion of linkage of the АРОВ gene to the LDL 
subfraction pattern in these families. The remaining 15 families had lod scores 
between -0.021 and +0.028 (Class II families), providing no information on 
linkage. Only one family had a positive lod score of + 0 . 5 9 7 , which may favor 
linkage, although not reaching statistical significance The total lod score of all 18 
families was -7 999 at 0 = 0 (Table 4). 
The results for the APOE-C1-C2 gene cluster revealed 2 class I families and 6 class 
II families. The sum of the lod scores at 0 = 0 from all families was -5 516 
Among the 12 families informative for the APOA2 MS marker, linkage analysis 
revealed 1 class I family with a lod score of -2.504, whereas 11 families were 
defined as class II families (lod scores between -0.012 and + 0.012) The total lod 
score including all families was -2.514 at 0 = 0 . 
For both the LDLR gene and the LPL gene, linkage analysis revealed only 1 family 
with a lod score of -2.521 and -2.508, respectively (class I family), whereas the 
remaining families presented non-informative lod scores (between 0 002 and 0.005 
174 
LINKAGE ANALYSIS AND THE LDL SUBFRACTION PROFILE 
at 0 = 0 for the LDLR gene and between -0.005 and 0.034 at 0 = 0 for the LPL 
gene). 
For the HL gene a small, negative total lod score was found (-0.259 at 0 = 0), 
which did not reach statistical significance, thus providing no information on 
linkage of the LDL subfraction profile with the HL gene. 
Only for the APOA1-C3-A4 gene cluster, the inheritance of the LDL subfraction 
phenotype ( = parameter K) was compatible with segregation of the APOA1-C3-A4 
alleles. This, however, was not statistically significant (lod score 0.166 at 0 = 0, 
Table 4). 
In Table 5, the cumulative lod scores, including all families, computed at different 
recombination fractions are shown. The total lod score analysis, including all 
families, gave high negative numbers (between -7.999 and -2.485 at О = 0) for all 
markers, except for the HL and APOA1-C3-A4 gene cluster (-0.259 and 0.166 at 
0 = 0, respectively). These data strongly support the hypothesis that the АРОВ, the 
APOA2, the APOE-C1-C2, the LDLR, and the LPL gene are not the direct cause of 
the dense LDL subfraction profile. However, as shown in Table 4, lod score 
analysis of all families excluded any absolute linkage between these genes and the 
LDL subfraction profile in only 1 or 2 families (Class I families), whereas the 
possibility of linkage in the rest of the families could not be excluded (Class II 
families). 
TABLE 4. The results of the linkage analysis of the LDL subfraction pattern, defined by parameter 
K, with the haplotyping of 7 candidate genes, stratified by lod score value. 
LOD SCORES AT Θ = 0 
АРОВ 
APO E-C 1 
AP0A2 
LDLR 
LPL 
HL 
-C2 
AP0A1-C3-A4 
CLASS 1 families 
min 
-6.091 
-3 0 3 8 
-2.504 
-2.521 
-2.508 
-0.253 
max 
-2 499 
-2.496 
-0.105 
sum 
-8.590 (n = 
-5.534 (n = 
-2.504 (n = 
-2.521 (n = 
-2.508 (n = 
-0.358 |n = 
 2) 
 2) 
 1) 
 i i 
 1) 
 2] 
CLASS II families 
mm 
-0.021 
-0 013 
-0.012 
0 002 
-0 005 
-0.024 
-0.062 
max 
0 028 
0.026 
0.012 
0 005 
0 0 3 4 
0.098 
0 0 1 3 
sum 
-0.006 (n = 
0.018 (n = 
-0.009 (n = 
0.007 |n = 
0.023 (n = 
0.098 (n = 
-0.033 |n = 
 15) 
 6) 
 11) 
2) 
 4) 
 10) 
8) 
Total LOD 
-7.999 (n = 
-5.516 (n = 
-2.514 (n = 
-2 513 (n = 
-2.485 (n = 
-0.259 |n = 
0.166 |n = 
= 18) 
= 8) 
= 12) 
= 3) 
= 51 
 12) 
 9) 
Class I families are defined by negative lod scores, which suggest no linkage of the LDL subfrac­
tion profile to the gene. Only those families with lod scores <-2 provide strong evidence against 
linkage. Class II families have lod values close to zero (-0.100< lod score < 0 . 1 0 0 ) which do not 
provide significant information regarding linkage. For both the АРОВ and AP0A1-C3-A4 gene 
cluster, only 1 class III family was found with a positive lod score of 0.597 and 0.198, respec­
tively, which is in favor of linkage, although non-significant. The total lod score was calculated by 
summing the lod scores of all individual families. 
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TABLE S. Total lod scores for linkage of the LOL subfraction pattern, defined by parameter K, with 
the haplotypmg of 7 candidate genes 
Recombination fraction (Θ) 
АРОВ 
APOE-C1 
APOA2 
LDLR 
LPL 
HL 
-C2 
APOA1-C3-A4 
0 00 
-7 999 
-5 516 
-2 514 
-2 513 
-2 485 
-0 259 
0 166 
0 01 
-3 256 
-2 288 
-1 165 
-1 264 
-1 222 
-0 256 
0 105 
0 05 
-1 987 
-1 023 
-0 566 
-0 656 
-0 591 
-0 229 
0 169 
0 10 
-1 167 
-0 555 
-0 359 
-0 429 
-0 349 
-0 179 
0 158 
0 20 
-0 489 
-0 195 
-0 156 
-0 220 
-0 148 
-0 088 
0 111 
0 30 
-0 208 
-0 063 
-0 061 
-0 097 
-0 058 
-0 033 
0 057 
0 40 
0 053 
-0 013 
-0 014 
0 024 
-0 014 
-0 007 
0 015 
APO, apoprotein, LPL, lipoprotein lipase, HL, hepatic lipase, LDLR, LDL receptor 
DISCUSSION 
Several studies have indicated that a major locus may be involved in determining 
the LDL subfraction profile (31-35). In an attempt to map the chromosomal location 
of this hypothetical susceptibility gene, we evaluated the impact of 7 candidate 
genes on the LDL subfraction profile, by performing linkage analysis, using the 
candidate gene approach; the products of all the genes studied in this report, 
including those encoding apolipoproteins (АРОВ, APOA2, APOE-C1-C2, and 
APOA1-C3-A4), enzymes (lipoprotein and hepatic lipase) and receptors (LDL 
receptor), are known to be involved in the atherogenic process and lipid 
metabolism, and may thus contribute to LDL heterogeneity. 
Our results indicate that when searching for linkage between the candidate genes 
and the LDL subfraction profile, by defining the LDL subfraction affection status, 
i.e., a light (A) or heavy (B) LDL subfraction pattern, not enough information was 
provided to confirm or exclude linkage; the peak lod scores ranged between -0 311 
and 0.312, at a recombination fraction (Θ) of zero (Table 3). 
However, application of the continuous parameter K, which accurately describes 
each individual LDL subfraction profile, resulted in a higher power of the linkage 
analysis. No cosegregation of the LDL subfraction profile, defined by the 
continuous parameter K, with one of the candidate genes haplotypes was found 
(Table 5); the maximal lod scores for linkage of parameter К to the АРОВ gene, the 
APOE-C1-C2 gene cluster, the AP0A2 gene, the LDL receptor gene, and the 
lipoprotein lipase gene, were -7.999, -5.516, -2.514, -2.513, and -2 485, 
respectively, at a recombination fraction of zero. So, under the assumption of a 
single gene model, it is unlikely that the АРОВ gene, the APOA2 gene, the 
APOE-C1-C2 gene cluster, the LPL gene, or the LDLR gene are involved in 
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determining the LDL subfraction profile. However, it should be noted that lod score 
analysis of all families excluded any absolute linkage between these genes and the 
LDL subfraction profile in only 1 or 2 families (class I), which revealed significant 
negative lod scores (<-2), whereas in the remaining families (class II) the 
possibility of linkage could not be excluded (Table 4) For the HL gene a 
nonsignificant negative lod score was found, providing no information on linkage 
of the LDL subfraction pattern to the HL gene, whereas the inheritance of the LDL 
subfraction phenotype ( = parameter K) was compatible with segregation of the 
APOA1-C3-A4 alleles, although not reaching statistical significance (lod score 
0 166 at 0 = 0, Table 4) 
Recently, several studies have demonstrated that the proposed gene responsible 
for the LDL subfraction profile is unlikely to be the АРОВ gene, in both healthy 
families (55,56) and in families with FCH (57) However, for the other candidate 
genes, confirmation in additional sets of families will be necessary 
Recently, linkage of FCH to the APOA1 C3 A4 gene cluster on chromosome 11 
(58) and linkage of the so called "atherogenic lipoprotein phenotype" (ALP) to the 
LDL receptor on chromosome 19 (59) has been demonstrated Both conditions are 
strongly associated with coronary artery disease and characterized by the presence 
of predominantly small, dense LDL particles, with the associated plasma lipoprotein 
changes, that is, relatively increased plasma triglyceride and decreased HDL 
cholesterol levels The fact that linkage of the small, dense LDL subfraction profile 
with the A1-C3-A4 cluster or the LDL receptor could not be reconfirmed in our 
families may suggest heterogeneity between families in the etiology of a small, 
dense LDL subfraction profile So, the cause of a dense LDL subfraction profile 
may not be the same in each affected individual Furthermore, the underlying 
mechanisms involved in a dense LDL subfraction profile may differ among subjects 
with FCH or the "atherogenic lipoprotein profile" The LDL subfraction profile may 
thus be genetically heterogeneous, so that families are analyzed together that 
actually have different susceptibility genes 
The LDL subfraction patterns in the present report were based on the density 
distribution of the LDL particles, as LDL subfractions were detected by a density 
gradient ultracentrifugation method (4) Austin et al (19,32) detected LDL 
subfractions by gradient gel electrophoresis, which separates the LDL particles on 
the basis of size differences These two properties of the LDL subfractions - i e , 
the size and the density - could have different susceptibility genes, which may 
complicate the comparison of the results on genetic studies of LDL heterogeneity 
However, recently, we showed that both methods show a high degree of 
agreement for some important physicochemical characteristics of LDL 
heterogeneity (5) Confirmably, a similar frequency of the light (A) and heavy (B) 
LDL subfractions was reported in different populations, in spite of the different 
isolation and classification procedures used (35) 
Comparison of the results of the linkage analyses in different studies should also 
be interpreted with caution, as different assumptions may have been used, 
influencing the outcome Firstly, linkage analysis assumes that the mode of 
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inheritance and allele frequency of the trait have been correctly specified, and that 
there is no heterogeneity of major genes, determining the trait values. So, the 
results of the segregation analysis were used to obtain the most acceptable genetic 
model for performing maximum likelihood methods of linkage analysis. It should be 
noted that the segregation analysis (POINTER computer program) does not include 
multiple alleles and two or more major loci. 
In 3 independent studies, considering either primarily healthy families (32,35) or 
FCH families (34), the results of the segregation analysis have indicated that the 
LDL subfraction profile is a monogenically inherited trait, that is, the differences in 
LDL subfraction patterns are due to the actions of alleles of a single gene. 
However, among healthy Mormon families, a major locus with a dominant mode 
of inheritance with reduced penetrance was reported (32), whereas in FCH families 
the mode of inheritance for the major locus was either dominant or additive and in 
addition a significant multifactorial inheritance component was found (34). The 
genetic model best fitting the distribution of parameter К in our healthy Dutch 
families included a recessive mode of inheritance for the single major genetic locus 
with a significant multifactorial component (35). The selection of families (Mormon 
families, families with FCH, Dutch families) may lead to some mode of inheritance 
being unintentionally preferred. So, the mode of inheritance of the LDL subfraction 
pattern assumed in the linkage analyses was different for each study, which should 
be realized when comparing the results of the different studies. We repeated the 
linkage analysis, now assuming a dominant mode of inheritance with 9 0 % 
penetrance, in analogy by Austin et al. (32). No linkage of the LDL subfraction 
profile to one of the candidate genes was found (for all candidate genes the total 
lod score was <-2 at 0 = 0). Theoretically, the LDL subfraction profile may still 
result from the genetic variability due to the synergistic effects of genes at 
different loci (epistasis). 
Secondly, in most studies, LINKAGE analysis are performed on qualitative traits; 
Austin et al. (32,34) distinguished only two discrete LDL subfraction patterns, 
which were denoted a light (A) or heavy (B) pattern, and which were characterized 
by a predominance of large and small LDL particles, respectively. However, as the 
distribution of LDL particles by size within the LDL density range shows a 
continuity, the dichotomization of the LDL subfraction patterns into two discrete 
phenotypes (19,32) may result in considerable overlap between patterns A and В 
and a high interindividual variability in LDL particle size among subjects with either 
pattern A or B. In a recent study, we confirm that a dichotomous classification of 
the LDL subfraction profile into patterns A and B, could indeed not fully reflect the 
great interindividual variation in LDL subfraction patterns, that was observed 
among 131 healthy subjects, when detecting LDL subfractions by density gradient 
ultracentrifugation (21). So, the LDL subfraction pattern can be considered a 
quantitative rather than a qualitative trait. When a quantitative trait like the LDL 
subfraction pattern is reduced to a dichotomy (LDL subfraction patterns A and B), 
relevant information is lost. Hence, in the present report, we introduced a 
continuous variable, parameter K, to describe each individual LDL subfraction 
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pattern. When considering the LDL subfraction profile a quantitative trait, then 
each genotype is associated with a range of values of parameter K; the variation 
within each genotype being due to environmental influences. So, the fact that the 
genetically influenced dense LDL subfraction profile could be produced or 
eliminated by modifying environmental exposure is considered, when defining the 
LDL subfraction profile by the standardized parameter K. Parameter К thus includes 
more information resulting in a more firm conclusion, which suggests no linkage 
of the LDL subfraction profile to the 7 candidate genes (Table 5). Most likely, due 
to this extensive comingling of genetic and environmental influences and the 
limited information provided by the pattern A or В classification, no firm evidence 
for or against linkage was found, when considering the LDL subfraction pattern a 
qualitative trait (Table 3). 
In conclusion, our results suggest that if a major gene does determine LDL 
heterogeneity, its identity in our families remains to be determined. 
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High levels of plasma low density lipoprotein (LDL) cholesterol are associated with 
an increased risk for developing coronary artery disease However, many subjects 
who develop atherosclerosis have normal LDL cholesterol levels It is now well 
recognized that human plasma LDL is composed of discrete subfractions, varying 
in size, density, and chemical composition and that subjects with similar LDL 
cholesterol levels may have different distributions of LDL subfractions Recently, 
a predominance of small, dense LDL subfractions has been associated with an 
atherogenic lipoprotein profile and an increased risk of atherosclerosis So, despite 
normal LDL cholesterol levels, a subject may exhibit an atherogenic LDL subfraction 
pattern, characterized by a predominance of small, dense LDL particles 
The aim of the research described in this thesis was to examine the metabolic and 
genetic factors contributing to LDL heterogeneity, and to reveal the mechanisms 
involved in the enhanced atherogenicity of small, dense LDL per se 
Chapter 2 compares the advantages, limitations, and similarities of two methods, 
used to detect and separate LDL subfractions In 41 healthy individuals, the 
discrimination of distinct LDL subfractions, identified on the basis of either 
differences in buoyant density, by means of density gradient ultracentrifugation 
(DGU), or differences in LDL particle size, by means of gradient gel electrophoresis 
(GGE), were compared DGU revealed from 1 to 3 different LDL subfractions - i e , 
very light LDL1 1 030-1 033 g/ml, light LDL2 1 033 1 040 g/ml, and dense LDL3 
1.040-1 045 g/ml - whereas by GGE the number of LDL subfractions ranged from 
1 to 5. In 90% of the subjects, the number of LDL subfractions found by both 
methods agreed Furthermore, a strong correlation was found between the density 
of the predominant LDL subfraction in the tube after DGU, and the migration 
distance ( = particle size) of that subfraction in the gel after GGE (r = 0 85, 
p < 0 0001) So, while there is in generala high correspondence of size and density 
of LDL, intra- and intenndividual variation in apparent size of LDL species of similar 
density has led to the identification of a larger number of LDL subspecies by GGE 
than can be discriminated by density banding 
DGU requires expensive equipment, experienced personnel, and is time consuming, 
whereas GGE is a relatively simple, inexpensive method for detecting LDL 
subfractions in a small sample-volume So, GGE may be more suitable for screening 
purposes, although it gives no information on particle composition in its standard 
application The results indicate that both DGU and GGE are valid methods to 
analyze LDL heterogeneity, even after storage of plasma samples for 12 weeks at 
-80°C 
Several lines of evidence suggest that the heavy LDL3 subfraction in particular 
predisposes to coronary heart disease (CHD) However, the mechanisms which 
may contribute to the enhanced atherogenicity of small, dense LDL have not yet 
been elucidated An early event in the development of atherosclerosis is the 
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accumulation of lipid loaded "foam cells" in the subendothelial space of the vessel 
wall. Recent studies have demonstrated that most of these foam cells are derived 
from monocyte macrophages. Native LDL is taken up by these macrophages 
through the LDL receptor at a rather low rate and without marked accumulation of 
cholesterol. However, the uptake of modified forms of LDL occurs through the so-
called scavenger receptor on macrophages and results in foam cell formation in 
vitro. In vivo, the most likely process responsible for this modification of LDL is 
lipid peroxidation. 
Chapter 3 shows that the 3 normohpidemic LDL subfractions, very light LDL1, light 
LDL2, and dense LDL3, differ in their susceptibility to lipid peroxidation in vitro 
LDL2 and LDL3 are more susceptible to oxidative modification in vitro than LDL1 
To explain the differences in oxidizability between the LDL subfractions, the 
antioxidant vitamin E and the polyunsaturated fatty acids (PUFAs) composition and 
concentration in the LDL subfractions were determined The vitamin E concentra-
tion in the LDL subfractions could not help to explain why dense LDL3 was less 
well protected against oxidative modification than very light LDL1 Apparently, 
additional antioxidants present in LDL are important in protecting LDL1 from 
oxidation. The concentration of PUFAs in dense LDL3 was higher than in very light 
LDL1, which may explain why dense LDL3 was more extensively modified in time 
than LDL1. These findings suggest an intriguing possible explanation for the 
suggested higher atherogenicity of the more dense LDL subfractions LDL2 and 
LDL3 are more susceptible to oxidative modification and, therefore, contribute 
more to foam cell formation during atherogenesis than does the lightest LDL 
subfraction, LDL1 In addition, the relatively faster oxidative modification of heavy, 
dense LDL3 in the vessel wall, combined with the elevated plasma LDL3 
concentration in subjects with familial combined hyperlipoproteinemia (FCH), 
hyperapobetalipoprotememia, or the atherogenic lipoprotein phenotype (ALP) may 
result in the excessive uptake of the modified LDL3 by the scavenger receptor, 
converting macrophages into foam cells, contributing to the higher incidence of 
CHD in these conditions. 
A suggested alternative mechanism leading to foam cell formation is the uptake of 
native LDL through the upregulated LDL receptor in activated macrophages 
Chapter 4 shows that the 3 LDL subfractions, LDL1, LDL2, and LDL3, have 
different rates of LDL receptor mediated catabolism by human monocyte-denved 
macrophages. The association, degradation, and cholesteryl ester formation 
decreases progressively with increasing density. So, assuming overexpression of 
the LDL receptor, very light LDL1 may induce more foam cell formation in activated 
macrophages than dense LDL3, suggesting an enhanced atherogenicity of the very 
light LDL1 particles. These results may seem to contradict the data presented in 
chapter 3 and the epidemiological data that correlate coronary heart disease with 
small, dense LDL. However, the decreased association and degradation of LDL3 in 
vitro may result in an increased residence time of LDL3 in the circulation in vivo 
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An increased residence time of LDL3 together with an enhanced susceptibility to 
oxidation, as described in chapter 3, may render the dense LDL3 particles more 
susceptible to the uptake by the scavenger receptor on macrophages, also resulting 
in foam cell formation. So, further elucidation of the relevance of the LDL receptor 
and the scavenger receptor in generation of foam cells in vivo may contribute to 
the unravelling of the mechanisms involved in the different atherogenic potentials 
among LDL subfractions. 
Epidemiological studies have demonstrated a relationship between oral contracep­
tive (OC) use and coronary heart disease, especially among women over 35 who 
smoke. Chapter 5 indicates that OC use is strongly associated with a more dense 
LDL subfraction profile, characterized by an increased relative contribution of dense 
LDL3 and a decreased relative contribution of very light LDL1 to total LDL, which 
reportedly has been associated with an increased risk of atherosclerosis. In 
addition, the dense LDL subfraction patterns were significantly correlated with an 
atherogenic lipoprotein profile, i.e., relatively increased very low density lipoprotein 
(VLDL) lipid levels and decreased levels of high density lipoprotein (HDL) 
cholesterol. However, statistical analysis revealed that OC use was significantly 
associated with a dense LDL subfraction profile, even after correcting for the 
influence of these lipid and lipoprotein levels, suggesting that the dense LDL 
subfraction may be an independent risk factor for CHD. Thus, OC use is associated 
with compositional changes of LDL, resulting in a more dense LDL subfraction 
profile, which may contribute to the atherogenic risk profile among OC users. 
Chapter 6 demonstrates that simvastatin, an HMG-CoA reductase inhibitor, was 
not only an effective drug to lower the concentrations of plasma LDL (-36%) in 
sera of patients with familial hypercholesterolemia (n = 26), but also induces 
compositional changes in LDL, as evidenced by the reversion to normal of the 
increased cholesterol to protein ratio (mean 1.51 before vs 1.38 after therapy, 
ρ < 0 . 0 1 ; mean 1.36 among normolipidemic subjects). Despite these compositional 
changes in LDL, simvastatin therapy did not significantly alter the LDL subfraction 
profile observed after DGU, which consisted both before and after therapy of 3 LDL 
subfractions, present in a relatively narrow density range, very similar to that 
among normolipidemic subjects. The relative contribution of the 3 LDL subfractions 
(% mass) to total LDL did not change after therapy (29% LDL1, 4 5 % LDL2, and 
2 6 % LDL3). When the subjects were stratified by their plasma triglyceride levels 
or their change in plasma triglyceride level during simvastatin therapy, a strong 
dependence of the LDL subfraction profile and its composition on the plasma 
triglyceride level was found. With increasing plasma triglyceride levels, a more 
dense LDL subfraction profile was found, characterized by a relatively higher 
contribution of dense LDL3 to total LDL and a lower cholesterol to protein ratio. 
These results confirm the concept that the serum triglyceride concentration plays 
an important role in determining the properties of LDL (see chapter 7). 
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Chapter 7 investigates the impact of plasma triglyceride levels on LDL 
heterogeneity and its atherogenic potentials in 9 moderately hypertriglycendemic 
and 3 chylomicronemic subjects. Among the moderately hypertriglycendemic 
subjects (plasma triglyceride levels 2 5-7 mmol/l) up to 5 LDL subfractions could 
be detected (LDL1-LDL5), covering a wide density range (1 030-1 054 g/ml), with 
the mam LDL subfractions being abnormally small and dense (LDL3-LDL5, 
d = 1.040-1.054 g/ml). In the chylomicronemic subjects (plasma triglyceride levels 
11 5-30.0 mmol/l) only one very dense LDL subfraction, -ι e , LDL5 (d = 1 049-
1 054 g/ml) - was found In 10 normolipidemic control subjects, matched for age, 
sex, and body weight, three LDL subfractions (LDL1-LDL3) were present in a 
relatively small, light density range (1 030-1 045 g/ml) So, with increasing plasma 
triglyceride levels, a shift m the LDL subfraction profile towards a more dense LDL 
subfraction pattern was observed. However, the number and relative distribution 
of the LDL subfractions over total LDL was dependent on the degree of hypertrigly­
ceridemia Clofibrate treatment of the moderately hypertriglycendemic subjects 
reduced the plasma triglyceride concentration by 5 6 % and corrected the abnormal 
composition of LDL, resulting in a lighter LDL subfraction profile (LDL1-LDL4) 
These results support the hypothesis, advanced in Chapter 6, that the plasma 
triglyceride level is an important factor contributing to LDL heterogeneity 
Furthermore, the results of this study show that among both the control and the 
hypertriglycendemic subjects, the small dense LDL subfractions appeared more 
proneto oxidative modification in vitro than the light LDL subfractions, suggesting 
an enhanced atherogenic potential of the small, dense LDL subfractions, confirm 
the results presented in chapter 3 The dense LDL subfractions (LDL3-LDL5) 
present in the untreated hypertriglycendemic subjects showed an enhanced 
susceptibility to oxidative modification in vitro compared to the light LDL 
subfractions (LDL1-LDL3) present in the control subjects and the hypertnglycen 
demie subjects after Clofibrate therapy The lag time, preceding the onset of the 
lipid peroxidation process, decreased with increasing density of the LDL 
subfractions, probably related to the progeressive decrease in vitamin E content 
from LDL1 to LDL5 After Clofibrate therapy, the vitamin E content and the lag time 
of the LDL subfractions increased, indicating an enhanced resistance to oxidation 
These results suggest reduced atherogenic potentials of LDL in subjects with 
hypertriglyceridemia after Clofibrate treatment, which may contribute to the 
beneficial effect of fibrate treatment on the prevention of atherosclerosis in 
hypertriglycendemic subjects 
Chapter 8 and 9 examine the genetic factors contributing to LDL heterogeneity 
Chapter 8 investigates possible genetic control of the LDL subfraction pattern 
distribution, among healthy Dutch families, using complex segregation analysis In 
19 healthy nuclear families, including 162 individuals, the distribution of the LDL 
subfraction pattern was determined using density gradient ultracentnfugation For 
each subject, a specific LDL subfraction profile was found, characterized by the 
relative contribution of the 3 major LDL subfractions, LDL1, LDL2, and LDL3, to 
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total LDL. Due to the great intermdividual variability in LDL subfraction pattern, we 
defined a continuous, quantitative variable - i.e., parameter К - to characterize each 
individual LDL subfraction profile. Complex segregation analysis of this quantitative 
trait revealed that the LDL subfraction pattern distribution in these families is 
controlled by a major autosomal recessive gene with a population frequency of 
0.19 and a significant multifactorial inheritance component The penetrance of the 
dense LDL subfraction profile was dependent on age, gender, and use of oral 
contraceptives, and postmenopausal status in women, indicating that the 
phenotypic expression of the major locus, responsible for the dense LDL 
subfraction profile, is strongly modulated by environmental, behavioral, and/or 
genetic background. Approximately 6 4 % of the total variance in transmission of 
the dense LDL subfraction pattern was represented by the major locus, whereas 
1 1 % was accounted for by multifactorial inheritance, and 2 5 % by random 
environmental influences, suggesting etiological heterogeneity in the LDL 
subfraction profile. 
The dense LDL subfraction profile was associated with an atherogenic lipoprotein 
profile, i.e., relatively increased plasma triglyceride levels and decreased HDL 
cholesterol levels. Further statistical analysis indicated that approximately 6 0 % of 
the variation in the LDL subfraction pattern could be accounted for by alterations 
in age, gender, relative body weight, smoking habits, hormonal status in women, 
and lipid and lipoprotein levels. The results of this study indicate that the 
distribution of the LDL subfraction patterns in Dutch families is the result of a 
combination of underlying genetic traits and environmental or behavioral traits As 
the dense LDL subfraction profile is associated with an increased of 
atherosclerosis, these results may contribute to the explanation of familial 
clustering of coronary heart disease. 
To verify whether a major locus is implicated in determining the LDL subfraction 
profile, Chapter 9 evaluates the impact of 7 genes, that is, the АРОВ gene, the 
APOA1-C3-A4 gene, the APOA2 gene, the APOE-C1-C2 gene, the hepatic lipase 
gene, the lipoprotein lipase gene, and the LDL receptor gene on the LDL subfraction 
profile by performing linkage analysis, using the candidate gene approach. 
However, no cosegregation of the LDL subfraction profile with one of the candidate 
genes haplotypes was found; for most genes the maximal LOD scores were <-2.0 
at a recombination fraction of zero, indicating that under the assumption of a single 
gene model it is unlikely that these genes are involved in determining the LDL 
subfraction profile in these families. So, if a major gene does determine LDL 
heterogeneity, as suggested in Chapter 8, its identity in our families remains to be 
determined. 
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1. The small, dense LDL particles have direct atherogenic potentials, which 
may contribute to the increased risk of atherosclerosis in subjects with a 
heavy, dense LDL subfraction profile, a relationship which was shown to be 
in part independent of the associated atherogenic lipid and lipoprotein profile 
(Chapter 3-5). 
2. Both metabolic (chapter 6-7) and genetic factors (chapter 8-9) were shown 
to contribute to LDL heterogeneity. 
3. Plasma triglyceride levels appeared to be especially important in determining 
the composition of the LDL subfractions and the relative distribution of the 
LDL subfractions over total LDL (chapter 6-7). 
Hence, both LDL heterogeneity and concentration are factors that may act together 
in the complex array of processes that result in coronary heart disease and 
myocardial infarction. 
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SAMENVATTING 
Een verhoogd cholesterolgehalte van het serum verhoogt de kans op het ontstaan 
van coronaire atherosclerotische hartziekten Het belangrijkste cholesterol 
transporterende deeltje in de bloedbaan is het lage dichtheidslipoproteine, LDL 
Reeds vele studies hebben aangetoond dat de LDL-deeltjes niet allemaal hetzelfde 
zijn maar verschillen in samenstelling, grootte, dichtheid, metabool gedrag, en 
athérosclérose bevorderende eigenschappen Vooral de zeer kleine, zware LDL 
deeltjes, met een relatief hoge dichtheid, zijn geassocieerd met athérosclérose 
Echter, de metabole en genetische processen die betrokken zijn bij het ontstaan 
van LDL-subfracties en de fysiologische betekenis van LDL-subfracties zijn nog 
onduidelijk 
In dit proefschrift zijn de resultaten gepresenteerd van studies naar de metabole en 
genetische factoren die van invloed zijn op het LDL-subfractiepatroon Tevens zijn 
mechanismen bestudeerd die mogelijk betrokken zijn bij het verschil in atherogene 
eigenschappen tussen LDL-subfracties 
In de literatuur worden verschillende technieken beschreven voor de detectie en 
isolatie van LDL-subfracties In hoofdstuk 2 zijn twee methoden voor de detectie 
met elkaar vergeleken De dichtheidsgradient-ultracentrifugatie (DGU) methode 
scheidt LDL-subfracties op basis van verschil in dichtheid Met behulp van deze 
methode konden wij in plasma van 41 gezonde personen 3 LDL-subfracties 
onderscheiden, de lichte LDL1 (1 030 1 033 g/ml), de intermediaire LDL2 (1 033-
1 040 g/ml), en de zware LDL3 (1 040-1 045 g/ml) leder individu toonde een 
specifiek LDL-subfractiepatroon, gekarakteriseerd door de relatieve bijdrage van de 
drie subfracties aan totaal LDL Met gradientgelelectrophorese (GGE) konden 1 tot 
5 LDL-subfracties worden gedetecteerd, gebaseerd op verschil in grootte van de 
LDL-deeltjes In 9 0 % van de proefpersonen bleek het aantal subfracties gevonden 
met DGU en GGE hetzelfde te zijn Verder werd een zeer sterke correlatie gevonden 
tussen de dichtheid van de belangrijkste LDL-subfractie in de buis na DGU, en de 
migratie afstand van deze subfractie in de gel na GGE (r = 0 85, p < 0 0001) De 
dichtheid en grootte (gereflecteerd aan de migratie afstand in de gel) van de 
subfracties zijn dus sterk aan elkaar gecorreleerd De resultaten van beide 
methoden bleken goed reproduceerbaar, ook bij gebruik van plasma, dat gedurende 
3 maanden ingevroren was. DGU is een tijdrovende, dure procedure die veel 
ervaring eist terwijl GGE relatief eenvoudig, snel en goedkoop is, vandaar dat GGE 
meer geschikt lijkt voor "screenings"-doeleinden Het voordeel van DGU is, dat men 
beschikt over de mogelijkheid om de LDL-subfracties te isoleren en vervolgens te 
gebruiken voor biochemische of metabole studies 
Zoals gezegd zijn vooral de zware LDL-deeltjes geassocieerd met een verhoogd 
risico op hart- en vaatziekten Het mechanisme, dat verantwoordelijk is voor het 
verschil in atherogene eigenschappen tussen de LDL-subfracties, is echter niet 
bekend De laatste jaren is veel onderzoek gedaan naar de mogelijke mechanismen 
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die leiden tot het ontstaan van atherosclerotische plaques De atherosclerotische 
plaques worden gekenmerkt door de aanwezigheid van zogenaamde schuimcellen 
Dit zijn macrofagen met vetdruppeltjes in het cytoplasma, die de cel een schunnig 
uiterlijk geven, tengevolge van overmatige opname van cholesterol. Natief LDL 
wordt echter slechts in beperkte mate opgenomen door de macrofaag via de LDL 
receptor, dankzij een goed gereguleerd terugkoppelings-mechanisme, dat 
ongelimiteerde opname van LDL-cholesterol voorkomt De huidige hypothese 
betreffende het ontstaan van plaques veronderstelt nu dat LDL eerst gemodificeerd 
moet worden alvorens het duidelijke atherogene eigenschappen krijgt De meest 
waarschijnlijke vorm van LDL modificatie in vivo is lipidperoxidatie Eenmaal in de 
vaatwand wordt LDL gemodificeerd door interactie met vrije radicalen en 
lipoxygenases geproduceerd door de cellen in de vaatwand o a. endotheelcellen, 
gladde spiercellen en macrofagen Er ontstaan Produkten van lipidperoxidatie, zoals 
geconjugeerde dienen en aldehyden, die een interactie aangaan met het belangrijk­
ste eiwit van LDL, het zogenaamde apolipoproteme В De structurele en composi-
tionele veranderingen in het LDL tengevolge van de lipidperoxidatie geven het 
gemodificeerde LDL karakteristieke eigenschappen die bijdragen aan de ontwikke­
ling van atherosclerotische plaques Het gemodificeerde LDL wordt opgenomen 
door de macrofaag via de "scavenger-receptor" De opname via deze receptor 
wordt niet geremd door terugkoppeling bij voldoende opname van cholesterol De 
ongelimiteerde opname van het gemodificeerde LDL in de macrofaag geeft 
aanleiding tot stapeling van cholesterolester-druppels in het cytoplasma van de 
macrofaag 
De resultaten in hoofdstuk 3 laten zien dat de kleine, zware LDL-deeltjes (LDL2 en 
LDL3) in vitro eerder en sneller te oxideren zijn dan de grote, lichte LDL-deeltjes 
(LDL1) De zwaardere subfracties LDL2 en LDL3 zijn dus minder goed beschermd 
tegen oxidatie Om dit verschil in oxideerbaarheid tussen verschillende LDL-
subfracties te kunnen verklaren werden de concentraties van vitamine E en van 
meervoudig onverzadigde vetzuren in de LDL-subf racties bepaald Vitamine E is een 
belangrijk antioxidans in LDL dat het beschermt tegen oxidatie Echter, de 
concentratie van vitamine E verschilde met tussen de subfracties Waarschijnlijk 
spelen andere antioxidants zoals ß-caroteen en ubiquinol een belangrijke rol in de 
bescherming van LDL tegen oxidatie De concentratie aan meervoudig onverzadigde 
vetzuren in LDL3 was hoger dan in LDL1 hetgeen zou kunnen bijdragen aan het feit 
dat LDL3 sneller oxideert dan LDL1 Deze resultaten geven een mogelijke verklaring 
voor de verhoogde atherogeniciteit van de zware LDL-subfracties, LDL2 en LDL3, 
de zwaardere LDL deeltjes zijn gemakkelijker te modificeren ( = oxideren) hetgeen 
resulteert in ongelimiteerde, snelle opname door de macrofaag via de "scavenger-
receptor", leidend tot vorming van schuimcellen, het kenmerk van atherosclero-
tische plaques. 
Recent onderzoek heeft aangetoond dat schuimcellen toch ook kunnen ontstaan 
door verhoogde opname van natief, niet gemodificeerd LDL, maar alleen wanneer 
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de macrofaag in een geactiveerde toestand verkeerd (bijvoorbeeld tijdens infecties) 
In de geactiveerde toestand kan namelijk de activiteit van de LDL receptor op de 
macrofaag worden gestimuleerd, hetgeen leidt tot excessieve opname van natief 
LDL. 
In hoofdstuk 4 laten we zien dat de 3 LDL-subfracties verschilden in binding en 
opname door de LDL-receptor op de macrofaag De associatie, degradatie en mate 
van cholesteryl-estervorming namen af met toenemende dichtheid van de LDL 
subfracties Wanneer er dus sprake zou zijn van overexpressie van de LDL receptor 
aktiviteit, dan suggereren deze resultaten dat licht LDL1 meer schuimcelvorming 
geeft dan zwaar LDL3 Dit lijkt in tegenspraak met de eerder genoemde resultaten 
in hoofdstuk 3 en ook tegenstrijdig met de epidemiologische data die zwaar LDL3 
associëren met hart- en vaatziekten Echter, de afgenomen associatie en degradatie 
van LDL3 zou kunnen leiden tot een langere circulatietijd van LDL3 in vivo De 
langere circulatie tijd tezamen met de verhoogde oxideerbaarheid van LDL3 zou 
wederom kunnen leiden tot een verhoogde opname van LDL3 via de "scavenger 
receptor", ook resulterend in de vorming van schuimcellen Verder onderzoek naar 
de relevantie van de LDL-receptor en de "scavenger-receptor" in de ontwikkeling 
van schuimcellen in vivo is noodzakelijk om de mechanismen betrokken bij het 
verschil in atherogeniciteit tussen LDL-subfracties te kunnen verklaren 
Epidemiologische studies hebben aangetoond dat het gebruik van orale anticoncep 
tiva (OAC, de "pil") het risico op hart- en vaatziekten verhoogt, vooral bij vrouwen 
ouder dan 35 jaar die roken. De resultaten van onderzoek bij 20 vrouwen, 
beschreven in hoofdstuk 5, laten zien dat pilgebruik is geassocieerd met een zwaar 
LDL-subfractiepatroon, gekarakteriseerd door een hoge relatieve bijdrage van zwaar 
LDL3 en een lage relatieve bijdrage van licht LDL1 aan totaal LDL Verder was het 
zware LDL-subfractiepatroon geassocieerd met een "atherogeen lipidenprofiel" 
gekenmerkt door relatief hoge plasma tnglyceriden-spiegels en lage hoge 
dichtheidslipoproteine (HDL)-cholesterol spiegels Reeds vele studies hebben 
aangetoond dat een zwaar LDL-subfractiepatroon geassocieerd is, niet alleen met 
een verhoogd risico op hart- en vaatziekten, maar ook met een "atherogeen 
lipidenprofiel" De vraag is dus of het zware LDL-subfractiepatroon wel een 
onafhankelijke risico factor voor hart- en vaatziekten is Uit ons onderzoek bleek 
dat pilgebruik significant geassocieerd is met een zwaar LDL-subfractiepatroon 
onafhankelijk van de plasma lipiden- en lipoproteinenspiegels Deze resultaten 
suggereren dat het zware LDL-subfractiepatroon een onafhankelijke risicofactor is 
voor athérosclérose Dus pilgebruik induceert veranderingen in de compositie van 
LDL, resulterend in een zwaar LDL-subfractiepatroon, hetgeen bijdraagt aan het 
atherogene hpidenprofiel van pilgebruiksters 
Ten einde meer inzicht te verkrijgen in de metabole factoren die van invloed kunnen 
zijn op het LDL-subfractiepatroon, werd het effect van medicamenteus ingrijpen in 
de synthese en afbraak van lipoproteinen bij patiënten met hyperlipoproteinemie 
bestudeerd BIJ 26 patiënten met familiaire hypercholesterolemie (FH) (hoofdstuk 6) 
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en 12 patiënten met milde tot ernstige hypertriglyceridemie (HTG) (hoofdstuk 7) 
werd het effect van behandeling met respectievelijk simvastatine en clofibraat 
bestudeerd. Simvastatine remt het enzym HMG-CoA-reductase, dat de snelheid van 
de cholesterolsynthese bepaalt. Clofibraat verlaagt vooral het triglyceridengehalte 
van het plasma. Het werkingsmechanisme van clofibraat is grotendeels onbekend. 
Zowel voor als na behandeling van de FH patiënten met simvastatine (1 maal daags 
40 mg, gedurende 3 maanden) werd een LDL subfractie-patroon gezien bestaande 
uit 3 LDL-subfracties in de dichtheidsrange 1.030-1.045 g/ml, gelijkend op dat in 
normolipidemische personen (hoofdstuk 6). De relatieve bijdrage van de 3 
subfracties aan totaal LDL veranderde niet na therapie met simvastatine (29% 
LDL1, 45% LDL2 en 26% LDL3). De chemische samenstelling van de geïsoleerde 
LDL-subfracties werd bepaald; de LDL-partikels in patiënten met FH voor 
behandeling met simvastatine waren relatief verrijkt met cholesterol en eiwit-arm. 
Er was dus sprake van een een hoge cholesterol/proteïne ratio (gemiddeld 1.51 in 
FH patiënten voor behandeling versus 1.36 in gezonde personen). Na behandeling 
met simvastatine daalde de hoge cholesterol/proteïne ratio van alle LDL-subfracties, 
hetgeen resulteerde in een normalisering van de gemiddelde cholesterol/proteïne 
ratio van LDL (gemiddeld 1.38 na behandeling). Deze resultaten laten zien dat 
simvastatine niet alleen het totaal cholesterol en de hoeveelheid LDL-cholesterol in 
het plasma verlaagt, maar ook de compositie van de LDL-deeltjes beïnvloedt. 
Verder bleek zowel het LDL-subfractiepatroon als de compositie van de geïsoleerde 
LDL subfracties sterk afhankelijk te zijn van de plasma triglyceridenspiegels. 
Naarmate de plasma triglyceridenspiegel in deze groep patiënten hoger was, was 
de cholesterol/proteïne ratio lager en het LDL-subfractiepatroon zwaarder, dat wil 
zeggen dat de relatieve bijdrage van LDL3 aan totaal LDL groter was. 
In hoofdstuk 7 is het effect van de hoogte van de plasma triglyceridenspiegel op 
het LDL-subfractiepatroon nader bestudeerd in 9 matig en 3 ernstig hypertriglyceri-
demische patiënten, voor en na behandeling met clofibraat. In het plasma van de 
matig hypertriglyceridemische patiënten (plasma triglyceriden 2.5-7.0 mmol/l) 
konden 2 tot 5 LDL-subfracties onderscheiden worden, verdeeld over een brede 
dichtheidsrange (1.030-1.054 g/ml). Kwantitatief de belangrijkste subfracties 
waren de zware subfracties LDL3, LDL4 en LDL5 (1.040-1.054 g/ml). De ernstig 
hypertriglyceridemische patiënten met plasma triglyceridenspiegels tussen de 11.5 
en 30.0 mmol/l hadden slechts 1 LDL-fractie, namelijk het zeer zware LDL5 (1.049-
1.054 g/ml). In een controle-groep bestaande uit 10 gezonde personen, gematched 
op leeftijd, geslacht en gewicht, bestond het LDL-subfractiepatroon uit 3 LDL-
subfracties in een relatief lichte, smalle dichtheidsrange (LDL1-LDL3, 1.030-1.045 
g/ml). 
Met het stijgen van de plasma triglyceriden-concentratie werd dus een zwaarder 
LDL-subfractiepatroon gevonden. Het aantal subfracties en de relatieve verdeling 
van de LDL-subfracties over totaal LDL was afhankelijk van de ernst van de 
hypertriglyceridemie. 
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SAMENVATTING EN CONCLUSIES 
Na behandeling met clofibraat (2 maal daags 1 gram, gedurende 2 maanden) 
daalden de plasma triglycendenspiegels met gemiddeld 56% en de abnormale 
samenstelling van het LDL-subfractiepatroon herstelde zich, resulterend in een 
lichter LDL-subfractiepatroon (LDL1-LDL4) 
Deze resultaten bevestigen de hypothese dat de plasma triglycendenspiegels een 
belangrijke rol spelen in de compositie van LDL-partikels 
De oxideerbaarheid van de LDL-subfracties werd in vitro gemeten, voor en na 
behandeling met clofibraat, met het doel mogelijke veranderingen in atherogene 
eigenschappen van de LDL-subfracties vast te stellen 
De zware LDL subfracties (LDL3-LDL5) van de hypertriglycendemische patiënten 
voor therapie waren gevoeliger voor oxidatie dan de lichte LDL subfracties, 
aanwezig in de hypertriglycendemische patiënten na therapie en in de controle-
groep (LDL1-LDL3) 
De "lag"-tijd, dat wil zeggen de tijd dat de LDL-subfracties beschermd waren tegen 
oxidatie dankzij de endogene antioxidants, nam af gaande van LDL1 naar LDL5 
Dit zou mogelijk verklaard kunnen worden door de door ons gevonden afname van 
de concentratie van vitamine E met toenemende dichtheid van de LDL-subfracties 
Na behandeling met clofibraat herstelde het LDL-subfractiepatroon zich (LDL1-
LDL4) en de "lag"-tijd en de vitamine E concentraties van de LDL-subfracties 
namen toe Deze resultaten suggereren een afname van de atherogene eigenschap-
pen van LDL in hypertriglycendemische patiënten na behandeling met clofibraat 
In hoofdstuk 8 en 9 worden de mogelijke genetische invloeden op het LDL-
subfractiepatroon bestudeerd In 19 gezinnen met gemiddeld 7 kinderen per gezin 
werd het LDL-subfractiepatroon bepaald met behulp van DGU ledere persoon 
toonde zijn eigen, specifieke LDL-subfractiepatroon, gekarakteriseerd door de 
relatieve bijdrage van de 3 LDL-subfracties aan totaal LDL Ten einde elk individueel 
LDL-subfractiepatroon te kunnen beschrijven werd er een continue variabele 
gedefinieerd, parameter К De waarde van К varieerde tussen 1 en + 1 ledere 
waarde beschrijft een specifiek LDL-subfractiepatroon, waarin de relatieve bijdrage 
van de 3 subfracties aan totaal LDL is weergegeven 
De segregatie van het LDL-subfractiepatroon in de gezinnen werd bestudeerd met 
behulp van "complexe segregatie analyse", gebruikmakend van het computer­
programma POINTER (hoofdstuk 8) In dit programma wordt verondersteld dat het 
LDL-subfractiepatroon het resultaat is van een optelsom van de effecten van 1 een 
"major locus", 2. een "multifactonele" overervingscomponent en 3 "at random" 
omgevingsinvloeden. De resultaten laten zien dat in deze Nederlandse gezinnen het 
LDL-subfractiepatroon wordt beïnvloed door een autosomaal, recessief gen met een 
populatiefrequentie van 19% en een significante multifactonele overervingscom 
ponent. De penetrance van het zware LDL-subfractiepatroon was afhankelijk van 
leeftijd, geslacht, pilgebruik en pre- of postmenopausale status van de vrouw Dit 
impliceert dat de fenotypische expressie van de "major locus", die resulteert in een 
zwaar LDL-subfractiepatroon, sterk gemoduleerd wordt door omgevingsfactoren, 
gedragscomponenten en genetische achtergrond. Naar schatting ongeveer 64% 
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van de totale variantie in de transmissie van het zware LDL-subfractiepatroon kan 
worden toegeschreven aan de "major locus", het recessieve gen, terwijl respec-
tievelijk 11 % en 25% kunnen worden verklaard door de multifactonele component 
en omgevingsfactoren. Deze resultaten suggereren dat meerdere factoren bijdragen 
aan het ontstaan van het LDL-subfractiepatroon (etiologische heterogeniteit) 
Ook in deze populatie was het zware LDL-subfractiepatroon geassocieerd met een 
"atherogeen lipidenprofiel" met relatief hoge plasma triglycerides en relatief lage 
HDL-cholesterolspiegels Ongeveer 60% van de variatie in het LDL-subfractiepa-
troon kon worden verklaard uit de variabelen leeftijd, geslacht, gewicht, roken, 
hormonole status van de vrouw en de plasmalipiden en -lipoproteinen 
Deze studie leert ons dat het LDL-subfractiepatroon het resultaat is van een 
combinatie van genetische factoren, omgevingsinvloedenen gedragscomponenten 
Daar het zware LDL-subfractiepatroon is geassocieerd met een verhoogd risico op 
hart- en vaatziekten, zouden deze resultaten kunnen bijdragen aan de verklaring van 
"clustering" van hart en vaatziekten in bepaalde families 
De resultaten in hoofdstuk 8 suggereren dus dat een "major locus", het autosomaal 
recessieve gen, het LDL subfractiepatroon mede bepaald 
Verschillende genen zijn betrokken bij het lipidenmetabolisme en zijn dus kandidaat 
voor hun mogelijke betrokkenheid bij het ontstaan van het LDL-subfractiepatroon 
In hoofdstuk 9 zijn 7 kandidaat-genen (het APOB-gen, het AP0A2 gen, het 
hepatisch-hpase gen, het lipoproteine-lipase-gen, het LDL-receptor-gen en de gen-
clusters AP0A1-C3-A4 en APOE-C1-C2) getest op "linkage" met het LDL-
subfractiepatroon, gebruikmakendevan het computer programmaLINKAGE Echter, 
cosegregatie van het LDL-subfractiepatroon met een van de 7 kandidaat-gen-
haplotypen werd niet waargenomen (de maximale LOD score voor de meeste genen 
was kleiner dan -2 bij een recombinatie-fractie van 0 = 0) Dus uitgaande van een 
"single-gene" model lijkt het onwaarschijnlijk dat deze genen betrokken kunnen zijn 
bij het ontstaan van het LDL-subfractiepatroon 
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SAMENVATTING EN CONCLUSIES 
CONCLUSIES 
1. De zware LDL-subfracties hebben direct atherogene eigenschappen die 
bijdragen aan het verhoogde risico op hart- en vaatziekten bij personen met 
een zwaar LDL-subfractiepatroon, onafhankelijk van het "atherogene 
lipidenprofiel" geassocieerd met dit zware LDL-subfractiepatroon (hoofdstuk 
3-5). 
2. Het LDL-subfractiepatroon wordt gemoduleerd door diverse metabole 
(hoofdstuk 6,7) en genetische (hoofdstuk 8,9) factoren. De relatieve 
bijdragen van deze verschillende metabole en genetische invloeden, die per 
persoon sterk kunnen wisselen, zullen uiteindelijk het individuele LDL-
subfractiepatroon bepalen (etiologische heterogeniteit). 
3. Vooral het niveau van de plasma-triglyceriden lijkt een belangrijke invloed te 
hebben op de compositie van de LDL-subfracties en de distributie van de 
LDL-subfracties over totaal LDL (hoofdstuk 6,7). 
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MET DANK AAN ... 
MET DANK AAN ... 
Het ei is gelegd, de klus is geklaard, het proefschrift is afgerond! Meer dan ooit ben 
ik me er echter van bewust dat ik nooit in mijn eentje deze dissertatie had kunnen 
voltooien en ik ben dan ook blij op deze plaats allen te mogen danken die mij 
geholpen hebben en zonder wiens hulp dit boekje niet aan U gepresenteerd had 
kunnen worden. 
Allereerst wil ik dr. Stalenhoef bedanken. Anton, toen jij mij vroeg voor deze 
baan, wist ik, geloof ik, niet echt waar ik aan begon, "that is", misschien maar 
goed ookl Jij gaf mij volledige vrijheid en totaal vertrouwen, hetgeen ik altijd zeer 
heb gewaardeerd. 
Veel dank ben ik ook verschuldigd aan dr. Demacker. Pierre, als geen ander 
ken jij de "ups and downs" die het doen van onderzoek eigen zijn. Zo ben ik ook 
door die diepe dalen en over die hoge bergen gegaan; je was er altijd, stimulerend, 
motiverend en vooral ook belangrijk, relativerend. Je kritische beschouwingen van 
de manuscripten dreven mij soms tot waanzin, maar ik wist dat het altijd tot 
verbetering van het uiteindelijke produkt zou leiden en dus.... 
Heidi Hak-Lemmers, beste Heidi, jij was degene die zorgde voor een goed 
verloop van het onderzoek. Met grote kundigheid, precisie en inzet kon je ieder 
subfractie patroon de baas, met 100% reproduceerbaarheid. Als vaste rots in de 
branding was je er altijd, niet alleen als analiste maar ook als goede vriendin. Tot 
op de laatste dag zullen we alles samen doen; met jou als paranimf kan de 
verdediging niet stuk. 
Jan Hendriks en Ton de Haan, beste Jan en Ton, ik ben jullie heel wat meer 
dan dank-je-wel verschuldigd. Zonder jullie zou het proefschrift zonder significantie 
zijn gebleven! De vele uren die jullie ten behoeve van mij gewerkt hebben en jullie 
onvoorwaardelijke bereidheid tot steeds weer een paar aanvullende analyses of tot 
verdere discussie met betrekking tot de interpretatie van resultaten heb ik zeer 
gewaardeerd. Jan, als een man van weinig woorden, moet je af en toe wel gek zijn 
geworden van mijn geklep. Dank voor al je geduld als je ¡ets weer voor de 
honderste keer moest uitleggen. Statistiek blijft voor mij mystiek. 
Dorine Swinkels, beste Dorine, alsof het je eigen promotie betrof, stond jij 
altijd voor mij klaar: de wervelende en zeer grondige wijze waarop je de manuscrip-
ten corrigeerde en je opbouwende kritiek heeft op mij altijd een motiverende 
uitwerking gehad. Je onuitputtelijke energie en zucht naar perfectie maken jou een 
bijzonder mens. 
Af en toe, ik bedoel met zeer grote regelmaat, moest er stoom afgeblazen 
worden. Dan kon ik altijd, ten alle tijden, terecht bij mijn "lunch-enzo-maatjes". 
Beste Tom, Matthijs, Henne, Marijke, en Gerard, onze "lunches-enzo" hebben het 
werk en leven aanzienlijk veraangenaamd. Niets is zo belangrijk als te weten dat 
je niet alleen staat. Ik mis jullie zeer. 
Het "lipiden-lab", beste allemaal, 4 jaren lang waren jullie mijn "work-home". 
Bedankt voor de prettige en stimulerende werksfeer en al jullie goede zorgen. Als 
reünist meld ik mij vast aan voor de volgende ski-vakantie. 
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To all my friends abroad, I hope you will be all confinced now that I did work 
in between my travelling and partying. Thanks for all the love and good time we 
shared; it always reminded me to appreciate my "research-career", as it allowed 
me to meet you all. 
Toen ik dacht dat het grote werk erop zat, werd ik, als "computerfanaat", 
geconfronteerd met een voor mij haast onmogelijke taak, de lay-out van het 
proefschrift. Lieve Ron, met jouw eindeloze geduld en rustgevende invloed ben ik 
je oneindig dankbaar dat jij deze taak op je hebt willen nemen en dat je mij hebt 
gesteund in het nemen van beslissingen. Je mag trots zijn op het resultaat. 
Lieve pa en moe, ik weet dat mijn reis-manies en mijn voortdurende zucht 
naar het onbekende, jullie soms deden wanhopen. Ik ben blij dat jullie toch steeds 
vertrouwen in mij gesteld hebben en altijd ondersteunend en stimulerend aanwezig 
waren. Aan jullie draag ik dit proefschrift op. 
De studente Nardy Dietz heeft met haar project in het kader van een stage 
voor de studie Scheikunde meegeholpen met het opzetten van de methoden voor 
de meting van de lipidperoxidatieproducten. 
Ik bedank alle patiënten, proefpersonen, en families die aan de verschillende 
onderzoeken hebben meegewerkt. 
Tenslotte dank ik al mijn verdere vrienden en familieleden voor hun 
belangstelling en relativerende inbreng. Daar ik niemand te kort wil doen, zal ik 
geen namen noemen. 
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CURRICULUM VITAE 
Jacqueline de Graaf werd geboren op 14 augustus 1962 te Delft. Na het behalen 
van het diploma Atheneum-B aan de Stedelijke Scholengemeenschap te Nijmegen, 
werd in 1980 begonnen met de studie Geneeskunde aan de Katholieke Universiteit 
te Nijmegen. Het doctoraalexamen werd behaald in juni 1985. Als voorbereiding 
op haar co-schappen liep zij van juli tot december 1985 diverse klinische stages in 
Israël (Ichilov Hospital, Tel-Aviv, dr. Shibolot; Chaim Sheba Medical Center, 
Telhashomer, dr. Adar; Beilinson Hospital, Petah-Tikwa, Dr. Moor). In september 
1987 werd het semi-artsexamen behaald. Tijdens het co-assistentschap heeft zij 
de Dr. Hayo Bruinings Prijs in ontvangst mogen nemen voor haar werkstuk getiteld 
"Hyperviscositeit bij de pasgeborene". De wetenschappelijke stage van de 
medische studie werd volbracht aan de Rockefeller University in the Laboratory of 
Biochemical Genetics and Metabolism (Head: Prof. dr. Jan L. Breslow) te New 
York, Amerika, onder supervisie van dr. Li-Shin Huang (januari tot augustus 1987). 
Op 30 september 1988 behaalde zij het artsexamen. Van oktober 1988 tot april 
1992 was zij als wetenschappelijk medewerkster verbonden aan de afdeling 
Algemeen Interne Geneeskunde (hoofd: Prof. dr. A. van ' t Laar) van de Kliniek voor 
Inwendige Ziekten van het St. Radboudziekenhuis te Nijmegen, alwaar dit 
proefschrift werd bewerkt. Tijdens het onderzoek volgde zij de cursus "proef-
dierkunde" en verwierf zij de titel van artikel-9 functionaris. Voor haar 
wetenschappelijk werk ontving zij in november 1991 het dr. Frye Stipendium. Dit 
stipendium stelde haar in gelegenheid 3 maanden door te brengen in het 
laboratorium van Dr. H.B. Brewer Jr., Chief Molecular Disease Branch, National 
Institute of Health, te Bethesda, Amerika, alwaar zij werkte onder supervisie van 
dr. Dan Rader (juni tot september 1992). Sedert oktober 1992 is zij werkzaam als 
arts-assistente in opleiding tot internist in de Kliniek voor Inwendige Ziekten (hoofd: 
dr. I.H. Go) van het Canisius Wilhelmina Ziekenhuis te Nijmegen. Zij woont samen 
met haar "twee jongens". 
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STELLINGEN 
behorende bij het proefschrift 
THE INFLUENCE OF METABOLIC AND 
GENETIC FACTORS ON THE LOW 
DENSITY LIPOPROTEIN SUBFRACTION 
PROFILE 
In het openbaar te verdedigen op woensdag 31 maart 
des namiddags te 3.30 uur precies door 
Jacqueline de Graaf 
STELLINGEN 
1 Niet alleen een hoog plasma LDL-cholesterolgehalte maar ook een zwaar 
LDL-subfractiepatroon draagt bij aan een verhoogd risico op hart- en 
vaatziekten. 
Dit proefschrift 
2 Het verschil in oxideerbaarheid en metabole verwerking tussen LDL-
subfracties suggereert een verschil in atherogene eigenschappen. 
Dit proefschrift, hoofdstuk 3 en 4 
3 Het LDL-subfractiepatroon wordt mede bepaald door een recessief gen 
waarvan de expressie wordt gemoduleerd door omgevingsinvloeden. 
Dit proefschrift, hoofdstuk 8 
4 De concentratie van plasma-triglyceriden heeft een belangrijke invloed op 
het LDL-subfractiepatroon. 
Dit proefschrift, hoofdstuk 6 en 7 
5 De oxidatiesnelheid en de hoeveelheid dienen die worden gevormd tijdens 
de oxidatie van LDL zijn o.a. afhankelijk van de linolzuur/oliezuur 
verhouding. 
Dr. H.A. Kleinveld et al., ongepubliceerde waarneming 
6 Het introduceren van verschillende benamingen voor gelijksoortige 
aandoeningen (bijvoorbeeld hyperapobetalipoproteinemia, familial 
combined hyperlipidemia en the atherogenic lipoprotein phenotype) 
vertroebelt de wetenschappelijke discussie. 
7 De nieuwe inzichten die volgen uit de oxidatie-theorie omtrent het 
ontstaan van aderverkalkmg leren ons dat in voorlichtingscampagnes als 
"Let op Vet" niet zo zeer de meervoudig onverzadigde vetzuren maar 
veeleer de enkelvoudig onverzadigde vetzuren gepropageerd zouden 
moeten worden. 
D. Steinberg et al., N Eng J Med 1989;320:915-924 
8 In tegenstelling tot wat veel mensen denken, komt een hoog serum 
cholesterolgehalte niet alleen voor bij zwaarlijvige mensen, maar ook bij 
dunne mensen. 
9 Ontdekkingen worden vaak gedaan door instructies niet op te volgen, af 
te slaan van de hoofdweg en te proberen wat nog niet geprobeerd is. Een 
gezonde dosis eigenwijsheid is dus een vereiste voor een promovenda. 
10 Het verwijt dat Nederland ver achterligt op andere landen op het gebied 
van de klinische research is volledig ongegrond. 
Prof. dr. A. van 't Laar, afscheidscollege, 8-5-1992 KUN 
11 Het niet-uitvoering geven aan de algemene maatregel van bestuur 
betreffende de werktijdenregeling van assistent-geneeskundigen is een 
overtreding van de wet. 
12 The delivery of medical care is to do as much nothing as possible. 
Samuel Shem, The House of God, Law no XIII 
13 Met het afschaffen van de stellingen is het meest gelezen gedeelte van 
het proefschrift verloren gegaan. 
14 Kattenliefde is pas echte liefde, want de kat alleen bepaalt aan wie en 
wanneer ZIJ die liefde geeft. 



